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Detrimental effects upon the cardiac system are a major cause of drug attrition. Current in-
vitro methodologies for identification of drug-induced structural and functional cardiotoxicity 
and their underlying mechanism are sub-optimal and have limited utility for longer-term 
analyses and clinical translation. The emergence of innovative technologies combined with 
human stem-cell-derived cardiomyocytes has revolutionised preclinical identification of drug-
induced cardiotoxicity. However, major limitations to these approaches include their 
complexity, specialised culture conditions, high cost and incomplete ability to fully detect 
drug-induced cardiotoxicity. A supplementary option is the use of immortalised cardiac cell 
lines, with capability for continuous growth and screening approaches. However, the 
limitations of these models for detecting both structural and functional cardiotoxicity are 
unknown. In this study, pathophysiological responsiveness of current cardiac cell lines to both 
structural and functional cardiotoxicants were evaluated using two-dimensional real-time 
impedance-based methodologies (xCELLigence) and three-dimensional spheroid systems. 
Specifically, using these cardiac cell models, the study evaluated effects of the histone 
deacetylase inhibitor (HDACi) sub-classes of drugs. The AC10 cell-line, although non-
contractile, was able to detect HDACi-induced structural changes. The HL-1 cell-line exhibited 
a contractile phenotype in vitro, albeit non-uniformly and time-limited, and also detected 
drug-induced structural cardiotoxicity. In terms of HDACi, the occurrence of structural changes 
in both AC10 cells and HL-1 cells in response to sub-pharmacologically active concentrations 
of the drugs was observed, implicating their potential for clinical cardiotoxicity. In summary, 
this study supports the inclusion of cardiac cell-lines alongside primary cells and stem-cell-
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EGTA                    Ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid 
ELISA                    Enzyme linked immunosorbent assay 
E-Pacing               Electrical pacing 
ESC                       European society of cardiology 
ETC                       Electron transport chain 
FB                         Fibroblast 
FBS                       Foetal bovine serum 
FCCP                     Carbonyl cyanide-4-phenylhydrazone 
FCS                       Foetal calf serum (also see FBS) 
FDA                      Food and drug administration 
FP                           Field potential 
FPD                        Field potential duration 
XX 
 
FPDc                      Corrected field potential duration 
h                            Hour 
HBSS                     Hank’s balanced salt solution 
HCL                        Hydrochloric acid 
HDAC                    Histone deacetylase 
HDACi                   Histone deacetylase inhibitor 
HERG                    Human Ether-à-go-go-Related Gene 
HF                         Heart failure 
HFpEF                   Heart failure with preserved ejection fraction 
hiPSC-CM             Human induced pluripotent stem cell derived cardiomyocytes 
HL-1                      HL-1 murine atrial cell line 
HRP                       Horseradish peroxidase 
hSC-CM                Human stem cell derived cardiomyocyte 
ICa-L                                    Calcium channel current L-type 
ICa-T                                    Calcium channel current T-type 
IC50                        Half maximal inhibitory concentration 
ICH                        International Council for Harmonisation of Technical Requirements for    
                              Pharmaceuticals for Human Use 
IF                                         Pacemaker ‘funny’ current 
IGF                        Insulin-like growth factor 
IKr                                       Delayed rectifier, fast current 
IKAch                                 G-protein gated potassium channel 
IKATP                                  ATP-sensitive potassium current 
IKP                                      Background current 
IKs                          Delayed rectifier, slow current 
IKur                         Delayed rectifier, ultra rapid current 
INa                         Sodium current 
Ito                          Transient outward current 
iPSC                      Induced pluripotent stem cell 
XXI 
 
ITS                        Insulin transferrin selenium 
IVIVE                    In-vitro-in-vivo extrapolation 
K                           Potassium 
kDa                       kilodalton 
KDAC                    Lysine deacetylase (also HDAC) 
LONG R3 IGF       Recombinant analogue of human insulin-like growth factor-I 
LQTS                      Long QT syndrome 
M                           Molar 
MEA                      Multi electrode array 
MI                          Myocardial infarction 
MID-3                    Model informed drug discovery and development 
ms                          Millisecond 
MS-275                 N-(2-aminophenyl)-4-[N-(pyridine-3yl-methoxy-carbonyl) aminomethyl]  
                               Benzamide  (also Entinostat) 
MTT                       3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
mV                         Millivolt 
Na                          Sodium 
NAD                       Nicotinamide adenine dinucleotide 
NCE                        Novel chemical entity 
NC3R                     The National Centre for the Replacement, Refinement, and Reduction of  
                               Animals in Research 
NCX                       Sodium calcium exchanger 
NE                          Norepinephrine 
OCR                       Oxygen consumption rate 
PBS                        Phosphate buffered saline 
PCR                        Polymerase chain reaction 
PFA                        Paraformaldehyde 
PVDF                     Polyvinylidene difluoride 
QRS                       Electrocardiogram QRS wave complex 
XXII 
 
QT                          Electrocardiogram QT segment 
QTc                        Corrected electrocardiogram QT interval 
RA                          Retinoic acid 
RCF                        Relative centrifugal force 
RTCA                      Real time cell analyser 
Ryr                         Ryanodine receptor 
SA                           Spike amplitude 
SAHA                     Suberanilohydroxamic acid (also Vorinostat) 
SAN                        Sinoatrial node 
SCD                        Sudden cardiac death 
SD                           Standard deviation 
SDS                         Sodium dodecyl sulphate 
SDS-PAGE              Sodium dodecyl sulphate–polyacrylamide gel electrophoresis 
SEM                        Standard error of the mean 
SIRT                        Sirtuin 
SR                            Sarcoplasmic reticulum 
ST                            Electrocardiogram ST segment 
SV40                       Simian vacuolating virus 40 
TBS-T                      Tris-buffered saline and Tween-20 
TdP                         Torsade de pointes 
TEMED                   Tetramethylethylenediamine 
TSA                          Trichostatin A 
T-tubule                 Transverse tubule 
ULA                         Ultra low adhesion 
WP                          Whole peak 
2D                           Two-dimensional 



























































Over the past 30 years, increasing evidence has proven that a wide number of compounds and 
drugs are responsible for critical and potentially life-threatening cardiac damage. Cardiac 
toxicity remains one of the primary causes of drug attrition and withdrawal from the market 
(Gintant, Sager, and Stockbridge 2016b; Vicente, Stockbridge, and Strauss 2016).  An 
increasing number of reports since the early 1980s have led to the conclusion that even non-
cardiovascular agents could contribute to serious risk to the normal functioning of the heart, 
thus leading to potentially dangerous outcomes. The urgent need for the development of 
standardised paradigms for the prediction and assessment of cardiotoxicity was thus 
recognised.  
The cardiotoxic effects of a compound relate to its ability to induce either disruption of cardiac 
function or structural alterations of the heart. To date most efforts, in terms of identifying the 
potential for drug-induced cardiac liabilities, have focused on preclinical evaluation of acute 
effects and drug-induced functional disturbances. In particular, the in-vitro characterisation of 
disturbances in the electrophysiological regulation of cardiomyocyte contraction, primarily 
related to the interference and disruption of cardiac ion channels  (Pointon et al. 2013). 
However, in contrast to preclinical evaluation of potential drug-induced functional 
disturbances, much less has been developed towards robust in-vitro methodologies for 
detection of drug-induced morphological and structural effects upon the heart. Currently, 
drug-induced structural cardiotoxicity and morphological cardiac disturbances are detected 
during in-vivo studies, with no in-vitro methodologies reliably available to either identify or 
imply such a potential risk (Fermini et al. 2016). Major limitations in this context are the low 
number of cardiac cell models for such purposes, a lack of optimisation of culture 
methodologies for cardiomyocyte models, poor understanding of the interplay between 
cardiomyocytes themselves and the other cell types present in cardiac tissue, and until 
recently, lack of technologies to non-invasively assess such changes. Additionally, unlike the 
mechanisms of drug-induced functional disturbances in cardiac tissue, a lot remains yet to be 







1.1 Mammalian cardiac system 
 
The human heart is an organ situated in the middle mediastinum within the thoracic cavity, 
positioned posteriorly to the sternum and the costal cartilages and surrounded by the 
pericardium. The main function of this vital organ is to achieve efficient perfusion in all organs 
and tissues via the circulatory system, which is essential in order to maintain optimal organ 
oxygenation and homeostasis, and provide nutrients to the organism (Netter 2014).  
Anatomically, the heart is divided into four main chambers, the upper part consisting of the 
left and right atria and the lower part consisting of the left and right ventricles. The left heart 
and the right heart are separated by the interatrial septum and the interventricular septum, 
whereas each atrioventricular portion is separated by an atrioventricular valve, the bicuspid 





Figure 1.1. Basic gross anatomy of the human heart: diagram shows the frontal cross section   
revealing the cardiac lumen. The four cardiac chambers, valves and major vessels are labelled. 
(Image adatpted from Servier Medical Art). 
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In the right heart, deoxygenated blood is collected and drained to undergo pulmonary 
circulation and re-oxygenation; oxygenated blood enters the left heart where it is pumped 
back into systemic circulation via the aorta (Silverthorn 2016). 
 
1.1.1 Cellular structure of the cardiac system 
 
The human heart is composed of a variety of cell types, broadly classified into myocytes and 
non-myocytes, which vary in proportion depending on their location and function within the 
organ, as well as depending on the age of the subject (Bergmann et al. 2015). The different 
layers of the mammalian adult heart contribute to distinct roles, providing both functional and 
structural features, with the myocardium being the muscular contractile layer, the 
endocardium being the innermost layer that lines the heart chambers, and the epicardium 
constituting the outermost layer of the cardiac wall. Myocyte-type cells occupy a large 
proportion of the adult human heart, accounting for approximately 70 to 85% of its volume 
(Zhou and Pu 2016). Non myocyte-type cells include endothelial cells (ECs) and cardiac 
fibroblasts (FBs), with ECs accounting for the largest proportion of non-myocyte-type cells in 
the adult human myocardium (Pinto et al. 2016). In minor proportion, macrophages are found 
in healthy myocardium where they are thought to be involved in the maintenance of tissue 
homeostasis as well as having a role in pathological diastolic dysfunctions (Nahrendorf 2019). 
Figure 1.2 Illustration of the cardiac wall structure, from the innermost endocardial layer 





Cardiomyocytes are among the first cells to develop in the embryo, with cardiac progenitor 
cells forming shortly after gastrulation. Neonatal cardiomyocytes retain a limited ability to 
divide after differentiation, with cell division terminating approximately three days postnatally 
(Litviňuková et al. 2020). Despite recent attempts at identification of cell division and 
regeneration mechanisms in adult cardiomyocytes and cardiomyocyte progenitor cells, the 
current consensus is that human cardiomyocytes are not generated ex-novo in adult life, and 
any limited occurrence of generation of new cardiomyocytes is to be attributed to cell cycle 
re-entry mechanisms of pre-existing adult cells (Gray et al. 2018). Cardiomyocytes constitute 
roughly 32% of the total number of heart cells in humans and rodents (Bergmann et al. 2015), 
and are key resident cells of the myocardium: given that they form the contractile core of the 
heart, and considering their limited regenerative capacity, it is perhaps not surprising that any 
myocardial injury (and subsequent cardiomyocyte damage or loss) would severely undermine 
the physiological functionality of the heart. 
Cardiomyocytes are typically mononucleated and organised into myofilaments, with 
individual myocytes being surrounded by the sarcolemmal cell membrane. Effective 
contractility of the heart is ensured by the coordinated contraction of cardiomyocytes as 
discussed in section 1.1.2 and 1.1.3. The direct electrical contact between individual myocytes 
and other cardiac cells is achieved through a distinct pattern of cell-cell interactions, gap 
junctions and ion channels expressed in the cardiomyocytes (Netter 2014). The integrity of 
the cardiomyocytes as well as the efficiency of these cellular communication mechanisms are 
at the basis of the excitation-contraction coupling mechanism of the cardiac muscle as 
described in section 1.1.3. 
 
1.1.1.2 Cardiac fibroblasts 
 
Cardiac fibroblast (CF) cells are of mesenchymal origin and are the second largest cardiac cell 
lineage by number in the adult human heart (Pinto et al. 2016). CFs have a key role in 
maintaining cardiac tissue homeostasis, and are essential in providing structural features in 
the heart by synthesising the cardiac extracellular matrix (ECM) components, including 
collagens and fibronectin (Tocchetti et al. 2020). The ECM has the critical role of providing 
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structural support to the cardiac cells, but recent evidence has demonstrated its involvement 
as the main signalling mediator between fibroblasts and cardiomyocytes (Tocchetti et al. 
2020; Pellman, Zhang, and Sheikh 2016), where it is involved in the modulation and 
conduction of electrical signals. Interestingly, fibroblasts themselves are incapable of initiating 
an action potential, but were shown to exhibit distinct conductive features (Pellman, Zhang, 
and Sheikh 2016). 
A major function of CFs includes the ability to provide tissue reparative mechanisms following 
disease states such as myocardial infarction (MI), by undergoing a phenotype transition into 
proliferative myofibroblasts capable of increasing matrix formation, and thus favouring scar 
tissue generation (Humeres and Frangogiannis 2019). Disruption of cardiac fibroblast 
homeostasis following cardiac injury is directly linked to fibrosis and cardiac remodelling that 
could result in severe pathological outcomes (Humeres and Frangogiannis 2019). In terms of 
drug-induced effects upon the cardiac system, cardiac fibroblasts are now believed to be 
centrally involved rather than just spectators in these effects. The importance of cardiac 
fibroblasts for cardiotoxicity of cancer therapeutics was recently highlighted at the joint 
meeting of the European Society of Cardiology (ESC) myocardial function and cellular biology 
of the heart working groups, wherein several interactions between fibroblasts and 
cardiomyocytes were defined in pathogenesis of cancer drug-induced heart failure (Tocchetti 
et al. 2020). Drug-induced toxicity against cardiac fibroblasts thereby has an indirect 
secondary effect upon cardiomyocyte survival and stability, alongside contributing to cardiac 
remodelling and subsequent cardiac failure. 
 
1.1.1.3 Cardiac endothelial cells and pericytes 
 
Excluding myocyte-type cells, endothelial cells (ECs) make up the largest proportion of cardiac 
cells (Pinto et al. 2016). Cardiac ECs provide vital functions which underpin the maintenance 
of vascular homeostasis, as well as contributing to healing and vascular regeneration following 
myocardial injury (Lother et al. 2018). ECs are located on the innermost vascular layer of 
cardiac vessels, where they are critical in the successful perfusion of the heart, and in the 
endocardium lining cardiac chambers: here they are involved in a range of EC-to-
cardiomyocyte paracrine communication pathways (Pinto et al. 2016). Cardiac ECs have been 
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shown to have a crucial role in the communication with immune cells, and subsequently have 
a role in cardiac inflammatory responses (Lother et al. 2018). Cardiac pericyte cells are 
perivascular cells, meaning they are found adjacent to ECs, where they provide synergetic 
structural support and EC stabilisation during angiogenesis, vascular maturation and vascular 
remodelling (Chen et al. 2015). 
 With regards drug-induced cardiotoxicity, ECs are now known to also play a significant 
contribution and underpin the development of heart failure. In cancer treatment, several 
therapeutics have now been shown to affect the ECs, resulting in a loss of barrier function, 
causing increased tissue permeability and myocardial injury (Tocchetti et al. 2020). 
Furthermore, ECs are believed to be the main contributor to heart failure caused by radiation 
therapy since cardiomyocytes and predominantly non-proliferative and considered resistant 
to this insult (Tocchetti et al. 2020). However, the mechanisms and interplay of ECs with 

















1.1.2 Cardiac contraction: Excitation-contraction coupling  
 
Cardiac muscle contraction is dependent on the integrity of the anatomical structure of the 
heart. Normal physiological cardiac contraction is initiated at the sinoatrial node (SAN), with 
a synchronised electrical signal travelling across the atria, through the atrioventricular (AV) 
node located in the interatrial septum, down the bundle of His and bilateral Purkinje fibres, 
and across the ventricles towards the apex of the heart, culminating in contraction of the 
cardiac muscle. This coordinated process allows the atrial chambers to transfer blood into the 
corresponding right and left ventricular chambers, and then subsequently eject blood into the 
pulmonary artery and aorta, respectively (Silverthorn 2016). 
In order for the cardiac muscle to contract, the excitation process needs to be translated into 
a mechanical force. Cardiac muscle is arranged into myofibrils containing contractile proteins, 
namely actin (thin) filaments and myosin (thick) filaments, together with regulatory proteins 
troponin and tropomyosin (Silverthorn 2016). Contraction involves the controlled movement 
of these filaments and fibres over one another, causing their shortening and a contraction 
(cardiac systole), followed by their relaxation (cardiac diastole) (Bers 2002). Cardiac excitation-
contraction coupling describes the series of events required to translate the electrical impulse 
into this mechanical contraction. At the level of the cardiomyocyte, the received electrical 
impulse triggers the initiation of an action potential (AP) and depolarisation of the sarcolemma 
through the concerted action of a sequential series of ion-selective channels (Bers 2002). 
The different regions of the heart exhibit a different expression and activity profile of ion 
channels and cell gap junction interactions to facilitate their respective roles (Bers 2002; 
Silverthorn 2016). The action potential triggered in atrial and ventricular cardiomyocytes, 
following initiation of a signal from the SAN and propagation of the contraction, has five 
specific phases (Figure 1.3 and table 1-1), each associated with movement of defined ions and 
activation of specific ion channels (Table 1-3), controlling initiation of contraction and 
relaxation. Upon receipt of an electrical signal from adjacent cardiomyocytes and attainment 
of the required threshold potential of -70mV, phase 0 of the action potential is triggered and 
depolarisation is initiated through activation and opening of fast Na+ voltage-gated time-
dependent channels, allowing Na+ entry into the cell. When the membrane potential reaches 
approximately -40mV Ca2+ channels are triggered to open, allowing Ca2+ to flow into the 
cardiomyocyte. Upon reaching approximately +30mV, wherein the membrane is depolarised, 
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the Na+ channels are closed and K+ channels are activated to open, initiating a partial 
repolarisation of the cardiomyocyte sarcolemma and phase 1 of the action potential. As the 
membrane potential approaches 0mV, the rate of Ca2+ entry is counterbalanced by K+ efflux 
from the cardiomyocyte for a short period of time, resulting in phase 2 of the action potential, 
termed the plateau phase. It is during phase 2 of the action potential that cardiomyocyte 
contraction occurs. Phase 3 of the action potential occurs when the Ca2+ channels that opened 
during phase 1 begin to close and the permeability of the cardiomyocyte to K+ increases, 
triggering further K+ channels to open and rectify the membrane potential and cause 
subsequent repolarisation of the cardiomyocyte. This allows the membrane potential to 
return to baseline and phase 4 of the action potential. In phase 4, also known as resting phase, 
K+ currents are the main determinant of the sarcolemma membrane potential as specific K+ 
ion channels remain open whilst Na+ and Ca2+ channels remain closed. Therefore, at rest, the 
membrane potential is close to the equilibrium potential for K+ at -90mV (Grant 2009; Bartos, 






Figure 1.3 Ventricular cardiomyocyte action potential. Depolarisation and repolarisation of 
the sarcolemmal membrane depend on ionic current mechanisms and are modulated by the 






In contrast to the atrial and ventricular cardiomyocytes, an action potential of cardiomyocytes 
within the SAN occurs in response to spontaneous membrane depolarisation and is termed 
the pacemaker potential. Compared to non-pacemaker (atrial and ventricular) 
cardiomyocytes, those in the SAN lack phases 1 and 2 of the action potential, with the baseline 
of phase 4 being unstable and an action potential been triggered spontaneously by Ca2+ 
flowing into the cell primarily via T-type calcium channels. In these cells there are two principal 
mechanisms contributing to the initiation of the action potential, one being dominated by the 
If ionic current (known as the “funny current”), and one being dominated by the Ca2+ 
intracellular handling, which is spontaneously released from the sarcoplasmic reticulum (SR)  






Table 1-1 Phases of the ventricular cardiomyocyte action potential. 





Table 1-3 Membrane currents involved in the generation of cardiac AP. Adapted from (Grant 2009) 
Current Description AP Phase Activation Mechanism 
Action potential: inward current channels 
INa Sodium current Phase 0 Voltage, depolarisation 
ICa,L Calcium current, L type Phase 2 Voltage, depolarisation 
ICa,T Calcium current, T type Phase 2 Voltage, depolarisation 
Action potential: Outward K+ current channels 
Ito,f Transient outward current, fast Phase 1 Voltage, depolarisation 
Ito,s Transient outward current, slow Phase 1 Voltage, depolarisation 
IKur Delayed rectifier, ultra-rapid Phase 1 Voltage, depolarisation 
IKr Delayed rectifier, fast Phase 3 Voltage, depolarisation 
IKs Delayed rectifier, slow Phase 3 Voltage, depolarisation 
IK1 Inward rectifier Phase 3 and 4 Voltage, depolarisation 
IKATP ADP activated potassium current Phase 1 and 2 [ADP]/[ATP]↑ 
IKAch Muscarinic-gated potassium 
current 
Phase 4 Acetylcholine 
IKP Background current All phases Metabolic, mechanical 
IF Pacemaker “funny” current Phase 4 Voltage, depolarisation 
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As defined above, cardiomyocyte contraction occurs during phase 2 of the action potential 
and is driven by Ca2+ movement into the cardiomyocyte. The deep invaginations of the 
sarcolemma, known as transverse tubules (t-tubules), facilitate the entry of Ca2+ through L-
type Ca2+ channels in response to membrane depolarisation driven by voltage-gated Na+ 
channels in phase 0 and 1 of the action potential, as described above. The Ca2+ influx into the 
intracellular fluid through L-type Ca2+ channels triggers the activation of ryanodine receptors 
located on the sarcoplasmic reticulum, releasing further Ca2+ and further increasing the 
intracellular Ca2+ concentration: a positive-feedback process known as calcium-induced 
calcium release (CICR) (Bers 2002) (illustrated in Figure 1.4). The free Ca2+ in the cytosol 
interacts with the myofibrils by binding to the troponin, causing troponin to undergo a 
configuration change. This ultimately allows actin to interact with myosin, shifting the actin 
filament towards the centre of the sarcomere, resulting in the contraction of the 
cardiomyocyte (Figure 1.4). The subsequent depolarisation of the cardiomyocyte, closure of 
the L-type Ca2+ channels, and disassociation of Ca2+ from the troponin complex, coupled to 
return of Ca2+ to stores in the sarcoplasmic reticulum and exportation of Ca2+ from the cytosol 
via several mechanisms including Ca2+ ATPase enzymes, resulting in cessation of 

















Figure 1.4. Excitation-contraction coupling mechanisms in the adult cardiac muscle. 
Depolarisation of the cardiomyocyte membrane, allowing calcium influx into cytosolic space 
via L-type Ca2+ channels. This triggers the release of additional Ca2+ stored in the sarcoplasmic 
reticulum, increasing levels of free Ca2+ in the cytosol. The release of Ca2+ modulates the 
activity of contractile proteins troponin and tropomyosin in the cardiac myofibrils, triggering 
muscle contraction and relaxation. 
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1.2 Drug-induced cardiotoxicity 
 
 
Cardiotoxicity is a term first coined in the 1940’s in relation to the effects on the heart 
observed with the use of local anaesthetics, and plant preparations derived from digitalis 
purpurea such as digoxin (Banerjee, Chung, and Kumar Ghosh 2018).  In the 1970’s, the term 
cardiotoxicity was increasingly used to describe the more complex cardiomyopathy-inducing 
effects caused by the anthracycline class of cancer chemotherapeutics (Banerjee, Chung, and 
Kumar Ghosh 2018). Increasing evidence and understanding of xenobiotic-induced adverse 
effects on the cardiovascular system have led to the evolution of the concept of cardiotoxicity 
as it is currently defined, inducing both cardiac dysfunction, such as dysrhythmias, ischaemia 
and cardiac conduction defects, and injury to cells of the myocardium (Ferdinandy et al. 2019). 
Several different pathophysiological mechanisms underpin the development of drug-induced 
cardiac dysfunction: disruption of excitation/contraction coupling mechanisms and 
intracellular calcium homeostasis, perturbations in mitochondrial respiration and activity, 
changes in cardiac rate and the force-frequency relationship, mismatch of cardiac preload and 
afterload, unbalancing of the dynamic relationship between cardiomyocytes and cardiac 
support cells, and alterations of the composition of the myocardial extracellular matrix 
composition (Ferdinandy et al. 2019; Melendez et al. 2020; Poluzzi et al. 2017). Adverse effects 
that occur at the structural level can manifest as either reversible or irreversible, involving 
sub-toxic effects such as increases in cellular permeability and restructuring of cellular 
membranes, alongside lethal irreversible damage as a result of drug-induced induction of cell 
death (Cardinale et al. 2020). Functional and structural drug-induced cardiotoxicities are often 
‘hidden’, presenting only in the presence of an additional pre-existing cardiac condition, 
providing an explanation for the disparity in drug-induced cardiac effects between preclinical 
evaluation in healthy subjects and clinical use in patients with comorbidities (Ferdinandy et al. 




















Figure 1.5 Spectrum of cardiac abnormalities associated with drug-induced events. The 
yellow area indicates ventricular arrhythmias overall. The orange area indicates sudden 
cardiac death secondary to ventricular tachyarrhythmias. Horizontal lines indicate 
polymorphic tachycardia and vertical lines represent QTc prolongation. Torsade de Pointes is 
represented by the intersection of horizontal and vertical lines. The purple area indicates 
atrial fibrillation, and the green area indicates events with a concurrent/causative effect of 
drugs used by the patient. BS Brugada syndrome, CAD coronary artery disease, CPTV 
catecholaminergic polymorphic ventricular tachycardia, D-I drug-induced, LQTS long QT 




1.2.1 Functional drug-induced cardiotoxicity 
 
Disruption of cardiac ion channel mechanisms by xenobiotics can lead to the development of 
life-threatening arrhythmias, or to the occurrence of proarrhythmic events which can 
exacerbate pre-existing cardiac dysfunctions (Saxena et al. 2016). In this context, one of the 
most studied and well-defined ion channel disruptions involves the human ether-à-go-go 
(hERG) gene-related K+ channel. Numerous studies have identified a direct relationship 
between drug-induced hERG potassium channel blockade and the development of 
asymptomatic long QT interval (Vicente, Stockbridge, and Strauss 2016), which has been 
directly correlated with the incidence of the dangerous ventricular arrhythmia Torsade de 
Pointes (TdP) (figure 1.6)(Grilo, Carrupt, and Abriel 2010).  Specifically, the hERG gene encodes 
for the α-subunit of the Ikr channel, which is critical for cardiomyocyte repolarisation during 
phase 3 of the ventricular action potential: as a consequence of its blockade, a slower 
membrane repolarisation occurs thus prolonging the QT wave interval detected via surface 
electrocardiography (Figure 1.6). This slowed repolarisation determines the reactivation of 
Ca2+ and Na+ channels, which in turn trigger the initiation of early afterdepolarisations (EADs). 
These EADs can result in a series of uncoordinated and erratic ventricular contractions, 
ultimately leading to TdP.  A range of structurally diverse drugs, including antiarrhythmics, 
antipsychotics, antimicrobials and antihistamines, have demonstrated the “off target” ability 
to bind to the Ikr (hERG) channel subunit causing significant functional disturbances in cardiac 
rhythm (Saxena et al. 2016). Despite estimations that “as many as 60% of novel molecular 
entities developed as potential therapeutic agents, when assessed for hERG blocking liability, 
test positive and are thus abandoned early in development” (Poluzzi et al. 2017; Gintant, 
Sager, and Stockbridge 2016a; Sager et al. 2014) recent evidence clearly suggests that hERG 
blockade alone is not specific for the prediction of early afterdepolarisation or other forms of 
proarrhythmia (Gintant, Sager, and Stockbridge 2016b). For example, the antiarrhythmic drug 
verapamil is a potent Ikr blocker but does not cause significant QT prolongation due to its 
ability to simultaneously block the inward ICaL channel Cav1.2 subunit which buffers the effects 







Despite evidence suggesting that hERG channel blockade underlies the majority of drug-
induced cases of QT prolongation, functional cardiotoxicity is not exclusively mediated by the 
disruption of hERG. A series of leading studies by Hondeghem and Katzung, and subsequently 
expanded by Campbell and Vaughn-Williams, demonstrated that drug-mediated Na+ channel 
interactions are time and voltage dependent (Hondeghem and Katzung 1977; Vaughan 
Williams 1989).  
Figure 1.6: Correlation between hERG channel blockade and development of TdP. 
Prolongation of cardiac AP, observed on ECG as a prolongation in QT interval, is directly 
correlated to the development of the ventricular arrhythmia Torsade de Pointes (TdP) 







The lack of tight association between hERG inhibition and clinical development of TdP led to 
concerns by several pharmaceutical and drug development companies as to the predictability 
and specificity of hERG inhibition as an indicator of clinical TdP risk, as dictated by the ICH S7B 
guidelines (E14/S7B 2020). Additionally, the value of non-human species for determination of 
functional and structural cardiotoxicity, in light of clear species-related differences, has also 
been questioned as a factor in drug attrition in preclinical development because of perceived 
cardiac liabilities (Fermini et al. 2016). Such issues have now led to the development of a new 
paradigm for preclinical evaluation of drug-induced cardiac liabilities, the Comprehensive in 
vitro Proarrhythmia Assay (CiPA) (“Https://Cipaproject.Org/” n.d.). The CiPA defines 
proarrhythmic risk based on an integrated assessment of drug effects on multiple ion 
channels, in silico reconstructions of human ventricular electrical activity, confirmation of 
effects in human stem-cell derived cardiomyocytes (hSC-CMs) and finally clinical ECG of the 
drugs in early phase clinical trial. This assay paradigm ultimately provides an assessment of 
drug-induced cardiac liabilities based on multi-parametric integrated signatures of human 
cardiomyocyte responses, as opposed to the single ion channel and non-human evaluation 
outlined in the ICH S7 guidelines. The potential greater predictability of the CiPA will only 
become apparent over the next few years, but outcomes so far have supported the value of 













1.2.2  Drug-induced structural cardiotoxicity 
 
Structural cardiotoxicity comprises two associated but distinct definitions: i) the alteration in 
overall cardiac cellular balance as a consequence of drug-induced loss of cardiac cells, 
resulting in cardiac restructuring, ii) the modification of sub-cellular components of cardiac 
cells, such as the cytoskeleton or mitochondria, resulting in a change in cellular morphology 
or a change in cellular contractility (Pointon et al. 2013; Doherty et al. 2015). Structural 
cardiotoxicity can manifest in the clinic as a cardiomyopathy, caused by the imbalance of 
cardiomyocytes versus cardiac support cells, or changes in cellular morphology and overall 
‘shape’/size of the heart (Higgins, O’Halloran, and Chang 2015; Zamorano et al. 2016; Michel 
and Rassaf 2019). Unlike functional (electrophysiological) cardiotoxicity, structural 
cardiotoxicity is commonly irreversible. Several classes of drugs have demonstrated direct 
structural cardiac or more widespread vascular alterations, including antiretroviral 
compounds, antidiabetics and several substances of abuse (Ferdinandy et al. 2019). The most 
notable direct structural cardiotoxicants, however, belong to the oncological 
chemotherapeutic class of drugs, which notoriously include anthracyclines, kinase inhibitors, 














1.3 Drug-induced cardiotoxicity of oncology therapeutics 
 
Recent progress in the development of oncological therapeutics over the past decade has 
significantly increased therapeutic outcomes and patient survival. The downside to this 
success is that this is unfortunately often associated with adverse toxic effects, with a tangible 
increase of chemotherapy-induced cardiac damage (Alameddine et al. 2014; Dy and Adjei 
2013; Raschi et al. 2010; Tocchetti et al. 2020). Furthermore, improvements in patient survival 
raise an issue with cardiotoxicity as the long-term detrimental effects of the specific 
therapeutics are now becoming apparent, significantly impacting upon a patient’s quality of 
life (Mann and Krone 2010). The prognosis of a patient presenting with drug-induced 
cardiotoxicity worsens dramatically, often overtaking the underlying primary condition, thus 
outweighing the therapeutic risk-to-benefit ratio (Higgins, O’Halloran, and Chang 2015). 
Cancer chemotherapy over the past decade has undergone significant advancements, moving 
from approaches based on ‘conventional’ chemotherapies, inhibiting cellular division and 
inducing cell death, to one which now incorporates ‘molecular targeted’ therapies focused on 
targeting the molecular characteristics and exploiting the hallmarks of cancer (Hanahan and 
Weinberg 2011). An underlying theory behind this effort is that by making cancer therapeutics 
more targeted, some of the toxicities seen with conventional cytotoxic chemotherapeutics 
could be eliminated or at least ameliorated.  This unfortunately has not been the case for 
many chemotherapy-related toxicities, cardiovascular toxicity included. One hypothesis was 
that the cardiovascular toxicity associated with cancer chemotherapy was due to the activity 
of the ‘conventional’ cytotoxic chemotherapeutic agent administered alongside the 
‘molecular-targeted’ therapeutic within the regimen (Swain, Whaley, and Ewer 2003), and 
that the toxic effects would be removed with increased targeting of cancer therapies (Ky, et 
al., 2013). However, this simplistic hypothesis has now been invalidated due to our greater 
understanding of molecular pharmacology and improved understanding of drug-induced 
cardiovascular toxicity in cancer patients (Dy and Adjei 2013; Eschenhagen et al. 2011; Poluzzi 
et al. 2017). Many of these molecular-targeted agents have demonstrated adverse effects 
upon the heart, from mild electrophysiological changes, to myocarditis and fatal heart failure 
(Bellinger et al. 2015; Varricchi et al. 2017). Consequently, we now know that drug-induced 
detrimental effects upon the heart are not limited to the ‘conventional’ cytotoxins or a single 
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type of therapeutic but are an inherent problem with many oncology agents, including 
molecular-targeted agents (Bellinger et al. 2015; Tocchetti et al. 2020).  
Cardiotoxicity induced by oncology therapeutics, both ‘conventional’ and ‘molecular-
targeted’, can elicit both functional and structural effects, and can be classified into three 
types: symptomatic acute toxicity occurring soon after administration, and early- and late-
onset toxicity, occurring before or after one year of treatment, respectively (Bagnes, Panchuk, 
and Recondo 2009; Curigliano et al. 2010). In order to address the clinical issue and current 
high level of attrition during cancer drug development, efforts are needed to better 
understand the mechanistic basis of drug-induced cardiotoxicity in oncology, both in the acute 
and longer term, and in preclinical studies to predict cardiotoxicity of putative 
chemotherapeutics. In order to fulfil this objective better predictive and translatable models 
for assessment of drug-induced cardiotoxicity, amenable to molecular characterisation and 
manipulation, and models with scope for integrated evaluation of both functional and 
structural cardiotoxicity are urgently required. 
The cytotoxic and antineoplastic functions of chemotherapeutics determine the development 
of adverse effects, resulting in a range of cardiovascular problems including functional 
abnormalities, dysrhythmias and cardiac conduction defects, alongside structural effects, such 
as cardiomyocyte death and cardiac remodelling, cellular hypertrophy, and drug-induced 
cardiomyopathies (Varricchi et al. 2017; Gill et al. 2019). Although several cancer 
chemotherapeutics are reported to cause acute effects, such as drug-induced proarrhythmias 
observed with kinase inhibitors and conduction disturbances associated with the newly 
identified immune-checkpoint inhibitor drugs, a more prevalent problem is development of 
delayed cardiotoxicity as a consequence of the required cellular-lethal nature of many of these 
drugs (Gintant, Sager, and Stockbridge 2016a). Consequently, improved understanding and 
better preclinical models for prediction and evaluation of sub-acute drug-induced 







1.3.1 Histone/Lysine deacetylases (HDACs/KDACs) and their Inhibitors as therapeutic 
agents 
 
Histone deacetylases (HDACs) are known to be essential players in the posttranslational 
regulation of several processes and pathways, dysregulated in many diseases such as 
inflammatory conditions, and notably, cancer (R. R. Shah 2019; Gryder, Sodji, and Oyelere 
2012a). The action of these enzymes was primarily characterised by their central role in 
nucleosomal histone deacetylation, as main drivers of epigenetic regulation of genetic 
expression (Falkenberg and Johnstone 2014). However, although initially believed to act 
purely as epigenetic regulators, this family of proteins is now known to play a role in 
acetylation of several proteins involved in regulation of both nuclear and cytoplasmic cellular 
functions (Toro and Watt 2020; Delcuve, Khan, and Davie 2012). These activities include DNA 
damage repair, RNA splicing, cell cycle control, metabolism, and cytoskeletal remodelling 
(Delcuve, Khan, and Davie 2012).  Members of this enzyme family also display tissue and 
organ-specific roles: for instance, recent discoveries evidenced their involvement in cardiac-
related events including fibrotic processes, hypertrophy protection, metabolic functions and 
contractility (Schiattarella et al. 2016; Weeks 2019). Consequently, recent studies have 
reclassified this enzyme family as lysine deacetylases (KDACs), rather than HDACs, to better 
represent their diverse activities (Toro and Watt 2020).  
Mammalian HDACs/KDACs are currently categorised into four different classes, based on 
similarities in their genetic and protein sequence and function (West and Johnstone 2014).  
Three of the classes, I, II and IV, are zinc-mediated modulatory enzymes, whereas the class III 
sub-family comprises the Sirtuins (SIRT1–7), which although share features with both class I 
and class II HDAC enzymes, are NAD+ dependent and functionally and structurally distinct 
(McKinsey 2012; De Ruijter et al. 2003). The sirtuin family is therefore omitted when 
considering the functions and roles of HDACs/KDACs, with the focus being upon those 
enzymes reliant on zinc for their catalytic activities (McKinsey 2012). In terms of members for 
each of the HDAC/KDAC sub-families; Class I of the family is comprised of HDAC/KDAC-1, -2, -
3 and -8, all of which have the simplest structure; class II is subdivided into class IIa comprising 
HDAC/KDAC-4, -5, -7 and -9 and class IIb consisting of HDAC/KDAC -6 and -10; class IV 
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HDAC/KDAC is a single member family of HDAC/KDAC11. These sub-families are indicated in 
Figure 1.6. 
HDACs/KDACs are expressed in different subcellular areas of the cell, with class I being 
expressed predominantly in the nucleus and playing a role in histone acetylation, acting as the 
‘conventional’ HDAC with a primary role in epigenetic regulation (Delcuve, Khan, and Davie 
2012). Class II HDACs/KDACs either remain in the cytoplasm wherein they post-translationally 
regulate activity of proteins, as demonstrated by class IIb HDAC6 mediated acetylation and 
stabilisation of tubulin, or shuttle between the cytoplasm and the nucleus wherein they 
regulate subcellular location of specific proteins and participate in macromolecular signalling 
pathways, demonstrated with HDAC4 and 5 (Toro and Watt 2020). A clear difference in 
function between class I and class IIa enzymes is also evidenced by the fact that class IIa 
enzymes demonstrate very little deacetylation activity, implying their primary role is unlikely 
to be primarily enzymatic in nature (Parra 2015). With regards class IV (HDAC/KDAC 11), 
despite having similarity to class I and class II and weak deacetylase activity, its role is believed 
to be primarily as a fatty-acid deacylase enzyme rather than a deacetylase (Kutil et al. 2018).  
Taken together, further to the differential roles and sub-cellular localisation of the 
HDACs/KDACs, emerging evidence increasingly now suggests that due to their complex 
regulatory and multi-functional roles, HDACs/KDACs should be considered as subunits of large 
regulatory complexes, facilitating a plethora of cellular activities (Toro and Watt 2020). For 
the purposes of this thesis, these enzymes will be termed HDACs rather than KDACs, due to 
the predominant use of this nomenclature within the literature. 
The ever-increasing association between HDAC expression and activity and development and 
progression of a wider number of diseases, especially cancers, led to development of 
inhibitors of HDACs as a therapeutic strategy. However, despite considerable efforts and many 
putative inhibitors being produced, only a very small number of pan-class inhibitors have 
actually progressed into the clinic to date as anticancer agents most notably the hydroxamates 
vorinostat, panobinostat and belinostat (R. R. Shah 2019). The improved and evolving 
appreciation of the role of specific deacetylase enzymes and sub-classes, and their 
associations with other non-cancer diseases, is however reinvigorating excitement in the 
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development of class or isoform-selective deacetylase enzyme inhibitors, with several such 
therapeutics in advanced clinical trials (Kulka et al. 2020).   
 
 
1.3.2 Cardiotoxicity of HDACi 
 
Inhibition of HDAC activity is showing significant promise as a therapeutic strategy, initially in 
cancer but now also in a range of other diseases including neurodegenerative disorders 
amongst others (Rodrigues et al. 2020). Since entry to the clinic, an increasing number of 
reports suggest an association with the development of cardiac adverse reactions , and there 
are now several reports of acute adverse effects in patients undergoing treatment with 
HDACis (M. H. Shah et al. 2006; R. R. Shah 2019). In patients undergoing HDACi treatment, a 
number of ECG changes, including QT prolongation and ST wave changes were observed (R. 
R. Shah 2019). In the case of the HDACi depsipeptide, during clinical trials alongside 
asymptomatic cases of ventricular tachycardia and delayed cardiac repolarisation, a case of 
fatal ventricular arrhythmia was reported (Lane and Chabner 2009; Gryder, Sodji, and Oyelere 
2012b; R. R. Shah 2019). Similarly, asymptomatic delayed cardiac repolarisation, ventricular 
tachycardia and unsustained torsade de pointes, was detected during clinical trial of the 
HDACi LAQ824 (Rowinsky et al. 2004). During preclinical studies of this depsipeptide, although 
moderate cardiomyopathy, elevated serum cardiac enzymes, and prolonged cardiac 
Figure 1.7. Classification of histone deacetylase family members. 
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repolarisation were detected in dogs, there was no evidence to support drug-induced cardiac 
dysrhythmia and associated risk of fatality (M. H. Shah et al. 2006). This observation raises a 
question as to predictability of QT-prolongation for detection of life-threatening dysrhythmias 
with these drugs, with involvements of other ion channels or molecular factors potentially 
implicated (Noonan et al. 2013). 
At present there are four HDACi currently approved in the clinic, vorinostat (SAHA), 
Romidepsin (FK228), belinostat (PXD101) and panobinostat (LBH589) for cancer therapy, 
predominantly against non-solid haematological malignancies (Kulka et al. 2020; R. R. Shah 
2019). All of these HDACi are linked to potential development of cardiotoxicity, with 
Panobinostat (the most potent of the approved HDACi) carrying a black box warning for severe 
cardiac abnormalities. As was the case with depsipeptide and LAQ824, several other similar 
pan-HDACi were also developed but failed to progress due to concerns regarding drug-
induced cardiotoxicity (Suraweera, O’Byrne, and Richard 2018; Gryder, Sodji, and Oyelere 
2012b; Shultz et al. 2011). The underlying cause of the cardiotoxicity observed with these pan-
HDACi hydroxamate-containing drugs is as yet still unresolved. It is unclear whether the 
adverse cardiac effects are a consequence of HDAC inhibition, a drug class effect or are due 
to the specific chemical structure in light of all these drugs containing highly reactive 
hydroxamate active headgroups. A further complexity is the fact that significant cardiotoxicity 
with depsipeptide was detected in the clinic in patients with metastatic neuroendocrine 
tumours but not in patients with haematological malignancies, potentially implying the 
presence of ‘hidden cardiotoxicity’ as a contributory factor in this context (M. H. Shah et al. 
2006; Cardinale et al. 2020). 
In an effort to improve therapeutic efficacy, develop drugs against specific HDAC associated 
with a disease, and to reduce potential off-target toxicities and adverse effects, significant 
efforts have been focused on development of class-selective or isoform-selective HDACi (Kulka 
et al. 2020). The vast majority of the drugs under development being class I selective. Such 
drugs would be expected to exhibit differential effects upon the heart due to their 
involvements in cardiac hypertrophy and cardioprotection. Class I HDACs are reported to 
demonstrate pro-hypertrophic effects (Morales et al. 2016). Therefore, specific inhibition of 
class I HDACs would be hypothesised to retard cardiac hypertrophy. In contrast, the class IIa 
HDAC, HDAC4, which is protective against cardiac hypertrophy would potentially exacerbate 
cardiac hypertrophy if inhibited (Backs et al. 2006; Xian Zhang et al. 2018). The caveat being 
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that due to the limited deacetylase activity exhibited by class IIa HDAC, any effects of HDACi 
would not be a consequence of enzyme inhibition but rather a factor of its predicted nuclear-
cytoplasmic transportation capacity. Evidence for potential reduced toxicity of class I selective 
HDAC-inhibition, relative to pan-HDACi, is provided by the observation that entinostat (MS-
275), a benzamide rather than a hydroxamate HDACi, showed efficacy against breast cancer 
in the absence of detectable adverse cardiac toxicity (Yardley, Ismail-Khan, and Klein 2011). 
Additionally, class I selective HDAC have also been shown to exhibit very limited effects on 
cardiac sodium currents and gap junctions, unlike pan HDACI, offering an additional 
advantageous mechanism to support the potential for reduced cardiotoxicity of class I 
selective HDACi (Xian Zhang et al. 2018) . Interestingly, the class IIb HDAC6 has been implicated 
in modulation of acetylation of the cardiac sodium channel Nav1.5 restricting its surface 
translocation and subsequent function, implying that specific inhibition of this isoform may be 
beneficial to prevention of cardiac arrhythmias (Xian Zhang et al. 2018). However, the 
significance of this for HDAC-selective drug development is as yet uncertain. Greater 
understanding the underlying mechanisms that contribute to cardiotoxicity of HDACi and the 
involvement of specific sub-classes and isoforms is necessary to mitigate putative HDACi-
induced cardiotoxicity in the clinic and development of HDACi with an improved therapeutic 
index. Evaluation of HDACi against relevant cellular cardiac models is therefore necessary to 













1.4 Preclinical assessment of drug safety 
 
In the drug development process, early decision-making is essential to avoid progression of 
detrimental compounds which could result in significant liabilities and financial loss. Early 
identification of safety issues is therefore a fundamental process that begins at the early 
stages of project development, as early as at target validation stages, and continues through 
to in-vivo studies and clinical development stages (figure 1.8) (Bendels et al. 2018; Bowes et 
al. 2012; Hornberg et al. 2014).  In this context, early in-silico and in-vitro pharmacological 
profiling was shown to provide major improvements towards the successful progression of 
late-stage clinical development (Bowes et al. 2012). In particular, in-vitro pharmacology 
profiling is increasingly implemented to assist with specific phases of the drug development 
process, and this can be categorised into three main objectives specific to each project phase: 
• hazard identification through early target identification/validation stages, 
• hazard elimination through hit-to-lead and lead optimisation stages,   
• mechanistic toxicology studies through candidate selection, preclinical and clinical 





Figure 1.8 Stages and scope of safety assessments in relation to the drug discovery pipeline. 





The alignment of in-vitro pharmacology and toxicology profiling to the drug development 
process allows to obtain a more comprehensive mechanistic understanding of the drug 
candidate before its introduction to first-in-human-trials. However, target assessment panels 
adopted across the industry have been designed to only cover a limited range of essential key 
targets, with the main rationale reflecting the cost-to-benefit ratio of an assessed target 
compared to the magnitude of the impact resulting from its hit (Bowes et al. 2012). 
Nonetheless, the development and integration of in-vitro models with the potentiality to 
screen for a wider array of targets would facilitate not only the understanding of the drug 
candidate pharmacological profile with a higher level of confidence, but also help address the 
translation of in-vitro findings to the clinic, whilst retaining cost feasibility. Additionally, 
effective in-vitro profiling has the potential of significantly improving the design of in-vivo 
studies, ultimately providing improvements towards the NC3R principles (Replacement, 
Reduction and Refining) for the use of animals in research (Https://nc3rs.org.uk/the-3rs 
2020). 
The routine implementation of various in-vitro methodologies in the drug discovery pipeline 
is a constantly evolving area, reliant on the continuous commitment and collaboration of 
regulatory, industry, government and academic experts to achieve scientific consensus.  To 
ensure this, the International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use (ICH) has gradually established a set of ICH guidelines to 
promote the adoption of updated research methodologies and common standards 
(Https://www.ich.org/ 2020). While the establishment of such guidelines has allowed to 
considerably improve the introduction of safe and effective medicines onto the market, 
improvement and optimisation of new safety guidelines are still required, particularly in the 
nonclinical evaluation of cardiotoxicity. 
 
1.4.1 Preclinical detection of drug-induced cardiotoxicity 
 
Current methods used in regulatory-compliant preclinical cardiotoxicity screening do not fully 
reflect the complexity of the human heart as they generally rely on overly-simplistic 
techniques and models, with significant limitations in the detection of both functional and 
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structural cardiotoxicity (Gintant, Sager, and Stockbridge 2016a). These methods involve 
varying models that differ in terms of complexity ranging from highly complex in-vivo models 
to simpler tissue sections and simple single-cell electrophysiology studies.  Several clinical 
cases in the last three decades, starting in the 1990s, linked the prolongation of QT interval to 
the development of life-threatening arrhythmias (Pollard et al. 2010; Redfern et al. 2003), 
particularly the rare and potentially fatal arrhythmia TdP, leading to the withdrawal of several 
compounds (R. R. Shah 2005). Consequently, the establishment of non-clinical guidelines for 
assessing the potential of a chemical entity to delay ventricular repolarisation was 
implemented by regulatory bodies in 2005. These regulatory guidelines are known as ICH S7B, 
and are complementary to the ICH S7A guidelines on safety pharmacology studies for human 
pharmaceuticals (E14/S7B 2005; Darpo, Nebout, and Sager 2006); the principles of the ICH 
S7B guidelines rely fundamentally on the study of hERG in in-vitro Ikr assays as well as in-vivo 




At present, detection of markers of cardiac damage and telemetry monitoring in animals are 
still the principal nonelective methods used to screen for drug-induced cardiac effects in-vivo, 
looking primarily for the development of hazardous arrhythmias and QT interval prolongation, 
particularly focusing on avoidance of TdP. Considering the complexity of cardiac anatomy and 
physiology, it is evident that these methods offer insufficient predictivity and a generally 
Figure 1.9 Nonclinical integrated testing strategy based on ICH guidelines. 
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limited overview of the mechanisms involved in drug-induced cardiac damage. The 
increasingly evident limitations of current ICH guidelines for cardiac toxicity assessments have 
recently led to the re-contextualisation of the current pharmaceutical/bioindustrial needs 
(Sager et al., 2014). Several assays have been designed in order to detect hERG channel 
blockade in the early stages of compound development: currently, these assays mainly rely on 
in-vitro assessments of the IKr current in mammalian cell lines expressing recombinant hERG 
(Grilo et al., 2010). Since the ICH guidelines are non-prescriptive, this is achieved using a 
number of different protocols. The disadvantages of these type of assays firstly lie in their non-
native nature, as recombinant hERG channels often do not comprise all the subunits observed 
in native hERG expression: despite some evidence suggesting that not all subunits are 
routinely needed for the purpose of the assay (Cavero et al. 2016), more physiologically-
relevant cardiac tissue models would provide improved pharmacological insights. A second 
major disadvantage lies in the lack of standardisation of these types of assays, consequently 
leading to the production of highly variable data. Factors such as conditions settings and 
measurement methods vary between different pharmaceutical laboratories, and have been 
proven to heavily affect the safety evaluations and regulations for a given novel compound 
(Sager et al. 2014).  
The development of novel technologies, including the advent of induced pluripotent stem cell 
derived cardiomyocytes (hiPSC-CM) and three-dimensional tissue culture techniques, has 
opened opportunities in terms of improving current preclinical cardiotoxicity screening. As 
one of the major issues in current cardiac safety testing is the high variability of data and 
biological platforms, industrially manufactured iPSC models offer a more robust alternative, 
suitable for high throughput screening (Clements et al. 2015). These advances have led to the 
establishment of the Comprehensive In-vitro Proarrhythmia Assay (CIPA) project, with the 
overall aim to facilitate the implementation of a new paradigm for assessment of TdP through 
the integration of novel in-vitro technologies with predictive in-silico methodologies 
(“Https://Cipaproject.Org/” n.d.). In particular, the CIPA initiative was designed to involve 
multiple working streams, each focusing on a core aspect of Proarrhythmia evaluation. These 
working streams involve the integration of individual ion channel studies, in-silico 
electrophysiology modelling, use of human stem-cell derived cardiomyocyte platforms and 
relevant assays, and use of ECG monitoring in humans. Among the CIPA main objectives are i) 
the standardisation and integration of these different streams, and ii) the subsequent 
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application of such standardised protocols to guide the clinical assessment of compounds 
(Fermini et al. 2016; Vicente, Stockbridge, and Strauss 2016). The substantial progress of the 
CIPA initiative and ICH safety guidelines to date have very recently led to the revision of some 
of the ICH S7B guidelines (E14/S7B 2020). While these important improvements are expected 
to positively impact preclinical cardiotoxicity screening in the near future, effective 
methodologies for the detection of structural cardiotoxicity currently remain mostly unsolved. 
 
1.4.2 In-vitro cardiac cell models 
 
Preclinical cardiotoxicity screening studies are typically focused on individual aspects of drug-
induced events, where only a few will result in a significant association with TdP (Poluzzi et al. 
2017), making current preclinical predictive evidence largely incomplete or not fully reliable. 
Whilst the assessment of specific proarrhythmic factors can be informative in relation to the 
most severe acute cardiotoxic events such as TdP and sudden cardiac death (SCD), novel 
preclinical predictive methods should be focused on a more inclusive and high-throughput 
screening, directed at the detection of sub-acute and structural effects. A limited number of 
cardiac cell-based in-vitro platforms is available, including isolated ex-vivo whole tissue 
perfused preparations, and primary CMs from medium and large animals (i.e. Rabbits, dogs) 
which are currently considered the gold standard for pharmacological target and 
proarrhythmia investigations (Sala, Bellin, and Mummery 2017). Despite recapitulating cardiac 
physiology with a high degree of complexity, primary perfused tissues and isolated CMs retain 
substantial inter-species differences, and are not scalable to support high-throughput 
screening (Sala, Bellin, and Mummery 2017). Similarly, primary CMs derived from human 
cardiac tissue obtained from surgical procedures, whilst providing a phenotypically mature 
and relevant model cannot be harvested on a large scale, and as such their use for 
standardised preclinical screening is very limited. The advent of human induced pluripotent 
stem cell derived CMs has drastically improved the scalability and standardisation of in-vitro 
cardiac models: hiPSC-CMs are currently increasingly implemented in preclinical cardiotoxicity 
screening, and are one of the pillar models within the CIPA paradigm. While the potential of 
hiPSC-CMs for use in preclinical screening has been abundantly documented, a number of 
limitations associated with this model remain unresolved, particularly in relation to its 
immature phenotype, electrophysiological differences and, not least, high maintenance costs 
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(Garg et al. 2018; Magdy et al. 2018). A limited number of immortalised cardiac cell lines is 
available, including the rat H9C2 non-contractile cardiomyoblast cell line, the HL-1 contractile 
murine atrial cell line and the non-contractile AC10/AC16 human ventricular cell line. Cell 
lines, unlike primary and hiPSC models, present the distinctive advantage of being 
continuously expandable, thus providing an unlimited and scalable source of CMs at relatively 
low maintenance costs. These models, particularly the HL-1 murine cardiomyocyte cell line 
and the AC10/AC16 human cardiomyocyte cell lines, have not been fully investigated for their 
potential in high throughput preclinical cardiotoxicity applications. Given the established 
limitations of the currently implemented models for the detection of sub-acute and structural 
cardiotoxicities, cell lines represent a potential source of relevant models for early toxicity 
screening. A full appraisal of hiPSC-CMs, HL-1 and AC10 cell models is discussed in chapters 3, 





Figure 1.10 Range of cardiac models. Cardiac models ranked based on model complexity and 
physiological relevance vs model acceptance and bioethical implications.  
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1.5 Thesis aims and objectives 
 
The overall aim of this thesis is the characterisation and evaluation of the predictive potential 
of in-vitro cardiac cell models for the assessment of drug-induced structural and functional 
cardiotoxicity, and the subsequent model qualification for preclinical drug-induced 
cardiotoxicity screening. Specifically, this research builds upon previous studies utilising hiPSC-
CM models and is aimed at qualifying and integrating the HL-1 murine atrial cell line and the 
AC10 human ventricular cell line as additional screening tools within the drug safety 
assessment pipeline.  
In addition to evaluation of ‘standard’ and known cardioactive drug panels with cardiotoxicity 
liability, this study aims to evaluate the potential for, and mode-of-action of, acute and longer-
term cardiotoxicity of the histone deacetylase inhibitor (HDACi) class of molecular-targeted 
therapeutics, which have recently progressed into clinical use. Through the integrated use of 
‘conventional’ cell and molecular biology methodologies with state-of-the-art real-time 
impedance-based technologies (xCELLigence RTCA), drug-induced effects upon 
cardiomyocyte viability and functional contractility, hyperplasia, and hypertrophy will be 
discussed. Additionally, the project evaluates the development of in-vitro three-dimensional 
cardiac models using these cell lines, in combination with cardiac fibroblasts and endothelial 
cells, and compares their potential to detect drug-induced cardiotoxicity to two-dimensional 
cardiac cell models. Furthermore, considering the current inadequacy and lack of preclinical 
in-vitro models for the detection of structural liabilities, this  project additionally addresses 
currently unmet needs by qualifying cell line-based models for the detection of structural 
perturbations.  
 
The overall objectives for this project are as follows: 
• Characterisation of in-vitro growth and cardiac phenotype of HL-1 and AC10 cell line 
models, with subsequent establishment of protocols for use in high-throughput drug 
toxicity studies 
• Evaluation of drug-induced functional and contractile alterations of hiPSC-CM, and HL-
1 cellular monolayers, using the xCELLigence real-time analyser (RTCA) systems  
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• Evaluation of drug-induced cellular structural alterations of hiPSC-CM, HL-1 and AC10 
cellular monolayers, using the xCELLigence real-time analyser (RTCA) systems 
• Characterisation and evaluation of structural drug-induced cardiotoxicity in cell line-
based three-dimensional spheroid models 
• Application of the cardiac cell models characterised within this project to identify and 
predict the potential for drug-induced cardiotoxicity of the HDAC drug class, appraising 










Figure 1.11 The project phases. Outline of the different project phases, aiming at the 
characterisation of in-vitro cardiac cell models for assessments of drug-induced structural and 






























2.1 Material source 
Unless otherwise stated, all reagents were purchased from Sigma - Merck, UK. 
2.2 Drug and compound treatment 
All tested compounds were weighted in a high precision analytical balance and diluted in 100% 
dimethylsulfoxide (DMSO) unless otherwise specified, with a final concentration that never 
exceeded 0.1% DMSO. 
2.3 Two-dimensional adherent tissue and cell culture 
All cell and tissue cultures were routinely maintained in CO2 incubator at 37°C and 5% CO2 
under humidified atmosphere. All culture vessels were purchased from Sarstedt, Germany, 










Table 2-1 Cardiac cell cultures, origin, cell culture conditions and source. DMEM, Dulbecco’s Modified Eagle’s Medium; FCS, foetal calf serum. 
Cell line/ Cell 
model 
Species Complete culture medium Source 
AC10/ventricular Human DMEM-F12, 10% (v/v) FCS, 2 mM L-Glutamine, 80 U/ml 
Penicillin/Streptomycin 
Donated by Dr Barbara Savoldo, Baylor College 
of Medicine, Houston TX, USA 
HL-1/atrial Mouse Claycomb, 10% (v/v) HL-1-screened FCS TMS016B, 2mM L-
Glutamine, 80 U/ml Penicillin/Streptomycin 
Donated by Dr Michael Dodd, University of 
Oxford, Oxford, UK 
hiPSC-CM 
/ventricular 
Human • Cor4U. / Axiogenesis hIPSC-CM maintenance medium 
• iCell2/ Fujifilm Cellular Dynamics maintenance medium 
Purchased from Axiogenesis and Fujifilm CDI 
Cardiac fibroblast 
 
Human DMEM-F12, 10% (v/v) FCS, 2 mM L-glutamine, 80 U/ml Penicillin 
Streptomycin 
Donated by Dr Parveen Sharma, University of 
Liverpool, Liverpool, UK 
Cardiac 
endothelial 
Human PromoCell endothelial cell kit (Basal Growth Medium MV + 
SupplementMix) 
Donated by Dr Parveen Sharma, University of 





2.3.1  AC10 human ventricular cell line culture 
 
The AC10 cell line is a proliferative human cardiomyocyte cell line derived from non-
proliferative primary adult ventricular cardiac tissue (Davidson et al. 2005). The AC10 cells 
were originally immortalised by fusing the primary cardiomyocytes with SV40 transformed 
uridine auxotroph human fibroblast, devoid of mitochondrial DNA, and removing unfused 
fibroblasts (Davidson et al. 2005). The resulting AC10 cell line is therefore a suitable 
cardiomyocyte ventricular cell model that can be passaged and maintained under simple 
culture conditions. AC10 cells were routinely cultured in Dulbecco’s Modified Eagle’s medium 
(DMEM) F-12 supplemented with 10% foetal calf serum (FCS), 80U/ml penicillin/streptomycin 
and 2mM L-glutamine. AC10 cells were passaged after reaching a confluency of 80-100%. 
Briefly, media was aspirated from the flask and cells were washed with 5ml of Hank’s Balanced 
Salt Solution (HBSS, Sigma, UK) before incubation with 0.25%   trypsin-EDTA solution (Sigma, 
UK) at 37°C for 5 minutes. Upon successful detachment of cells, trypsin was inactivated by 
adding FCS-containing media to the suspension. The suspension was transferred to a sterile 
centrifuge tube and centrifuged at 500 RCF for 5 minutes to pellet the cells. After 
centrifugation, supernatant was discarded, the cell pellet was re-suspended in fresh media 
and seeded accordingly. Cells were supplemented with fresh complete DMEM-F12 medium 
every 2-3 days. 
 
2.3.2  HL-1 murine atrial cell line culture 
 
 The HL-1 cell line is a proliferative murine atrial cardiomyocyte cell line first isolated by Dr 
Claycomb and his team (Claycomb et al. 1998). The HL-1 cell line has the unique ability to 
maintain a contractile cardiac phenotype upon extended culture. Hl-1 cells were originally 
derived from a precursor cardiac SV40-transformed tumour cell line known as AT-1, which 
cannot be passaged in culture but is routinely passaged in-vivo subcutaneously (Claycomb et 
al. 1998). The subcutaneous AT-1 tumours were originally excised and cells digested and 




maintains an atrial phenotype and can be serially passaged in culture. HL-1 cells were 
passaged only after reaching a confluency of 100%, observable by formation of contractile 
syncytia. Briefly, cells were washed twice with 5ml HBSS before incubation with 1X 0.025% 
trypsin-EDTA solution (0.05% trypsin in 0.02% EDTA-Na) (Sigma, UK). An equal volume of 
soybean trypsin inhibitor was added to inactivate trypsin digestion, and FCS-free and 
norepinephrine-free Claycomb medium were added to the cell suspension. The cell 
suspension was then transferred to a sterile centrifuge tube and centrifuged at 500 g for 5 
minutes to pellet the cells. The supernatant was discarded and the remaining HL-1 cell pellet 
was resuspended in complete Claycomb medium. Cells were supplemented with fresh 
complete Claycomb medium daily. 






















Claycomb medium formulation 
Total protein 261 mg/l 
 
Bovine albumin 48.85 mg/l 
 
Nonessential amino acids 0.1mM 
 
Fetuin 165 mg/l 
 
Transferrin 31.8 mg/l 
 
Retinoic acid 300 µg/l 
 
Human insulin (recombinant) 15 µg/l 
 
LONG®R3IGF-1 (recombinant) 0.1 µg/l 
 
LONG® EGF (recombinant) 0.1 µg/l 
 
Cholesterol 1.96 mg/l 
 
Linoleic acid 0.78 mg/l 
 
1-Oleoyl-2-palmitoyl-sn-glycero-3-phosphocholine 1.96 mg/l 
 
Ascorbic acid 0.3 mM 
 
Norepinephrine 100 µM 
 
L-glutamine 2 mM 
 







2.3.3 Human Induced Pluripotent Stem Cell-derived cardiomyocyte culture 
 
Throughout this project, hiPSC-CMs were sourced commercially, and used exclusively in 
combination with xCELLigence-based analysis. hIPSC-CMs were cryogenically stored under 
liquid nitrogen until use, and were therefore thawed and seeded as per manufacturer’s 
instructions prior to each experiment. Briefly, this involved quick thawing in a water bath at 
37°C. Under sterile conditions, hiPSC-CMs were then transferred dropwise to a small 
commercial Plating medium aliquot to minimise osmotic shock. The cells were counted and 
assessed for viability using the trypan blue method described in section 2.3.6, and immediately 
seeded onto an xCELLigence Cardio ECR E-plate precoated with a 0.1% gelatin solution (Stem 
Cell Technologies, Cat. No. 07903). hiPSC-CMs were subsequently incubated at 37°C and 5% 
CO2 under humidified atmosphere for 30 minutes before being transferred into the 
xCELLigence Cardio ECR cradle unit for continuous monitoring of contractility. hiPSC-CMs were 
supplemented with fresh commercial Maintenance medium daily, until stable contractility 
was attained (approximately 5 days from seeding).  
 
2.3.4 Human cardiac fibroblast culture 
 
Primary human cardiac fibroblasts were sourced from PromoCell (PromoCell, Heidelberg, 
Germany) and they were routinely cultured in DMEM-F12 medium supplemented with 10% 
FCS, 80U/ml penicillin/streptomycin and 2mM L-glutamine. Cells were passaged when 
reaching a confluency of 50%, for a maximum of 5 passages from thawing. Briefly, media was 
aspirated from the flask and cells were washed with 5ml of Hank’s Balanced Salt Solution 
(HBSS, Sigma, UK) before incubation with 0.25% trypsin-EDTA solution (Sigma, UK) at 37°C for 
5 minutes. Upon successful detachment of cells, trypsin was inactivated by adding FCS-
containing media to the suspension. The suspension was transferred to a sterile centrifuge 
tube and centrifuged at 500 RCF for 5 minutes to pellet the cells. After centrifugation, 
supernatant was discarded, the cell pellet was re-suspended in fresh media and seeded 




2.3.5 Human cardiac endothelial cell culture 
 
 Primary human cardiac endothelial cells were sourced from PromoCell (PromoCell, 
Heidelberg, Germany). ECs were routinely cultured in Endothelial Cell Growth MV medium kit 
(PromoCell), consisting of a basal growth medium supplemented with SupplementMix 
(PromoCell). Pre-mixed supplements are listed in table 2.3. Cells were passaged at sub-














Table 2-3 Cardiac endothelial cell media formulation. 
Endothelial cell medium formulation 
Basal Growth Medium MV 500 ml 
 
Fetal Calf Serum 0.05 ml / ml 
 
Endothelial Cell Growth Supplement 0.004 ml / m 
 
Epidermal Growth Factor (recombinant human) 5 ng / ml 
 
Heparin 90 μg / ml 
 





2.3.6  Assessment of cell viability and cell number determination 
 
Cell cultures were regularly inspected using bright field microscopy on a Zeiss inverted light 
instrument (AxioVert, Zeiss, Germany). Overall cell health, viability and confluency were 
monitored on a regular basis. For experimental purposes, cells were trypsinised and counted 
using either a manual Neubauer haemocytometer, or an automatic cell counter (Countess 
Automated Cell Counter, ThermoFisher Scientific, USA). To assess viability whilst counting 
cells, trypan blue dye exclusion was used. After trypsinisation, centrifugation and cell 
resuspension in fresh media, an aliquot of cells was diluted in a ratio of 1:1 (v/v) with 0.4% 
Trypan blue dye. The dyed cell suspension was counted using a haemocytometer, where non-
viable cells were identifiable due to their blue dye uptake. Viability was determined as follows: 
% 𝑐𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = 100 x (




2.3.7 Long-term cell storage 
 
All cell lines for long-term storage were stored in stocks in liquid nitrogen. Generally, confluent 
cells were trypsinised under sterile conditions, and transferred to an FCS and DMSO-based 
freezing medium formulation (medium composition 10% DMSO in FCS). The suspension was 
then transferred to a sterile cryovial and left to gradually cool within a freezing container filled 
with isopropanol, at -80°C for 24h. The vial was finally removed from the freezing container 
and stored in a liquid nitrogen tank under vapour phase. 
2.3.8  Cell stock revival 
 
Cryogenically preserved cell line stocks were regularly revived. This involved a rapid 37°C 
water bath thawing, and transfer of the thawed cell suspension to fresh supplemented media. 
Centrifugation at 500 RCF was usually performed to pellet the cells in order to discard the 
DMSO-containing freezing media residues. Cells were then resuspended in fresh 









For the formation and long-term culture of spheroids, ultra-low adhesion (ULA) 96-well round-
bottomed culture plates were used (Corning, NY, USA). All 3D cell and tissue cultures were 
routinely maintained in CO2 incubator at 37°C and 5% CO2 under humidified atmosphere. All 
culture vessels were purchased from Sarstedt, Germany, and Corning, UK. 
 
2.4.2 Monoculture spheroid seeding and culture 
 
Spheroids constructed using exclusively a single source of cardiomyocytes, and therefore 
containing only one main cell lineage, were referred to as monoculture spheroids. 
Monocluture spheroids for this thesis were constructed using cardiomyocyte cell lines, 
including the HL-1 atrial cell line and the AC10 ventricular cell line. 2D cultures were normally 
established and expanded a prior to spheroid construction. Cardiomyocytes were trypsinised 
and centrifuged at 500 RCF for 5 minutes before being counted using a manual 
haemocytometer. A number of 500 cells/100 µl complete media was added to each low-
adhesion plate well, as this quantity was previously optimised in the Sharma Lab (University 
of Liverpool) for the formation of 1 spheroid per well. The plate was briefly centrifuged at 182 
RCF for 5 minutes at room temperature to allow an even deposition of the cells towards the 
centre of the round bottomed well. The culture was subsequently left in a CO2 incubator at 
37°C and 5% CO2 under humidified atmosphere for a minimum of 48 hours to avoid any 
disruption to the early stages of spheroid formation. Spheroid formation was subsequently 









2.4.3 Triculture spheroid seeding and culture 
 
Spheroids constructed using a combination of cardiomyocytes, cardiac fibroblasts and cardiac 
endothelial cells were referred to as Triculture spheroids. For this project, triculture spheroids 
were constructed using cardiomyocyte cell lines (AC10 or HL-1), in addition to commercially 
sourced primary human cardiac fibroblasts (Promocell) and primary human cardiac 
endothelial cells (Promocell). All cell lineages were cultured in advance in regular 2D culture 
vessels as per specific protocols (described in section 2.2) until required. Cells were trypsinised 
and counted using a manual haemocytometer. A total number of 500 cells/well was 
considered optimal as established by (Ravenscroft et al. 2016), where different cell lineages 
were diluted using the proportion 1:2:4, where 1=cardiac endothelial cells, 2=cardiac 
fibroblasts and 4=cardiomyocytes. Triculture dilutions were added to ultra-low adhesion 
round-bottomed 96 well plates and spun at 182 RCF for 5 minutes at room temperature to 
allow an even deposition of the cells towards the centre of each well. The culture was 
subsequently left in a CO2 incubator at 37°C and 5% CO2 under humidified atmosphere for a 
minimum of 48 hours to avoid any disruption to the early stages of spheroid formation. 
Spheroid formation was subsequently confirmed by brightfield microscopy, and complete 
medium was changed every 72 hours thereafter. Tricultures were supplemented with 















2.5  Cell viability assays 
 
2.5.1 MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay 
 
MTT is a colourimetric assay used to assess cell viability. This assay relies on the conversion of 
MTT into purple formazan crystals by mitochondrial reductases in viable cells; these crystals 
are subsequently dissolved and can be quantified by measuring the absorbance of the 
resulting solution. The amount of solubilised product correlates with the number of viable 
cells. Typically, cells were seeded onto 96-well flat-bottomed plates and treated with the 
required compounds prior to the experiment (typically for 24 hour or 96 hours unless 
otherwise specified). Media was then removed from the culture plate, and 5mg/ml MTT in 
dH2O diluted 1:10 in cell medium was added in equal quantity (100µl) to each well. After a 4 
hour incubation at 37°C and 5% CO2 under humidified atmosphere, the MTT/medium was 
discarded. The remaining formazan crystals were solubilised using DMSO, and absorbance was 
measured at 550nm. Cell viability was calculated as a percentage relative to control. 
 
2.5.2 ATP Cell Titre Glo 2.0 and Cell Titre Glo 3D assays 
 
Cell Titre-glo assays (Promega, USA) are luminescent assays used to assess cell viability. These 
assays rely on the mono-oxygenation of luciferin by luciferase in the presence of adenosine 
triphosphate (ATP) in viable cells, which generates luminescence quantifiable by luminometry. 
Luminescence intensity therefore correlates with the number of viable cells. For two-
dimensional cell monolayers, Cell Titre-glo 2.0 (Promega, USA) was used. For three-
dimensional spheroid cultures, cell Titre-glo 3D was used (Promega, USA). Cells or spheroids 
were seeded onto 96-well plates (flat bottom for 2D, and ULA for 3D spheroids according to 
protocols described in section 2.3 and 2.4 respectively), and exposed to the compound of 
interest (typically for 24 or 96 hours unless otherwise specified). The plates were left to 
equilibrate at room temperature for 30 minutes prior to the addition of cell Titre-glo reagent. 
An equal amount of cell Titre-glo reagent was therefore added to each well, and mixed by 




cell lysate was transferred to a white polystyrene plate suitable for measurement of 
luminescence (Fisher Scientific, UK), and measured on a luminometer (Thermo Fisher 

























2.6 Live-cell metabolic assays: Seahorse XF analysis 
 
Live-cell metabolic assays were performed using a Seahorse XFe96 instrument (Agilent, Santa 
Clara, USA). The Seahorse instrument was used to measure oxygen consumption rates (OCR) 
and extracellular acidification rates (ECAR) in live cells to give an indication of mitochondrial 
activity, respiration and glycolysis.  
Mitochondrial stress tests were performed using Seahorse XF Mito Stress Test kits (Agilent, 
USA), and were used to assess mitochondrial activity and respiration in the cells of interest. 
The method relies on the use of electron transport chain-specific modulators (ETC), including 
oligomycin, carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP), rotenone and 
antimycin A. The experimental principles are illustrated in figure 2.1.  
A fresh XF sensor cartridge was rehydrated using Seahorse XF calibrant solution 24 before the 
start of each experiment, and left to incubate at 37°C in a non- CO2 incubator. Cells were plated 
directly in a Seahorse XF microplate according to individual experimental needs. Prior to the 
start of the Mito stress test, cells were washed twice in Seahorse assay medium (pH 7.4, 5.5 
mM glucose, 1mM pyruvate, 2mM l-glutamine, Seahorse XF base medium). 180µl assay 
medium were added to each microplate well and incubated at 37°C in non- CO2 incubator for 
1 hour prior to analysis. Following cartridge rehydration, ETC modulators and other 
compounds of interest were loaded into the injection ports into the cartridge in a specific 
order, as illustrated in table 2.3. The cartridge was then loaded in the Seahorse XF analyser for 
calibration before the addition of the microplate containing cells. Based on the required 



















Compound Injection port 
Concentration 




Chemical of interest A Various Various 
Oligomycin B 10 1 
FCCP C 50 5 
Rotenone/Antimycin 
A 
D 30 3 
Figure 2.2 Figure 2.1 Principles of a Mito Stress test using Seahorse XF analysers (adapted from 
Agilent, Mito stress test). Illustration of the parameters assessed throughout the test 





2.7  Impedance-based real time cell analysis 
 
Impedance-based cell analysers were used to monitor different cellular parameters, including 
cell viability, cell morphology and contractility over time, in real-time. The instruments used 
for impedance-based analysis were the xCELLigence DP16 instrument (ACEA Biosciences, 
Agilent, San Diego, USA) for the assessment of non-contractile cell models, the xCELLigence 
Cardio and Cardio ECR instruments (ACEA Biosciences, Agilent, San Diego, USA) for the 
assessment of contractile cell models. 
Impedance-based cellular monitoring is a non-invasive technology that relies on the use of 
special electrode-coated cell culture vessels and microtiter plates (E-Plates, ACEA Biosciences, 
USA), and the application of a non-invasive electric potential. The presence of adherent cells 
actively impedes the electron flow, and therefore the generated impedance is quantified and 
correlated with high sensitivity to the presence, adherence, size and morphology of the cells 
(Figure 2.2, Agilent, USA). The recorded impedance measurements are reported using the 
unitless variable Cell Index (CI), where  
𝐶𝐼 =





Figure 2.2 Principles of impedance-based cellular analysis (adapted from 




A more detailed overview of how a typical xCELLigence trace is generated is represented in 
figure 2.3. Prior to cell seeding the CI is close to a value of 0. As cells are seeded onto the E-
plate electrodes, the CI gradually increases in value reflecting cell adhesion, and cell growth 
kinetics in the case of proliferative cells. Typically, the CI reaches a plateau stage once all non-
proliferative cells are adhered, or, in the case of proliferative cells, once all cells have achieved 
a stationary phase. The dynamic monitoring of the cells allows to detect alterations to 
impedance throughout the experiment, therefore compounds and cytotoxic agents can be 
added at any experimental time point. For most studies in this thesis, cytotoxic compounds 
and drugs were added at plateau phase. Decrease of CI value reflects cell detachment from  
the electrodes or modifications in terms of cell size and/or morphology. 
 
Figure 2.3 Principles of xCELLigence impedance-based data acquisition. Impedance 
measurements are plotted as y=Cell Index over x=time. Cell Index values reflect cell growth, 




2.7.1  Overview and workflow of xCELLigence DP16 instrument 
 
The xCELLigence DP (Dual Purpose) instrument was used to monitor adherent non-contractile 
cells (Table 2.5). The typical experimental workflow was based on manufacturer’s instructions 
(ACEA Biosciences, USA) and was adapted in accordance with specific experimental needs.  
Briefly, a DP16 electrode-coated E-plate was selected and, if required, pre-coated with the 
desired agents (a list of precoating agents is illustrated in table 2.5). Experimental medium 
was added to the plate wells and a background scan was performed prior to cell seeding. The 
required amount of cells was added to the E-plate according to the appropriate experimental 
protocol and incubated at room temperature in the laminar flow hood for 30 minutes to allow 
even deposition of the cells onto the electrode surface. The E-plate was subsequently placed 
into the xCELLigence instrument cradle situated in a CO2 incubator at 37°C and 5% CO2 under 
humidified atmosphere. Duration and frequency of impedance recordings (sweeps) were 

















2.7.2 Overview and workflow of xCELLigence Cardio instrument 
 
The xCELLigence Cardio instrument was used to monitor adherent contractile cells (Table 2.5). 
As well as recording overall cell generated impedance values as described in section 2.5.1, the 
Cardio instrument is designed to detect rapid changes in impedance, such as those resulting 
from physical movement of the cells on the electrode surface. Specifically, data acquisition 
occurs at a rate of 12.9ms for contractility parameters (ACEA Biosciences, Agilent, USA). The 
typical experimental workflow depended on the origin of the cells used, but was essentially 
based on manufacturer’s instructions (ACEA Biosciences, USA). Briefly, this involved pre-
coating of a Cardio E-plate with a suitable matrix (pre-coating information for each cell model 
is in table 2.5). Experimental medium was added to the plate wells and left to achieve 
equilibrium at room temperature under laminar flow hood. Prior to cell seeding, a background 
scan was performed. Depending on the cardiomyocyte origin (i.e., hiPSC-CM, cell lines etc.) 
cells were either thawed prior to seeding or trypsinised, and subsequently counted using 
trypan blue exclusion technique on a manual haemocytometer. Cells were seeded onto the 
cardio E-plate at the desired density and left to incubate at room temperature under laminar 
flow hood for 30 minutes to allow even deposition of the cells onto the electrode surface. The 
E-plate was then inserted in the Cardio system cradle situated in a CO2 incubator at 37°C and 
5% CO2 under humidified atmosphere. Duration and frequency of impedance recordings 
(sweeps) were selected and modified using xCELLigence RTCA Cardio software version 1.2. 
Cardiomyocyte medium was changed based on the specific cardiomyocyte model needs, 
ranging from 12 to 48 hourly media changes on average. Media changes were usually 
performed in a 4-step process, ensuring the electrodes in the E-plate wells never remained 
dry. Prior to compound addition, baseline contractility parameters were recorded to exclude 
intrinsic beat rate irregularities 
The xCELLigence Cardio-generated impedance waveform was analysed for two parameters: 
beat rate and beat amplitude (Figure 2.5). These parameters were used to define the 
characteristics of contractile myocytes. Beat rate was calculated as the number of positive 
peaks per minute. Beat rate changes were double-normalised (∆∆) to baseline and vehicle 
control and are expressed as percentage change, with baseline values being 100%. Beat 




positive peak, and are expressed as a percentage change, double-normalised to baseline and 
vehicle control. 
Impedance values were exported using the RTCA Cardio ECR software (Beta), and parameters 
were subsequently analysed as follows: 
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑎𝑡𝑖𝑜𝑛 𝑡𝑜 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 (∆%)
= (𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝐼𝑚𝑝𝑒𝑑𝑎𝑛𝑐𝑒 𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝐼𝑚𝑝𝑒𝑑𝑎𝑛𝑐𝑒⁄ )𝑥100 
𝐷𝑜𝑢𝑏𝑙𝑒 𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑎𝑡𝑖𝑜𝑛 𝑡𝑜 𝑣𝑒ℎ𝑖𝑐𝑙𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 (∆∆%)









Figure 2.4: xCELLigence Cardio system impedance trace of cardiac cell contractility. Each 
beating corresponds to the excitation-contraction coupling of cardiomyocytes. These beats 
are defined as a sequence of positive peaks and negative peaks (+P and –P as labelled). 
Impedance beat rate was analysed based on the total number of positive peaks in one minute. 
Impedance beat amplitude analysis was performed on Whole Peak (WP) counts, from each 




2.7.3  Overview and workflow of xCELLigence Cardio ECR instrument 
 
The xCELLigence Cardio ECR instrument (ACEA Biosciences Agilent, USA) was used to monitor 
hiPSC-CMs. This instrument is designed to combine the previously described xCELLigence 
Cardio impedance technology (section 2.6.2) with multielectrode array (MEA) technology to 
assess electrophysiological cell properties. The xCELLigence Cardio ECR instrument has a faster 
impedance data acquisition rate of 1 millisecond compared to the 12.9 milliseconds achieved 
with the xCELLigence Cardio instrument, which allows for an extremely sensitive detection of 
dynamic changes in cell behaviour. In addition to the impedance data acquisition, the ECR 
Cardio instrument simultaneously acquires electrophysiology measurements which allow to 
assess parameters such as spike amplitude and field potential duration (FPD). The typical 
experimental workflow was essentially similar to the xCELLigence Cardio instrument protocol, 
and was based on manufacturer’s instructions. Briefly, hiPSC-CMs were thawed and counted 
before being seeded onto a fibronectin-coated Cardio ECR E-plate (ACEA). The Cardio ECR E-
plate had a 48-well capacity, where each well included a flat surface lined with impedance 
electrodes, and two electrodes for electrophysiology data acquisition. Cells were seeded onto 
the cardio E-plate at a density of 30,000 cells/well and left to incubate at room temperature 
under laminar flow hood for 30 minutes to allow even deposition of the cells onto the 
electrode surface. The E-plate was then inserted in the Cardio ECR system cradle situated in a 
CO2 incubator at 37°C and 5% CO2 under humidified atmosphere. Duration and frequency of 
impedance recordings (sweeps) were selected and modified using xCELLigence RTCA Cardio 
ECR software (Beta). Prior to compound addition, baseline contractility parameters were 
recorded to exclude intrinsic beat rate irregularities. 
Data generated with the xCELLigence Cardio ECR system was analysed for the impedance 
parameters described in section 2.7.1 and 2.7.2, including CI variations, beat rate (BR) and 
beat amplitude (BA). Additionally, electrophysiological parameters were analysed and 








Specifically, FPD was calculated from FP baseline to FP wave end, and was corrected for beat 








• FPDc= corrected Field Potential Duration 
• FPD= non-corrected Field Potential Duration 
• RR= Interval between two FP- peaks 
Step-by-step FPDc analysis: 
• Obtained raw FPD data values from RTCA software 




 to obtain beat period interval as BP/1s 












Spike amplitude defines the voltage (mV) difference between each FP+ positive and FP- peak, 
and this parameter was double-normalised to baseline and vehicle control, and is expressed 
as a percentage change. 
All xCELLigence raw data analysis was carried out using RTCA software (ACEA Bioscience 
Agilent, San Diego, CA). Statistical analysis was done using GraphPad Prism (GraphPad 
Software, San Diego, CA), Microsoft Excel (Microsoft, Washington, USA) and Visual Studio 










Figure 2.5. xCELLigence Cardio ECR system dual impedance/multi electrode array 
technology measurements. A. CI impedance is monitored in real-time, along with dynamic 
monitoring of cell contractility and electrical activity.B. ECR measurements including spike 









































CI Not required 
Table 2-5 Cardiac cell models appraised in this thesis used in combination with impedance-
based analysers. Analysed parameters included cell index (CI), beat rate (BR), impedance beat 


















2.8 Protein analysis assays 
 
2.8.1 Preparation of cell protein extracts 
 
Cells were harvested for protein at exponential or plateau phase according to experimental 
needs. Media was aspirated and discarded from the culture vessel and cell monolayers were 
rinsed twice with 1-5ml of sterile PBS. Cells were scraped directly into 250 μl of Tris-Triton lysis 
buffer (50mM Tris Cl, 1mM EGTA, 1mM EDTA, 1mM sodium orthovanadate, 10mM β-glycerol 
phosphate, 50mM sodium fluoride, 5mM sodium pyrophosphate, 0.27M sucrose, 1% triton 
x100) and transferred into a clean microcentrifuge tube. Samples were centrifuged at 1300 
rpm for 10 minutes at 4°C. Pelleted samples were kept on ice throughout the sample 
preparation process or kept at -20°C for long-term storage.  
 
2.8.2 Bradford protein assay 
 
Cell lysate total protein was quantified using the Bradford assay. Bovine serum albumin was 
used to make a set of known protein standards ranging from 0 μg/ml to 1000 μg/ml in sterile 
PCR-grade water. After centrifugation, the supernatant obtained from the cell lysates was 
transferred to a clean microcentrifuge tube.  For the Bradford assay, an amount of unknown 
sample was diluted 1:20 in sterile PCR-grade water. 10 μl of known BSA standards and 
unknown diluted sample were added in triplicates into the wells of a clean 96-well flat-
bottomed plate (Sarstedt, Germany). Bradford reagent (Bio-Rad, UK) was added to each well 
and incubated at room temperature for 5 minutes to allow development of the colour-
changing reaction. Absorbance was measured at 595 nm using a plate reader (Thermo Fisher 
Scientific, MA. USA). A standard curve was plotted from the absorbance values of the BSA 







2.8.3  Sodium-dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Sodium-dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is a technique that 
allows to separate and identify proteins by molecular weight. After purification and 
quantification, extracted proteins were processed to undergo denaturation by addition of a 
thiol-reducing agent, such as 2-mercaptoethanol or dithiothreitol (DTT) that allow to break S-
S bonds, and by heating to allow disruption of hydrogen bonds. The denatured proteins were 
then loaded onto a polyacrylamide gel matrix submerged in a running buffer solution (2.5M 
Trizma base, 1.9M glycine, 1%SDS, pH 8.3), and a voltage potential was applied at 100V 
promoting the migration of the negatively charged proteins through the gel towards the 
positively charged anode. Polyacrylamide gel composition was altered in accordance with the 
molecular mass of the protein of interest. The smaller the size of the protein of interest, the 
higher the gel percentage.  
Gels were cast between glass plates using casting trays (Bio-Rad, UK). The separation gel was 
prepared by mixing dH2O, 30% acrylamide solution (Bio-Rad, UK), 1.5M Tris (pH 8.8), 10% SDS, 
10% ammonium persulfate and 0.5% tetramethylethylenediamine (TEMED).  For most 
experiments, a polyacrylamide gel of 10% was used for the protein separation. A stacking 
polyacrylamide 5% gel layer was used to form the wells for protein loading, and to ensure an 
even alignment of proteins prior to protein separation stage. 
Before loading, proteins were diluted to 1-2µg/µl in a reducing sample buffer (dH2O, 0.5M 










2.8.4  Electrotransfer of proteins 
 
After separation, proteins were transferred onto a positively charged polyvinylidene (PVDF) 
membrane (GE Healthcare Life Science, UK). Polyacrylamide gels were removed from the 
electrophoresis apparatus and left to briefly equilibrate in 4°C cooled transfer buffer solution 
(dH2O, 25mM Tris base, 192mM glycine, 20% v/v methanol) prior to being assembled onto 
PVDF for protein transfer. A schematic overview of transfer gel-PVDF set up is summarised in 
figure 2.6.  
 
The assembled membrane/gel stack was placed in an electrotransfer apparatus (Bio-Rad, UK), 
and protein transfer was carried out at constant 300mA for 1 hour on wet ice. After the 
transfer, PVDF membranes were blocked for non-specific binding in 5% skimmed milk in TBS-
T (20mM Trizma base, 150mM NaCl, 0.1% Tween-20 detergent w/v) for 1 hour at room 
temperature. 
Blocked membranes were therefore incubated with the appropriate primary antibody 
overnight at 4°C. Next, after removal of primary antibody by three consecutive washes in TBS-
T, membranes were incubated with the relevant secondary horseradish peroxidase (HRP) 
conjugated antibody for 1 hour at room temperature. A list of primary and secondary 




Figure 2.6. Transfer stack assembly used for protein migration from polyacrylamide gel to 




2.8.5 Protein immunodetection 
 
A luminol-based substrate (enhanced chemiluminescence solution, ECL) (ECL1: 2.5mM 
luminol, 0.4mM p-coumaric acid, 100mM Tris HCL pH 8.5; ECL2: Hydrogen peroxide 30% v/v, 
100mM Tris HCL pH 8.5) was used to detect proteins on PVDF membranes. 1 ml of each ECL 
reagent was mixed and added to the membrane prior to immunodetection, and incubated for 
3 minutes under dark conditions at room temperature. Proteins were visualised using a Bio-
Rad ChemiDoc membrane imager (Bio-Rad, UK), where chemiluminescence image acquisition 
































Secondary HRP conjugated antibody 




     








2.9 Multiplex ELISA Immunoassay 
 
Quantification of free cardiac troponin I (cTnI) in culture media was done using a multiplex 
MSD ELISA kit (Meso Scale Diagnostics LLC, USA) as per manufacturer’s instructions. Briefly, a 
96 well plate was pre-coated with a specific biotinylated capture antibody solution 24 hours 
prior to each experiment. Aliquots of assay diluent solution, desired samples and a set of 
known calibrator controls were added to the plate, subsequently sealed and incubated at 
room temperature for 1 hour. Next, the plate was washed with an MSD supplied wash buffer, 
and aliquots of detection antibody solution were added. Antibody incubation was done at 
room temperature with shaking for 1 hour. Following washing with 1X MSD wash buffer, 
aliquots of MSD GOLD Read buffer were applied to each well prior to immunodetection using 























2.10  Spheroid imaging and immunocytochemistry 
 
To examine their internal structure and cellular organisation, spheroids were imaged using 
immunocytochemistry, a technique which allows to locate specific antigens/proteins in fixed 
tissues using targeted fluorophore-conjugated antibodies or fluorescent stains.  
 
2.10.1 Spheroid fixation, permeabilisation and staining  
 
Following media removal, cultured spheroids were washed three times with PBS before being 
fixed with 4% paraformaldehyde (PFA) (pH 7.2) for 1 hour at 4°C. After fixation, spheroids 
underwent permeabilisation to allow subsequent efficient stain/antibody penetration 
through the tissue. 100 µl permeabilisation buffer (PBS containing 0.5 v/v Tween 20, 0.2% v/v 
Triton X-100) were added and spheroids were incubated at 4°C overnight. After removal of 
permeabilisation buffer, spheroids were blocked for nonspecific binding using bovine serum 
albumin (BSA) for 2 hours at room temperature, and then incubated with a primary antibody 
solution overnight at 4°C (primary antibodies with respective dilutions used are illustrated in 
table X). Spheroids were therefore washed with an immunofluorescence wash buffer (PBS 
containing 0.1% Tween, 0.2% Triton-X 100) three times, each time left for 1 hour at room 
temperature. Next, spheroids were incubated with relevant secondary antibodies conjugated 
with fluorescent components as well as specific stains to highlight selected spheroid 
structures (relevant antibodies and stains used are illustrated in table 2.7), with incubation 































2.10.2 Spheroid mounting 
 
To allow immunofluorescence visualisation, spheroids underwent mounting onto microscope 
slides as follows. After washing with 1X PBS for 1 hour at room temperature, spheroids were 
transferred to a Superfrost microscope slide, and subsequently covered with 10 µl Prolong 
Gold Antifade Mountant solution. A glass coverslip was then carefully positioned over the 
slide, and sealed using clear nail polish. Slides were left to dry under dark conditions for 30 
minutes at room temperature, and subsequently stored at 4°C until bioimaging acquisition. 
 










Secondary conjugated antibody 
Anti-rabbit 
Alexa Fluor 488 
Goat polyclonal 1:1000 Thermo Fisher 
    
Anti-rabbit 
Alexa Fluor 568 
Goat polyclonal 1:1000 Thermo Fisher 
Stain 
Phalloidin n/a 1:250 Sigma Aldrich 
Hoechst n/a 1:5000 Sigma Aldrich 





2.10.3 Spheroid fluorescence bioimaging 
 
Spheroids were imaged using a Zeiss AxioObserver (Zeiss, Germany) inverted fluorescence 
microscope with Apotome platform, and acquired using Zeiss Zen software. To attain an 
accurate visualisation of 3D structures, images were acquired using a z-stack approach and 
visualised as maximum intensity projections (figure 2.8). To enable subsequent image analysis 
and signal intensity comparisons between spheroid subsets, images were acquired at equal 









Figure 2.7 Z-stack image acquisition of 3D structures. 3D spheroids were imaged using a Zeiss 
AxioObserver inverted fluorescence microscope with apotome platform. The visualisation of 
internal spheroid structures occurred through the acquisition of image slices (z-stacks), 
subsequently combined into maximum intensity projection images. A. User interface for z- 
stack image acquisition on Zen software where number of slices, range, interval and position 
parameters were set (Zeiss, Germany). B. Principle of z-stack image composition (adapted 





2.11  Statistical analysis 
 
Where required, statistical analysis was applied using a software combination that included 
Microsoft Office Excel (Microsoft, USA), Graph Pad Prism (Graph Pad Software, USA) and 
Visual Studio (Microsoft, USA) written with Python. 
For comparison of group means, the Shapiro-Wilk test was performed to ascertain normal 
distribution of samples. The appropriate tests were then applied for comparative purposes. 
For comparisons of multiple means that did not violate normality assumptions, the parametric 
one way or two-way analysis of variance (ANOVA) tests were applied as necessary, following 
appropriate post hoc modifications which included Bonferroni’s modification and Dunnett’s 
modification.  
For group means that rejected the normal distribution hypothesis, appropriate non-
parametric tests were applied. 
Where required, confidence intervals are provided in lieu of p values to quantify the 

















3 Characterisation and validation of hiPSC-CMs for in-vitro 






























Over the last few decades, cardiac drug safety in preclinical settings has been cantered on the 
evaluation of acute electrophysiological alterations, primarily in relation to hERG inhibition 
and detection of cardiac dysfunctions translatable to proarrhythmic risk (Gintant, Sager, and 
Stockbridge 2016b). Typically, preclinical drug development involves a set of standardised 
assessments that are streamlined to provide critical safety evaluations in the early drug 
development project stages. These evaluations have been optimised to minimise hazard, and 
rely on in-silico and in-vitro approaches: the results derived from early-stage evaluations thus 
offer an improved tool to design subsequent preclinical evaluations, including in-vivo and ICH 
regulatory-compliant studies (Https://www.ich.org/ 2020; E14/S7B 2005; 2020). 
The advent of pluripotent stem cell-derived technology has, under many aspects, 
revolutionised in-vitro organ modelling and preclinical research. Decades of ground-breaking 
research have provided crucial breakthroughs for the understanding of the molecular basis of 
hiPSC-to-cardiomyocyte re-differentiation (del Álamo et al. 2016). Recent hiPSC-CM 
differentiation protocols were optimised and developed to produce cell lineages yielding as 
much as 90-95% pure, highly enriched cardiomyocytes, which are now more commonly 
available on the market and commercialised by several bio-companies (del Álamo et al. 2016; 
Koivumäki et al. 2018). The commercial availability combined with the increasing number of 
studies and recent publications has incentivised the use of hiPSC-CM-based models in 
preclinical drug safety studies (Cavero and Holzgrefe 2015). A review conducted in 2015 by 
the National Centre for the Replacement, Refinement and Reduction of Animals in Research 
(NC3Rs) among the global safety community, including EFPIA, BTS, BPS and EuroTox, showed 
that a significant proportion of respondents currently use human-derived assays for safety 
screening studies (Holmes, Bonner, and Jones 2015). More remarkably, a large proportion of 
participants expressed their interest and intention to implement and use human tissue-based 
assays in the future. It is therefore not surprising that new iPSC technologies represent an 
enormous potential for early-stage drug discovery and toxicology. Despite the well-
documented limitations of hiPSC-CMs, particularly in relation to their functionally immature 
phenotype (Koivumäki et al. 2018; Knollmann 2013), these models have been extensively 




evaluation of cardiotoxicity; in this context, they are considered the most advantageous in-
vitro model and they demonstrated adequate utility for acute functional studies, and 
identification of highly torsadogenic compounds (Blinova et al. 2018). One of the key aspects 
for the integration of novel in-vitro technologies in preclinical setting is strictly attributed to 
the introduction of the CiPA initiative (discussed in section 1.4)(“Https://Cipaproject.Org/” 
n.d.). Introduced with the intention to improve, refine and enhance current ICH S7B guidelines 
for the assessment of preclinical cardiotoxicity, the CiPA paradigm has invested on the 
development of in-vitro strategies, including the validation and implementation of hiPSC-CM-
based platforms. Specifically, the in-vitro CiPA component aims at the investigation of 
electrophysiological effects using ventricular hiPSC-CMs (Cavero and Holzgrefe 2015). The 
understanding of the strengths and limitations of hiPSC-CM-based models is therefore critical 
for the successful identification of potential model-specific fallacies that could ultimately 
hinder early-stage predictability of adverse drug events. Not least importantly, the assessment 
of model-specific drawbacks also justifies opportunities for the integration and assessment of 














3.1.1 Chapter aims and objectives 
 
This chapter aims to assess commercially sourced hiPSC-CMs for their ability to detect 
functional and structural cardiotoxicity for nonclinical studies using xCELLigence ECR systems. 
In particular, validation and limitation studies of this model are presented through the 
following objectives: 
 
1) Appraisal of the advantages and limitations of hiPSC-CMs screened against a panel of 
known functional and structural cardioactive compounds. 
a) Assessment of impedance and electrophysiological parameters including Cell Index 
(CI), Beat Rate (BR), impedance Beat Amplitude (BA), Spike Amplitude (SA), corrected 
Field Potential Duration (FPDc). 
b) Evaluation of instrument and method detection limits, and their implications on the 
detection of cardiotoxicity. 
2) Detection of proarrhythmic events and structural cardiotoxicity associated with the HDACi 
class of drugs. 
a) Assessment of impedance and electrophysiological parameters in response to pan-
HDACi, evaluating Cell Index (CI), Beat Rate (BR), impedance Beat Amplitude (BA), 
Spike Amplitude (SA), corrected Field Potential Duration (FPDc). 
b) Assessment of impedance and electrophysiological parameters in response to 












3.2  Characterisation of hiPSC-CMs for studies of cardiotoxicity using 
xCELLigence systems 
 
Commercially sourced hiPSC-CMs iCELL2 (Fujifilm Cellular Dynamics International, Madison, 
USA) were thawed and plated on a fibronectin-coated Cardio ECR E-plates as described in the 
methods section 2.7.3, essentially based on manufacturer’s protocols. Post seeding, cells were 
monitored for viability and early contractility every 2 hours on the xCELLigence Cardio ECR 
instrument for the first 72 hours, and every hour thereafter. Spontaneous hiPSC-CM activity 
was recorded and assessed for each batch in order to detect and exclude wells displaying 
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Individual multi-elecdrode E-plate wells
Figure 3.1 Assessment of spontaneous contractility iCELL2 hIPSC-CMs following 
cryopreservation and revival recorded no significant beat rhythm irregularities (BRI) 5 days 
post seeding. Data is shown as ratio representing beat-to-beat variation recorded at baseline, 
where a value of < 0.1 for each E-plate well is indicative of no BRI. Data is representative of 





In order to validate different batches of hiPSC-CMs, for each experiment the cells were 
screened against a panel of compounds with known and well-defined cardioactive effects 
(Table 3.1). Analysed parameters included CI variations, beat rate, cell index (impedance) beat 
amplitude, spike amplitude and field potential duration. All parameters were determined and 
analysed as described in methods section 2.7. 
 
3.2.1 hiPSC-CMs demonstrate inconsistencies in response to known cardioactive 
agents 
 
Isoproterenol is an adrenoceptor agonist, which acts as a short-acting positive chronotrope 
without direct ion channel interaction, and selectively targets the β1 and β2 cardiac receptors. 
In this study, isoproterenol induced an expected transient increase in beat rate, with the 
highest peak resulting in a 40% beat rate increase 30 minutes post compound addition 
(p<0.001). Following the 30 minute time point post compound addition, beat rate showed a 
gradual decrease by 40% over 48 hours essentially returning to baseline values. Sodium spike 
amplitude was gradually increased with a maximum increase of 35% at 12 hours post 
compound addition, with a confidence interval of the mean (135%) [86.2% - 152%] for a 95% 
confidence level. The beat amplitude and cell viability were not affected and remained stable 
as expected. (Figures 3.3, 3.4). 
Dofetilide blocks the α subunit of the delayed rectifier outward potassium current (Ikr), and is 
therefore classed as a hERG channel inhibitor. Dofetilide generally shows successful inhibitory 
activity at concentrations even in the nanomolar range, where the occurrence of early 
afterdepolarisation (EAD) and torsadogenic events that would render ineffectual data analysis 
is usually averted. In this study, dofetilide induced an expected significant and gradual 
decrease in beat rate, decreasing by 30% 30 minutes post compound addition, and resulting 
in a maximum 40% decrease 48 hours post compound addition. Beat amplitude was 
transiently affected with a 10 to 20% decrease in the first 24 hours post compound addition 
(Figure 3.5). A partial decrease in spike amplitude was detected, albeit showing considerable 
dispersion as reflected in the relevant SD values, with a confidence interval of the mean at 12 




expected prolongation in FPD and FPDc, with marked T wave shifting and a reduction in 
repolarisation peak amplitude compared to baseline and vehicle control traces (Figure 3.6). 
Due to dofetilide being a well-established FPD altering compound, an in-depth analysis was 
carried out to assess FPD/FPDc parameters, comparing two different beat rate correction 
formulas to record any relevant differences. Interestingly, when FPD/FPDc parameters were 
corrected using the commonly accepted Frederica’s formula, FPDc resulted in a higher change 
achieving a 20% prolongation, compared to the lower 14% prolongation achieved using 
Bazett’s correction formula. This suggests that Frederica’s correction could result in an 
overcorrection or miscorrection of FPD values (Figure 3.7). 
Verapamil is an L-type calcium channel blocker with a relatively short-acting binding effect on 
the Cav1.2 calcium channel subunit, and as such it normally displays a negative inotropic 
activity resulting from the reduced calcium influx that propagates the AP signal in the heart. 
However, contrary to what expected, in this study verapamil induced a transient increase in 
beat rate, with a significant increase peak of 70% 30 minutes post compound addition. CI beat 
amplitude showed a mirrored transient percentage decrease, with the lowest values recorded 
as a 60% decrease 30 minutes post compound addition. Verapamil induced detectable 
variations in sodium spike amplitude. However, the confidence interval of the mean (145%) 
at 24h post compound addition is [32.4% – 256.9%] for a 95% confidence level, suggesting 
that any observed changes in spike amplitude are not deemed as necessarily significant in this 
case (Figures 3.8 and 3.9).  
Doxorubicin is a cytotoxic anthracycline, and it is a well-established structural and functional 
cardiotoxicant. The known acute effects of doxorubicin include drug-induced cytotoxicity, 
depression of myocardial contractility, tachycardia, decreases in QRS complex and QT 
prolongation. As expected, doxorubicin induced a significant (p<0.001) decrease in CI 6 hours 
post compound addition indicating potential loss of cell viability or structural toxicity. 
Doxorubicin induced an expected significant (p<0.001) increase in beat rate 12 hours post 
compound addition, increasing by a further 44% by 48 hours post compound addition. CI beat 
amplitude was temporarily increased by 20 % 6 hours post compound addition before showing 
a decreasing trend 24 hours post compound addition, reaching an overall maximum decrease 
of 70% after 48 hours. Sodium spike amplitude was gradually decreased, resulting in an 80% 






Figure 3.2.  Known cardioactive agent effects in hiPSC-CMs vs expected physiological effects 
detected using impedance-based technology. hiPSC-CMs iCELL2 were screened against a 
panel of known cardioactive agents on the xCELLigence Cardio ECR system. The table shows 
expected drug-induced effects vs detected effects on multiple parameters. Analysed 
parameters are: Cell Index (CI), Beat Rate (BR), Cell Index Beat Amplitude (BA), Spike 
Amplitude (SA), corrected Field Potential Duration (FPDc). All parameters in this table are 















BR↑ BA↑ SA↑ BR↑ BA- SA↑ 
Dofetilide Potassium channel 
blocker 
BR↓ SA↓ FPDc↑ BR↓ SA↓ FPDc↑ 
Verapamil Calcium channel 
blocker 
BR↓ BA↓ FPDc↓SA↓ BR↑ BA↓ SA↑ 
Doxorubicin Structural 
cardiotoxicant 
CI↓ BR↑ BA↓ SA↓ 
FPDc↑ 










































































Figure 3.3. Isoproterenol induces transient contractile changes in hiPSC-CMs. hiPSC-CMs 
iCELL2 were exposed to 20nM Isoproterenol for 48h in the Cardio ECR system. Isoproterenol 
did not affect cell viability and CI amplitude, but temporarily increased beat rate by 40%. Data 
are the average ± SD of at least 3 separate determinations, and are normalised to baseline and 










































































∆∆ FPDc % Change
Isoproterenol
20nM
Figure 3.4  Isoproterenol induces transient electrophysiological changes in hiPSC-CMs. 
hiPSC-CMs iCELL2 were exposed to 20nM Isoproterenol for 48h in the Cardio ECR system. 
Isoproterenol temporarily increased sodium spike amplitude by 20%. Isoproterenol induced 
transient non-significant FPDc shortening by 8% within 30 minutes post compound addition. 
Data shown for FPDc are corrected for beat rate using Fridericia’s formula. Data are the 
average ± SD of at least 3 separate determinations, and are normalised to baseline and DMSO 
















































































Figure 3.5. Dofetilide induces detectable contractile changes in hiPSC-CMs. hiPSC-CMs 
iCELL2 were exposed to 6nM Dofetilide for 48h in the Cardio ECR system. Dofetilide did not 
affect cell viability. Beat rate was gradually decreased by 40% at 48h. CI amplitude resulted in 
a 10 to 20% transient decrease. Data are the average ± SD of at least 3 separate 







































































Figure 3.6 Dofetilide induces detectable electrophysiological changes in hiPSC-CMs. hiPSC-
CMs iCELL2 were exposed to 6nM Dofetilide for 48h in the Cardio ECR system. Spike amplitude 
was decreased at 24h and 48h, albeit with high dispersion. Dofetilide induced FPDc 
prolongation by 20% within 48h post compound addition. Data shown for FPDc are corrected 
for beat rate using Fridericia’s formula. Data are the average ± SD of at least 3 separate 






































































∆∆ FPDc % Change Bazett's
Dofetilide 6nM
Figure 3.7. Fredericia’s correction formula can result in overcorrection of FPDc 
parameters in hiPSC-CMs. hiPSC-CMs iCELL2 were exposed to 6nM Dofetilide for 48h in 
the Cardio ECR system. Data shown for FPDc are corrected for beat rate using Fridericia’s 
formula and Bazett’s formula, and are the average ± SD of at least 3 separate 
determinations, normalised to baseline and vehicle control. Data shown for FPD are not 
corrected for beat rate, and are the average ± SD of at least 3 separate determinations, 
normalised to baseline and vehicle control. Tested by ANOVA followed by Dunnet’s post-
































































































Figure 3.8. Verapamil induces transient contractile changes in hiPSC-CMs. hiPSC-CMs iCELL2 
were exposed to 0.2µM Verapamil for 48h in the Cardio ECR system. Verapamil did not affect 
cell viability, but increased beat rate by 60% whilst simultaneously decreased CI amplitude by 
60%, in a mirrored manner. Data are the average ± SD of at least 3 separate determinations, 









































































∆∆ FPDc % change
Verapamil 200nM
Figure 3.9 Verapamil induces transient electrophysiological changes in hiPSC-CMs. hiPSC-
CMs iCELL2 were exposed to 0.2µM Verapamil for 48h in the Cardio ECR system. Data shown 
for FPDc are corrected for beat rate using Fredericia’s formula. Data are the average ± SD of at 

















































































Figure 3.10. Doxorubicin induces permanent contractile changes in hiPSC-CMs. hiPSC-CMs 
iCELL2 were exposed to 1µM Doxorubicin for 48h in the Cardio ECR system. Doxorubicin 
induced a 70% decrease in cell viability. Doxorubicin induced an increase in beat rate by 40% 
and a simultaneous decrease in CI amplitude by 70%. Spike amplitude was decreased by 80%. 
Data are the average ± SD of at least 3 separate determinations, and are normalised to 




































































Figure 3.11. Doxorubicin induces permanent electrophysiological changes in hiPSC-CMs. 
hiPSC-CMs iCELL2 were exposed to 1µM Doxorubicin for 48h in the Cardio ECR system. 
Doxorubicin induced a permanent decrease in spike amplitude and FPDc parameter. Data 
shown for FPDc are corrected for beat rate using Fridericia’s formula. Data are the average ± 






3.3 Pan-HDAC inhibition induces perturbations in viability and functional 
parameters in hiPSC-CMs 
 
The commercially-sourced hiPSC-CMs iCELL2 were screened against the pan-HDACi SAHA at a 
range of concentrations, between 20 µM and 0.05 µM, representing clinically applicable 
concentrations (clinical plasma Cmax = 1.2 ± 0.53 µM). These studies were carried out using 
the xCELLigence Cardio ECR system, as previously described (section 2.7.3), and were focused 
on detection of acute structural and functional perturbations. The assessed parameters 
included impedance CI, beat rate, beat amplitude, sodium spike amplitude and FPD/FPDc. All 
parameters were monitored in real-time and analysed at multiple time points to gain an 
insight into parameter changes and fluctuations. In order to confirm and validate the 
representative function of each batch of hiPSC-CMs, cells were grown for 5 days post plating 
before drug exposures. Each validated batch of hiPSC-CMs were then exposed to a single dose 
of SAHA for a maximum of 48 hours. This limited exposure period being based on evidence in 
the literature suggesting that longer-term culture of hiPSC-CM associates with a permanent 
loss of cardiac phenotype through de-differentiation (Ebert et al. 2019).  
In this study, SAHA did not induce proportional concentration-dependent changes in CI, with 
different responses observed at concentrations above the therapeutic range relative to those 
at or below the clinically-relevant concentrations. Double-normalised analysis showed a 
significant (p<0.001) progressive decrease in CI at concentrations greater than their 
therapeutic range (3 - 20 µM) from 12 hours post compound addition. In contrast, clinically 
relevant concentrations (0.05 - 0 1 µM) induced a 5 - 13% increase in CI by 24 hours post 
compound addition (Figure 3.12).  To ascertain whether the differential correlations between 
CI variations and SAHA concentration were due to loss of cellular viability or induction of cell 
death, an ATP quantification assay was performed on the treated cells (methodology outlined 
in section 2.5) upon termination of the Cardio ECR assay. No significant loss of cell viability 
was detected within the therapeutic range of SAHA, up to the termination of the assay at 48 
hours after drug addition. Within the concentration range 3-20 µM, associated with a 60-73% 
decrease in CI, only a 40% reduction in cellular viability was observed over the 48 hour 




that the reduction in CI is only partially due to cell death, with factors related to changes in 
cellular morphology or structural integrity playing a significant role.  
SAHA induced dose-dependent effects on contractility parameters. Beat rate changes were 
recorded as early as 12 hours post compound addition for SAHA concentrations 0.2-1 µM, and 
at 6 hours post compound addition for SAHA concentrations 3-20 µM. All concentrations 
between 3 µM and 20 µM resulted in complete loss of contractility 24 hours post compound 
addition (figure 3.14). Impedance beat amplitude parameters were affected in a similar 
manner, with a decrease in amplitude observed 12 hours post compound addition for 
concentrations 3-20 µM, and a significant decrease for concentrations 0.2-1 µM (change > 
20%; p < 0.001) decreased 12 hours post compound addition (Figure 3.15).  
Analysis of electrophysiological parameters demonstrated that changes in spike amplitude 
voltage were triggered following treatment with SAHA at most concentrations in a dose-
dependent manner (Figure 3.18). Depolarisation spike amplitude changes followed an 
increasing trend starting as early as 1 hour post SAHA exposure at most tested concentrations. 
After 12 to 24 hours post SAHA exposure, changes in spike amplitude demonstrated a 
decrease at all SAHA concentrations, with the exception of 0.05 µM and 0.2 µM where, on the 
contrary, both concentrations maintained an increasing trend. 
Additionally, changes in FPDc followed a decreasing trend starting 12 hours post compound 
addition at SAHA concentrations 3-20 µM, and 24 hours post compound addition at SAHA 





























































Figure 3.12 SAHA does not induce dose-dependent changes in CI. hiPSC-CMs in the Cardio 
ECR system were exposed to SAHA at a range of concentrations 0.05 µM to 20 µM for 48 h 
A. SAHA concentrations between 0.05 µM and 1 µM did not have effects on CI. B. SAHA 
concentrations between 3 µM and 20 µM induced a significant (% change > 20%, p < 0.001) 
decrease in CI from 12 h post compound addition. Data are the average ±SD of at least 3 
separate determinations, and are normalised to baseline and vehicle control. Tested by 






































Figure 3.13 CI decrease induced by pan-HDACi SAHA at cytotoxic concentrations is not 
exclusively attributed to loss of cell viability in hiPSC-CMs. A. hiPSC-CMs were exposed to 
SAHA at a range of concentrations for 48h. SAHA induced a CI decrease by 70% 48h post 
compound addition at concentrations between 3 µM and 20 µM. Data are representative 
xCELLigence Cardio ECR traces showing CI vs Time (h) ±SD. B. The Cell-Titer Glo ATP 
luminescence assay was performed on hiPSC-CMs in the Cardio ECR E-plate following exposure 
to SAHA for 48h, results show a dose-dependent decrease in cell viability, where at the highest 
concentration 60% cells were viable. Data are normalised to vehicle control and are the average 



























































Figure 3.14 SAHA induces dose and time dependent changes in beat rate at clinical and 
toxic concentrations in hiPSC-CMs. hiPSC-CMs were exposed to SAHA at a range of 
concentrations for 48 h. SAHA induced significant beat rate changes starting from 12 h post 
compound addition at concentrations between 0.6 µM and 20 µM in a dose-dependent 
manner. Data are the average ±SD of at least 3 separate determinations, and are normalised 
































































Figure 3.15 SAHA induces dose and time dependent changes in impedance beat amplitude 
at clinical and toxic concentrations in hiPSC-CMs. hiPSC-CMs were exposed to SAHA at a 
range of concentrations for 48 h. SAHA induced significant beat amplitude changes starting 
from 12 h post addition at concentrations between 0.6 µM and 20 µM in a dose-dependent 
manner. Data are the average ±SD of at least 3 separate determinations, and are normalised 




























































Figure 3.16 SAHA induces dose and time dependent changes in spike amplitude at clinical 
and toxic concentrations in hiPSC-CMs. hiPSC-CMs were exposed to SAHA at a range of 
concentrations for 48 h. SAHA induced significant spike amplitude changes starting from 6 h 
post addition, causing a decrease at concentrations between 0.6 µM and 20 µM, and an 
increase at 0.05 µM. Data are the average ±SD of at least 3 separate determinations, and are 



























































Figure 3.17 SAHA induces dose and time dependent changes in FPDc at clinical and toxic 
concentrations in hiPSC-CMs. hiPSC-CMs were exposed to SAHA at a range of concentrations 
for 48 h. SAHA induced a significant (P<0.001) decrease to FPDc starting from 6h post addition 
at concentrations between 3 µM and 20 µM, and from 12 h at concentrations between 0.05 
µM and 1 µM. Data are the average ±SD of at least 3 separate determinations. Tested by 




Taken together, these results indicate that nearly all measured parameters consistently 
decreased in response to SAHA concentrations 0.6-20 µM, and for most parameters the 
maximum changes to baseline were recorded after 24 hours from initial compound addition 
(Figure 3.18). Overall, the study suggests that SAHA-induced toxicity in hiPSC-CMs is likely 
attributed to a combination of mechanisms, related to the concentration being at or below 
the therapeutic range, or above these concentrations. In this regard, normalised FPDc values  
demonstrated a significant shortening in field potential duration at SAHA concentrations 
within the therapeutic range, that did not induce significant changes to other parameters 
including beat rate and CI. This is suggestive of SAHA affecting propagation of the AP through 
modulation of specific ionic currents, possibly hERG. Additionally, the significant (p< 0.05) 
increase in spike amplitude recorded at 24 hours post compound addition with SAHA 
concentrations of 0.05 µM and 0.2, is indicative that SAHA may also interfere with sodium-
related ion currents even at sub-clinical doses (Figure 3.20). Furthermore, the concomitant 
decrease in CI beat amplitude is also suggestive of a negative inotropic effect, imputable to 
either electrophysiological disruptions or structural cardiomyocyte disruptions, at a syncytial 
or metabolic level (Figure 3.18). Overall, this study demonstrates an acute effect of SAHA upon 
cardiac function at therapeutically relevant concentrations.  
These data thereby support an effect of pan-HDACi upon cardiomyocyte contractility, viability, 
and structural integrity and morphology, with several potential mechanisms involved. 
Although these effects may relate to actions upon HDACs (or other secondary protein targets) 
per se, it is highly likely that effects can be attributed to modulation of specific classes or even 
individual HDACs themselves. Therefore, an investigation on the effect of sub-selective class 
specific HDACi is needed. Ultimately, further investigations designed to discern additional 
structural and functional endpoints would be required to provide a more defined  mechanistic 





















Figure 3.18 SAHA induces maximum acute cardiotoxic effects in hiPSC-CMs after 24 h 
exposure. hiPSC-CMs iCELL2 exposed to SAHA on the xCELLigence Cardio ECR system detect 
maximum perturbations in BR, BA, SA and FPDc parameters 24 h post compound addition. 
Changes in BA and SA that did not otherwise induce significant perturbations are evident. 
Data are normalised to baseline and vehicle control (∆∆), and are the average ±SD of at least 
















SAHA 24h post-compound addition














Figure 3.19 SAHA induces shortening of FPD at sub-clinical concentrations in hiPSC-CMs. 
hiPSC-CMs exposed to 50 nM SAHA display a shortening in FPD compared to vehicle control. 


















Figure 3.20 SAHA induces an increase in depolarisation spike amplitude (mV) at sub-clinical 
concentrations in hiPSC-CMs.   hiPSC-CMs exposed to 50 nM SAHA result in an increased 
sodium depolarisation spike amplitude. This concentration did not elicit significant changes 
in other measured parameters (BR, BA, FPDc). Data shows selected representative traces of 




3.4 Selective HDAC inhibition in hiPSC-CMs elucidates different mechanisms of 
HDACi-induced cardiotoxicity 
 
 To establish whether HDACi-induced cardiotoxicity could be attributed to the inhibition of a 
specific sub-class of HDACs, an investigation into the effects of selective HDACi in hiPSC-CMs 
was carried out using the xCELLigence Cardio ECR system. The same experimental setup  
defined in section 3.3 was adopted, with the measured parameters being overall CI, beat rate, 
CI beat amplitude, spike amplitude and FPDc. 
In these studies, iCELL2 hiPSC-CMs were exposed to a class I-selective HDAC inhibitor (MS275) 
and a class IIb-selective HDAC inhibitor (Tubacin); MS-275 (Entinostat®) is currently in phase 
3 clinical trials, whereas Tubacin is an experimental compound not currently used in a clinical 
setting. The evaluation of a specific involvement or role for class IIa HDACs in HDACi-induced 
cardiotoxicity is not yet feasible due to an absence of available selective agents. It is however 
of note that class IIa HDACs demonstrate very low enzymatic activity and are only weakly 
affected by pan-HDACis, such as SAHA, implying the effects of SAHA are unlikely to be 
attributed to class IIa HDACs (Hsu et al. 2017).   
 
3.4.1 Class I selective HDACi induces changes in cardiomyocyte viability and 
functionality 
 
The study evidenced that class I HDACi MS-275 induced dose-dependent changes in CI, 
resulting in cytotoxicity at a supra-therapeutic concentration of 5 µM and no detectable 
cytotoxicity at therapeutically relevant concentrations of 1 µM and 0.5 µM; (Clinical plasma 
Cmax = 303 ± 223nM). Specifically, CI values were monitored for 48 hours, and a significant 
(p<0.05) increase in CI by 10% was observed in response to 1 µM and 0.5 µM MS-275 
concentrations. Conversely, 5 µM MS275 induced a noticeable, albeit non-significant, 5% 
increase in CI between 6 and 12 hours post compound addition, before inducing a significant 
(p< 0.001) decrease by 60% 48 hours post compound addition. 
MS-275 did not induce changes in beat rate until 24 hours post compound addition. In 




with 5 µM, and 48 hours post compound addition with 1 µM. Exposure to 0.5 µM 
concentration resulted in partial loss of contractility, significantly decreasing beat rate by 34% 
to baseline (p<0.001). 
The effects of MS-275 on beat rate were reflected in a similar manner on CI beat amplitude. 
Similarly to beat rate, beat amplitude decreased 24 hours post compound addition, and 
reached a maximum decrease by 40% to baseline with a MS-275 concentration of 0.5 µM. 
Since 5 µM and 1 µM concentrations of MS275 induced a complete loss of contractility by 24 
and 48hrs, respectively, beat amplitude parameters decreased accordingly. 
In terms of ECR parameters, spike amplitude resulted in a significant (p<0.001) transient 
increase by 30% to baseline after exposure to 1 µM MS-275, 12 hours post compound 
addition. Spike amplitude resulted in a gradual decrease after 24 hours from initial exposure 
at all three tested MS-275 concentrations.  
MS-275 did not induce significant changes to FPDc. The partial shortening in FPDc observed 
after 24 hours exposure to 1 µM MS-275 preceded the complete loss of cellular functionality 
and as such was not indicative of significance. 
This study demonstrates that class I HDACi MS-275 affects cardiomyocyte viability and 
functionality in hiPSC-CMs, reflective of the effects observed with pan-HDACi SAHA. 
Remarkably, the sustained significant increase in depolarisation spike amplitude paired with 
the simultaneous decrease in CI beat amplitude is suggestive of a possible impairment of ionic 
currents, and is therefore  in agreement with the similar effects described in section 3.3 with 
the use of pan-HDACi SAHA. However, specific assessments would be required to clarify the 


















































































Figure 3.21 MS-275 class I inhibitor induces dose-dependent changes in impedance 
parameters at non-clinical and toxic concentrations in hiPSC-CMs. . hiPSC-CMs iCELL2 were 
exposed to MS-275 at a range of concentrations for 48 h. A. MS-275 induced a significant 
decrease in CI at 5 µM. MS-275 induced significant (p<0.001) changes to beat rate(B.) and 
beat amplitude (C.) parameters at all used concentrations in a time and dose dose-dependent 
manner. Data are normalised to baseline and vehicle control (∆∆), and are the average ±SD 
of at least 3 separate determinations. Tested by ANOVA and Bonferroni post-hoc 
modifications. D. MTT assays evidenced a decrease in cell viability at 5µM but not at 1 and 











































Figure 3.22 MS-275 induces time and dose-dependent changes in spike amplitude but not 
FPDc in hiPSC-CMs. hiPSC-CMs iCELL2 were exposed to MS-275 at a range of concentrations 
for 48 h. A. MS-275 induced a significant (30% change p<0.001) increase in spike amplitude 
12 h post compound addition, and a significant (p<0.001) decrease 48 h post compound 
addition. B. MS-275 did not induce significant changes in FPDc. Data are normalised to 
baseline and vehicle control (∆∆), and are the average ±SD of at least 3 separate 


































3.4.2 Class IIb selective HDACi induces changes in cardiomyocyte functionality but 
does not alter cardiomyocyte viability 
 
The Class II b-selective HDACi Tubacin did not induce detectable changes in overall CI at any 
of the tested concentrations. 
Tubacin induced a significant (p<0.05) decrease in beat rate 12 hours post compound addition 
at 5 µM and 10 µM concentrations, however only a non-significant decrease in beat rate was 
observed post compound addition at 1µM. 
No significant changes in CI beat amplitude were observed at 5 µM and 1 µM Tubacin 
concentrations, however a transient significant (p<0.05) increase by 20% was observed 
following exposure to 10 µM 12 hours post compound addition. 
Tubacin induced multiple changes in ECR parameters. Specifically, non-significant 
perturbations in spike amplitude were observed within 6 hours post compound addition at 5 
µM and 1 µM concentrations, before a gradual decrease 24 hours post compound addition. A 
significant (p<0.001) decrease in spike amplitude was observed at all used concentrations at 
48 hours post compound addition. 
Tubacin-induced perturbations in FPDc measurements, with a marked sustained significant 
(p<0.05) prolongation in FPD after 24 hours exposure to the higher concentration of 10 µM. 
Exposure to 5 µM and 1 µM concentrations did not induce significant changes to FPDc. 
Overall, this study demonstrates that class IIb HDACi Tubacin does not significantly affect 
hiPSC-CM viability and syncytial morphology even at the highest tested concentrations. 
Conversely, Tubacin affects cellular functionality by slowing the beat rate, whilst also reducing 
depolarisation spikes and prolonging the FPD interval, suggesting a possible interaction with 
the K+ channels or relevant channel subunits. These findings therefore also support the 
observations described in section 3.3 following exposure to pan-HDACi, however specific 
electrophysiological assessments would be required to clarify acute functional toxicity 


















































































Figure 3.23 Tubacin induces changes in impedance contractility parameters but not CI. 
hiPSC-CMs iCELL2 were exposed to tubacin at a range of concentrations for 48 h. A. Tubacin 
did not affect cell index. B. Tubacin induced a decrease in beat rate 48 h post compound 
addition (p<0.05 for 5-1- µM) at all tested concentrations. C. Tubacin did not affect beat 
amplitude between 1-5 µM but induced a 20% increase at 10 µM 12 h post addition. D. MTT 
assays evidenced a viability decrease between 5-10µM. Data are normalised to baseline and 
vehicle control (∆∆), and are the average ±SD of at least 3 separate determinations. Tested 



































































Figure 3.24 Tubacin induces changes in spike amplitude and FPDc parameters. hiPSC-CMs 
iCELL2 were exposed to tubacin at a range of concentrations for 48 h. A. Tubacin induced a 
decrease in spike amplitude at all concentrations 24 h post compound addition. B. Tubacin 
induced an increase in FPDc at 10µM but not 1-5µM. Data are normalised to baseline and 
vehicle control (∆∆), and are the average ±SD of at least 3 separate determinations. Tested 







3.5 HDACis do not associate with an increased release of cardiac troponin I 
indicative of cardiomyocyte damage in hiPSC-CMs in-vitro 
 
Release of cardiac troponin I (cTnI) into the bloodstream is a biomarker of cardiac damage and 
cardiomyocyte necrosis in the clinic, associated with cardiac remodelling and subsequent 
cardiac failure (Babuin and Jaffe 2005). In order to assess these effects preclinically, an in-vitro 
high-sensitivity multiplex assay was developed to detect cTnI levels in culture media of hiPSC-
CM exposed to potential cardiotoxicants. This assay was utilised to evaluate whether HDACi 
induced damage to hiPSC-CMs, and thus whether they may associate with cardiac structural 
remodelling in-vivo. In this study, no elevation of cTnI levels were detected in the media of 
hiPSC-CMs exposed to HDACi at any of the concentrations tested (Figure 3.25). This 
contradicts the HDACi-induced loss of cellular viability detected by both impedance and ATP 
analyses. Consequently, this implies either the lack of sensitivity of the cTnI assay for detection 
of cardiomyocyte damage in-vitro, the inability of the cTnI assay to capture cumulative loss of 
cTnI, or HDACi-induced loss of cellular viability being due to an alternative non-necrotic 
mechanism of cell death. These findings suggest that detection of free cTnI alone is therefore 
not a reliable marker for detection of HDACi-induced cardiomyocyte cellular damage and the 
















































SAHA SAHA SAHA SAHA SAHA SAHA SAHA SAHA TSA
TSA MS-275 MS-275 MS-275 Tubacin Tubacin Tubacin DMSO
Figure 3.25 HDACi exposure does not cause an increase cTnI levels detectable in the culture 
media of hiPSC-CMs. . hiPSC-CMs iCELL2 were exposed to various HDACi at a range of 
concentrations for 48 h. cTnI released in media was measured using multiplex assays. 
Detected levels of cTnI remained similar in HDACi-treated vs vehicle-treated hiPSC-CMs. Data 
are the average of at least 3 separate determinations. Dashed line indicates vehicle control 




3.6  Discussion 
 
Preclinical evaluation of the risk of drug-induced cardiac liabilities until recently was 
dependent upon the limited hERG screen, which utilised a non-cardiac cell line engineered to 
express a single ion channel. The poor predictivity of this model has led to endeavours to 
identify a more suitable and representative cell model for this purpose, with hiPSC-CMs now 
at the forefront in this context. However, a number of uncertainties still remain in terms of 
defining the morphological and electrophysiological predictivity potential of hiPSC-CM.  
To characterise the limitations of hiPSC-CMs for detection of drug-induced cardiotoxicity, 
associated with different molecular mechanisms, these cells were first screened against a 
panel of known functional and structural cardioactive compounds. In this context, although 
commercially sourced hiPSC-CMs demonstrated the expected response to the majority of 
cardioactive agents, they exhibited a limited response to other agents (Table 3.1). Despite 
hiPSC-CMs showing a physiologically-relevant increase in beating contractility when exposed 
to the β-adrenoceptor agonist isoproterenol, no obvious increase in positive inotropy 
(recorded beat amplitude, a surrogate for contractile force) was detected (Figure 3.3) (Peters 
et al. 2015; Abassi et al. 2012).  Likewise, the response to the L-type calcium channel blocker 
verapamil did not elicit a fully physiologically relevant response; shown by an increase in beat 
rate rather than the expected decrease (Figure 3.3). These consistent phenomena are 
potentially due to the immature phenotypic features of hiPSC-CMs and altered ion channel 
activity profiles (Xiaoyu Zhang and Abassi 2018; Koivumäki et al. 2018). Several studies have 
demonstrated that hiPSC-CMs possess ion currents necessary for membrane depolarisation 
(INa;ICaL;If) and repolarisation (Ito;IKr;IKs;IK1)  and express excitation-contraction coupling 
components including L-type calcium channels and the sodium-calcium exchanger pump NCX 
(Karakikes et al. 2015; Koivumäki et al. 2018; Ma et al. 2011). However, one particular 
challenging aspect relates to the lack of T-tubules in hiPSC-CMs (del Álamo et al. 2016). In the 
adult CM, T-tubules are found as a complex network built in connection with the sarcoplasmic 
reticulum (SR), where they mediate the calcium-induced calcium release (CICR) which is 
critical in the excitation-contraction mechanism observed in cardiac muscle cells. Albeit 
present, the hiPSC-CM CICR calcium handling mechanism relies on the slow influx of Ca2+ from 




from the SR observed in healthy adult CMs. Evidence suggests that a certain degree of 
maturation allowing for the development of a CICR more representative of the adult 
cardiomyocyte is achievable via long-term culture, however the actual mechanism remains 
yet to be elucidated (Xiao hua Zhang and Morad 2020). A recent study by Zeng at al. describes 
a possible protocol for the resolution of the reversed rate effect of calcium channel blockers 
on hiPSC-CMs; this study relied on the partial blockade of sodium currents by either Na+ 
channel blocker tetrodotoxin or by voltage-dependent mechanisms by increasing the 
extracellular potassium concentration, which allowed to correct the tachycardic effect to a 
physiologically relevant bradycardic response. Remarkably, Zeng et al.’s study highlighted that 
action potentials of hiPSC-CMs are primarily INa driven, thus directly underpinning the 
discrepancies observed with the use of known cardioactive agents (Zeng et al. 2019; 2018). 
Since hiPSC-CMs are often sourced commercially, problems arise as plating and maintenance 
media formulations are usually patented and undisclosed, and making additional corrections 
to the media formulation could pose problems in terms of correct supplementation and 
protocol standardisation. 
In a bid to try and improve the accuracy and responsiveness of hiPSC-CMs to isoproterenol 
and FPD-altering compounds such as hERG blockers and calcium channel blockers, studies 
were reported on the effect of cardiomyocyte electrical pacing (E-pacing) (Wei et al. 2020). 
Electrical stimulation was hypothesised to induce hiPSC-CM maturation to a more adult-like 
phenotype, as well as reduce inter-batch baseline contractility variations by controlling AP 
firing (Wei et al. 2020). The study conducted by Feng Wei et al. showed a successful reduction 
in plate-to-plate baseline variations when cells were paced compared to spontaneous baseline 
activity. However, the study also indicated that E-paced cells exhibited reversed-rate effects 
and reduced sensitivity to IKr blockade, diminishing FPD prolongation in a pacing frequency-
dependent manner. As such, E-pacing can be considered a suitable solution exclusively for the 
evaluation of compounds that do not interfere with FPD: given that FPD and FPDc evaluations 
are the in-vitro surrogate of QT prolongation assays, this might lead to missed detection of 
dangerous EADs and other proarrhythmic events. In relation to FPD parameters, the study 
presented in this chapter further highlighted the lability of FP/FPDc interpretations that 
originate from the application of a set of correction formulas to generate FPDc values. 




application in similar contexts (Sala, Bellin, and Mummery 2017), however this formula was 
shown to result in possible overcorrection, thus leading to the misinterpretation of FPD-
altering compounds (Fig 3.7). This is because commonly adopted FPD correction formulas, 
such as Fredericia’s or Bazett’s, were originally developed to correct clinical QT/QTc 
parameters, and were not directly intended for experiments using hiPSC-CMs, where 
electrophysiological properties differ (Izumi-Nakaseko et al. 2017). Recently, a study reported 
by Izumi-Nakaseko et al. has developed a non-linear equation for the correction of FPD 
parameters relevant to in-vitro applications, however the adoption of similar equations for 
FPD analysis is yet to be standardised before being commonly implemented (Izumi-Nakaseko 
et al. 2017).  It is therefore evident that the concept of an individual/universal resolution that 
could overcome the limitations of hiPSC-CMs in response to known agents is not viable at the 
time of this writing.  
Overall, data presented in the first phase of this study (figures 3.3 to 3.11) demonstrates that 
both the clinically representative responses and the unexpected reversed-rate effects and 
discrepancies observed with the use of known cardioactive compounds are consistent 
between different hiPSC-CM cell batches, and in line with the most recent literature (Zeng et 
al. 2018; Peters et al. 2015; Zeng et al. 2019). The appraisal of these limitations is fundamental 
for the interpretation and evaluation of new chemical entities (NCEs) in nonclinical drug 
screening. 
The second objective of this study was to evaluate cardiotoxicity associated with the HDACi 
class of drugs using the hiPSC-CM model, particularly in terms of characterisation of the 
strengths and limitations of this model in the detection of functional and structural 
cardiotoxicity. HDACi are investigated for their therapeutic potential towards the treatment 
of oncological, immune, and inflammatory disorders (Falkenberg and Johnstone 2014; Gryder, 
Sodji, and Oyelere 2012b). Despite showing clinical promise, these agents have been 
associated with clinical cardiotoxicity, manifesting mainly through delayed arrhythmic events 
and sudden cardiac death (R. R. Shah 2019). HDACi-mediated functional cardiotoxicity has 
been documented in several studies (Xu et al. 2016; Schiattarella et al. 2016); a study 
conducted by Kopljar et al. identified transcriptional mechanisms induced by several HDACi 
compounds in a hiPSC-CM model, defining potential epigenetic changes linked to HDACi-




reported to induce delayed contractile dysfunction in a hiPSC-CM model, resulting in loss of 
contractility, arrhythmic events and electrophysiological alterations in FPD manifesting as late 
as 72 hours post compound addition at clinically relevant concentrations (Kopljar et al. 2016). 
The pan-HDACi SAHA induced significant functional alterations in hiPSC-CM contractility and 
electrophysiology as early as 48 hours post compound addition at a range of concentrations 
(figures 3.14 to 3.17), including at high supratherapeutic concentrations (3-20 µM), and 
clinically relevant concentrations (≤1 µM).  Whilst both supratherapeutic and therapeutic 
concentrations of SAHA resulted in acute arrhythmic events and progressive reduction of 
contractility in line with other reported findings, this study demonstrates that even sub-
therapeutic concentrations (<0.6 µM) of SAHA induce delayed cardiotoxicity in hiPSC-CMs, 
resulting in both contractile and electrophysiological perturbations. Remarkably, sub-clinical 
non-cytotoxic concentrations were shown to induce FPDc shortening and SA alterations, 
indicative of electrophysiological disruptive mechanisms (figure 3.16 and 3.17). These FPDc 
and SA alterations were however not correlated with a concomitant decrease in beat rate, but 
only with a partial reduction in beat amplitude (figures 3.18 and 3.19). As beat amplitude is a 
surrogate for the evaluation of extent of cardiomyocyte contractility, a negative inotropic 
effect with no simultaneous alteration in beat rate indicates a potential disruption of 
cardiomyocyte morphology and structure, thus suggesting that cardiotoxicity associated with 
HDACi could be mediated by the modulation of specific structural molecular targets rather 
than purely ion channel disruption. In agreement with this proposition, a study by Kopljar et 
al. hypothesised that clinically relevant pan-HDACi at Ceff values affected the expression of 
genes associated with the structural organisation of the cardiomyocyte (Kopljar et al. 2016). 
Additionally, increasing accumulating evidence reported the use of HDACi as possible 
therapeutic agents for the treatment of some forms of heart failure (Weeks 2019; Wallner et 
al. 2020), including those with preserved ejection fraction (HFpEF); in particular Wallner et al. 
reported that the pan-HDAC inhibitor SAHA determined a reduction in left ventricular 
hypertrophy in a HFpEF model (Wallner et al. 2020), hence fully supporting not only the 
HDACi-mediated role in cardiac structural modifications, but also its translatability to the 
clinic. The investigation into sub-selective HDACi effects on hiPSC-CMs in this study 
additionally showed that class I HDAC inhibition elicited a moderate effect on functional and 
cell viability parameters, and although the effects largely reflected those observed with pan-




inhibition was linked to more significant cardiomyocyte alterations compared to class IIb 
selective HDACi (figures 3.22-3.23 and 3.24-3.25). Similar findings were also reported in 
literature, where class I and class IIb selective HDACi evoked comparable effects to those 
observed in this study, which suggests that the HDACi cardiac safety profile could possibly be 
improved by targeting specific HDAC sub-sets (Kopljar et al. 2016). Further investigations in 
this study aimed at the quantification of HDACi-induced cardiomyocyte damage, specifically 
through the detection of release of cardiac troponin I, a validated clinical biomarker for 
detection of cardiomyocyte loss and subsequent cardiac remodelling (Adamcova et al. 2019). 
This study demonstrated no observable change in detectable levels of free cTnI in media upon 
HDACi exposure (figure 3.26), even at the highest tested HDACi concentrations. Although 
damage-dependent release of cTnI is conventionally correlated with loss of cardiomyocyte 
membrane integrity and cellular death, a recent study described the occurrence of additional 
drug-induced troponin-disruptive mechanisms whereby in response to the cardiotoxicant 
doxorubicin cTns undergo drug-induced structural rearrangements rather than extracellular 
release (Adamcova et al. 2019). Whilst the study presented in this thesis did not specifically 
investigate cTnI localisation and disruption at the cellular level following HDACi exposure, it is 
plausible to assume that the lack of detection of cTnI in media is not sufficient to exclude the 
eventuality of a structural cardiomyocyte alteration per se. Nonetheless, an important 
limitation of this study is the limited experimental timespan that hiPSC-CM-based models 
offer before undergoing de-differentiation and phenotypical alterations that would render 
them ineffectual, generally allowing a maximum of 48 to 72 hours for the assessment of drug-
induced effects (Ebert et al. 2019). Given that structural cardiac cell modifications often occur 
with a delayed onset, manifesting several days or weeks after drug exposure, it is possible that 
any major structural HDACi-induced cardiomyocyte disruption involving the release of cTnI 
could not be detected within the 48 hour experimental timeframe used in this study.  
Taken together, the results described in this study prove that despite providing a tangible 
improvement to the preclinical in-vitro screening scene, there are still numerous limitations 
that emerged with the use of standardised hiPSC-CM models for cardiotoxicity applications, 
not only in terms of physiological relevance but also in relation to the experimental and 
analytical methodologies. This supports the need for the investigation of a complementary 






























4 Characterisation of the HL-1 murine atrial cell line for use in 
































The lack of reliable and reproducible cardiac models for in-vitro preclinical screening is a well-
established issue. While it is undeniable that hiPSC-CM technology represents a considerable 
step towards the improvement of these necessary models, a variety of limitations remain 
unresolved and ultimately contribute to the lack of standardisation of such models (Da Rocha 
et al. 2017; Koivumäki et al. 2018). Numerous studies have evidenced the variability that 
commercial hiPSC-CM models present in terms of baseline parameters, both in terms of 
contractility and electrophysiology (Feyen et al. 2020; Wei et al. 2020; Zeng et al. 2019). Not 
least of all, the high costs associated with the use of hiPSC-CM technology signify that in-vitro 
studies are often designed in a limited number, adding further limitations in terms of reliability 
due to the small sample size. Given that, over the last decade, as many as 27% cardiovascular 
adverse events are reported for NCEs discovery projects prior to entering phase I clinical trials 
(Roche et al. 2019; Valentin and Redfern 2017), the design of cost-effective, reproducible, and 
standardised tests that could enhance the utility of preclinical screening is of paramount 
importance. The availability of immortalised cells, such as the HL-1 murine atrial 
cardiomyocyte cell line, represents an unexplored source of cost-effective models that could 
aid in the design of more feasible preclinical cardiotoxicity studies. 
Despite the inter-species differences that distinguish human-derived and mouse-derived atrial 
cells, murine models are widely accepted and are considered suitable for the study of cardiac 
electrophysiology and arrhythmic mechanisms (Kaese and Verheule 2012). The HL-1 cell line 
was first established from a genetically engineered atrial tumour grown in a transgenic mouse 
(Claycomb et al. 1998). The cell line was established to be immortalised, and as such it provides 
an expandable source of atrial-like cardiomyocytes. Several studies have demonstrated the 
cardiac phenotype of this cell line, which uniquely retains several cardiac markers as well as 
the ability to contract upon passaging (Claycomb et al. 1998) (Figure 4.1). HL-1 cells have been 
used in numerous electrophysiology studies due to the presence of native forms of several 
cardiac ion channels, making them a particularly suitable model for the study of atrial 
arrhythmias (Wiersma et al. 2019) (table 4-1). These features, coupled with the use of novel 
technologies such as high-throughput impedance-based cellular analysers, could offer 









Ikr hERG ☑ Encode α subunit of Ikr (Claycomb et al. 1998) 
If HCN ☑ 
All 4 isoforms present, HCN1 
and HCN2 at higher levels.  
Plausibly contributes to HL-1 
spontaneous contractility 
(Sartiani et al. 2002) 
Ica-L Cav1.2 or CACNA1C ☑ 
Presence in HL-1 dependent 
on culture conditions (i.e. 
Norepinephrine) 
(Xia et al. 2004) 
Ica-T CACNA1G ☑ 
Present in HL-1 cells.  
Dependent on culture 
conditions. Characteristic of 
SA node 




INa Scn5a ☑ Present in HL-1 cells 
(White, Constantin, 
and Claycomb 2004; 
Daimi et al. 2015) 
INa-Ca Ncx-1 ☑ Present in HL-1 cells 
(White, Constantin, 
and Claycomb 2004) 
IKATP SUR1, SUR2, Kir2.6 ☑ Present in HL-1 cells. 
(Fatima et al. 2012; 
Seymour et al. 2003) 
Table 4-1 Electrophysiological characterisation of the HL-1 murine atrial cell line. Previous studies reported in literature have described 


































Figure 4.1 HL-1 cells express cardiac markers and display syncytial formation in culture.  
HL-1 cells retain a cardiac phenotype in-vitro. Figure A. shows positive immunofluorescence 
staining for α-actinin, atrial natriuretic factor, myosin and titin. (image adapted from Sigma-






4.1.1 Aims and Objectives 
 
HL-1 cells express a range of cardiac markers and retain a contractile phenotype, however 
their use and characterisation for toxicological in-vitro applications has been very limited. For 
this reason, a set of studies is presented in this chapter, with the aim to characterise this cell 
line and determine the utility advantages and limitations of the HL-1 murine atrial cell model 
for use in early preclinical cardiotoxicity studies. Specifically, this is achieved through the 
following objectives: 
 
1. Development of a protocol for the use and application of HL-1 murine atrial cell line 
paired with high throughput impedance assays (xCELLigence systems). 
2. Characterisation and validation of the ability and limitations of the HL-1 cell line model 
to detect functional and structural drug-induced cardiotoxicity against a panel of 
known cardioactive agents. 
3. Evaluation of the ability of the HL-1 model to detect structural and functional 
















4.2  Determination and optimisation of HL-1 cell line culture conditions, 
growth kinetics and contractility 
 
To develop and optimise a protocol for the use of HL-1 murine atrial cell line on impedance-
based technology systems, the intrinsic properties of this cardiac cell model, including 
morphology, kinetics and contractile phenotype were studied and defined. Figure 4.2 shows 
growth characteristics of HL-1 cells seeded at different initial densities, and defines doubling 
time for each population. For the initial assessments, HL-1 cells were cultured in regular 
supplemented commercial Claycomb medium (Claycomb et al.) as described in section 2.2.2. 
and the experiment was performed using the xCELLigence Cardio system. HL-1 cells were 
seeded at 10,000, 5000, 2500 and 1250 cells/well, and at least 8 separate determinations in 
the same experiment were considered for significance. Determinations were averaged and 
data on exponential phase, plateau phase and monitoring of contractility were recorded. Cells 
seeded at 10,000 cells/well reached a cell index (CI) plateau stage 120 hours post-seeding, 
while early contractility was detected at 72 hours post-seeding, suggesting that the formation 
of functional syncytia occurred. Representative impedance traces of HL-1 contractility seeded 
at 10,000 cells/well are shown in figure 4.4A, where cells demonstrated early contractility at 
72 hours post-seeding: the noise recorded in the impedance waveform signal suggests early 
contractility is characterised by unorganised syncytial structures. Following exponential cell 
proliferation, the CI reached a plateau phase at which the impedance traces of contractility 
resulted in improved definition and reduced noise in the signal, albeit beat amplitude and 
beat-rate were decreased compared to pre-plateau timepoints.  
HL-1 cells seeded at an initial density of 5000 cells/well and 2500 cells/well reached a plateau 
phase at 150h and 170h post-seeding, respectively. Representative impedance traces of HL-1 
cells seeded at 5000 cell/well and 2500 cells/well are shown in figure 4.4B and 4.5A, where 
early contractility was recorded at 96 and 110 hours post-seeding respectively. The impedance 
signal noise of contractility traces appeared more defined throughout the experiment in the 
cell group plated at 5000 cells/well compared to the group plated at 2500 cells/well. 
HL-1 cells seeded at the lower initial density of 1250 cells/well reached a plateau phase at 212 




the noise recorded on the contractility impedance signal was consistent until a more stable 












Figure 4.2. Growth kinetics of HL-1 cells plated at different seeding densities. HL-1 cells were 
plated on an xCELLigence Cardio E-plate and monitored over time. Exponential and plateau 
growth phases are attained at different points post-seeding, with a positive correlation 
between initiation of these phases and higher cell densities. Final cell density per well is 

















Average duration of 
contractile activity, post 
media change  
10,000 120h ±2h 70h post seeding 210h post 
seeding 2h ±0.5h 
5,000 150h ±1.5h 96h post seeding 235h post 
seeding 4.5h ±1.7h 
2,500 170h ±3h 110h post 
seeding 
264h post 
seeding 5h ±1.3h 
1,250 212h ±3.5h 160h post 
seeding 
270h post 
seeding 4h ±1.2h 
Table 4-2 Different initial seeding density determines differences in contractility consistency 
and duration in HL-1 cells. HL-1 cells were seeded at different initial densities and monitored 
on the xCELLigence Cardio System. Different parameters were recorded, including growth 
kinetics, start and end timepoints of contractility and average duration of contractile activity. 
Figure 4.3 Native HL-1 average contractility analysed as beat rate/min. HL-1 cells were 
seeded at different initial densities and monitored on the xCELLigence Cardio system for early 
detection of contractility. Spontaneous beat rate/min is comparable between all initial 
























Figure 4.4. HL-1 cells seeded at different initial densities achieve contractility at different 
proliferation stages. HL-1 cells were seeded at different initial densities and monitored on the 
xCELLigence Cardio system for early detection of contractility. A. Representative contractility 
impedance traces for cells seeded at 10,000 cells/well and B. representative contractility 



























Figure 4.5. HL-1 cells seeded at different initial densities achieve contractility at different 
proliferation stages. HL-1 cells were seeded at different initial densities and monitored on 
the xCELLigence Cardio system for early detection of contractility. A. Representative 
contractility impedance traces for cells seeded at 2,500 cells/well and B. representative 
contractility impedance traces for cells seeded at 1,250 cells/well. All data are typical of at 







Together, these data suggest that HL-1 cells cultured in standard supplemented commercial 
Claycomb medium achieve a fully contractile phenotype when grown between 80% and 100% 
confluency. Despite different initial seeding densities, each group displayed erratic and noisy 
early contractility waveform signals, indicative of a non-homogeneous syncytial formation as 
well as a non-coordinated conduction of the electrical signal; brightfield microscopy on live 
cells at different initial exponential growth stages confirmed the presence of separate cell 
colonies forming individual syncytial structures, which consistently formed a more 
synchronised monolayer at plateau stages, as reflected by impedance contractility traces. 
Furthermore, the study demonstrated that consistent and stable contractility is maintained 
for a maximum of 4 to 5 hours on average after each complete media change and is 
subsequently progressively lost over time unless cell passaging occurs. This finding therefore 
suggests that HL-1 cells do not fully achieve complete contact inhibition upon syncytial 
monolayer formation. 
To determine whether native HL-1 contractility performance could be improved to generate 
a more stable, synchronised and reproducible impedance waveform, DMEM-based medium 
was formulated to i) selectively exclude individual components of the Claycomb growth 
medium to identify those indispensable for the induction and maintenance of HL-1 
contractility, and ii) optimise medium formulation and increase availability of key contractility 
components. All recordings were performed using the xCELLigence Cardio system where HL-1 
cells were grown to confluency in supplemented commercial Claycomb medium until 
contractility was detected. Cell media was then replaced with DMEM-based medium 
specifically excluding one of the following components: growth factors, retinoic acid, oleic and 
linoleic acids, cholesterol, Insulin-Transferrin-Selenium complex (ITS), ascorbic acid, and 
norepinephrine (NE). Changes in impedance and contractility were recorded and are 
described in figures 4.6 to 4.8. 
Figure 4.6 shows the overall effects on cell viability following selective omission/depletion of 
specific components and factors from the cellular media, relative to complete media 
containing all of the stipulated additional additives. No significant differences in viability were 




48 hours, significant decreases in CI were observed associated with omission of specific 
components. A lack of the ITS complex or growth factors (both EGF and R3IGF-1) resulted in 
approximately a 30% decrease, omission of cholesterol or ascorbic acid caused a 20% increase, 
and absence of linoleic/oleic acid associated with a 13% decrease in CI. As expected, HL-1 cells 
plated directly in multi-factor-depleted media formulations did not achieve successful growth 
and proliferation (Figure 4.8). 
However, whilst a decrease in CI gave was indicative of reduced cell viability, there was no 
observable direct correlation between decrease of CI and loss of contractility. Figure 4.7A 
illustrates representative impedance traces of contractility for each depleted component 
group, and figure 4.7B shows raw beat-rate changes at 24, 48 and 120 hours post 
deconstructed media addition. Notably, commercial Claycomb and in-house reconstructed 
Claycomb media formulations resulted in a beat-rate increase 48 hours post media addition. 
Conversely, a beat-rate decrease was detectable within 48 hours of changing to a factor-
depleted media, with the exception of omission of growth factors for which beat-rate 
remained stable throughout the study. Although omission of these factors from the media did 
not result in loss of contraction up to 48 hours, contractility ceased in all factor-depleted 
media conditions apart from growth-factors and ascorbic acid by 120 hours. Whilst beat-rate 
remained constant for growth-factor deficient media, a decrease in beat-rate was observed 
following omission of ascorbic acid (figure 4.7A and B). 
Data from this study demonstrates that selective depletion of key Claycomb media 
components does not result in complete loss of HL-1 contractile phenotype. Once cellular 
confluency and cell index plateau were achieved, the overall contractile stability and duration 
was improved in the absence of growth factor components (EGF and 3IGF-1) . Furthermore, 
maintenance of HL-1 contractility was shown to be dependent upon both retinoic acid and 
norepinephrine, with omission of the other constituents having only minor effects upon the 
HL-1 contractile phenotype. This thereby opens new dimensions and opportunities for utility 





Figure 4.6: Omission of supplements to growth medium affects HL-1 cell viability. HL-1 cells were grown in an xCELLigence Cardio E-plate in complete 
Claycomb medium until confluency was attained, thereafter exposed to deconstructed and supplement-omitted media formulations. Data shows 
normalised CI variations over time.Significant decrease in CI was observed in the absence of several supplements, including ITS complex, growth factors, 







Figure 4.7. Omission of selected Claycomb medium components does not prevent 
contractility (A) of HL-1 cells but affects beat-rate duration and stability (B). HL-1 cells were 
grown in an xCELLigence Cardio E-plate in complete Claycomb medium until confluency was 
attained, thereafter exposed to deconstructed and supplement-omitted media formulations. 
A) impedance contractility waveform traces at baseline, 24h and 48h; B) mean beat-rate/min, 
where data are the mean ±SE of at least 8 separate determinations of 3 independent 
experiments. Contractility remained observable at 120h in the absence of growth factors (GF) 
and ascorbic acid (AA). Significance defined as p<0.05 from baseline using one-way ANOVA 





































Figure 4.8 Omission of selected Claycomb medium components halts HL-1 early-stage 
proliferation. HL-1 cells were plated in an xCELLigence DP E-plate and exposed directly to 
deconstructed and supplement-omitted media formulations. A. Cells grown in complete 
Claycomb formulation achieved standard proliferation. B. Cells grown in FCS-depleted 
medium achieved a slowed proliferation. C. Cells grown in supplement-omitted media 




4.3  Medium-induced inhibition of cellular proliferation associates with 
improvement of HL-1 cellular contractility. 
 
Previous experiments suggested HL-1 cells reach optimal contractility when 80-95% confluent 
(just prior to reaching plateau) and evidenced their inability to achieve contact inhibition 
following the formation of functional syncytia, thus resulting in loss of contractility over time 
due to overcrowding of the culture vessel. Retinoic acid and norepinephrine are both 
confirmed as key components for maintenance of HL-1 cellular contractility (section 4.2.1), 
whereas omission of EGF from the growth media promoted stable contractility. This thereby 
implies that inhibition of cellular proliferation, without impacting cell viability, would improve 
consistency and robustness of HL-1 contractility. To address this assumption, a study was 
performed with the aim to optimise a medium formulation that would permit the 
maintenance of the contractile and differentiated phenotype of HL-1 cells, as well as inhibit 
their ability to proliferate. To achieve this, several formulations of basal media were tested 
(Table 4-3). For these studies, HL-1 cells were grown to confluency in complete Claycomb 
medium on the xCELLigence Cardio system, and at plateau stage the complete Claycomb 
formulation was substituted with the modified basal media batches. Cell viability and 












No consistent contractility baseline was observed in HL-1 cells grown in complete Claycomb 
medium prior to reaching 80% confluency (Figure 4.9A and 4.9B). Remarkably, HL-1 cells that 
were subsequently exposed to Claycomb media in the absence of FCS and growth-factors  
exhibited successful contractility, as opposed to cells that were kept in FCS-containing 
Claycomb media. However, the CI value decreased by 20% in Claycomb media devoid of 
growth factors and FCS, relative to FCS-containing Claycomb media. 
A change from complete Claycomb media to a base media of either DMEM or advanced 
DMEM, devoid of any supplements apart from norepinephrine or retinoic acid, resulted in 
steady and consistent contractility over time as demonstrated by beat-rate and beat 
amplitude uniformity, suggesting that proliferative inhibition resulted in the stabilisation of 
contractile syncytia. These results therefore indicate that growth factor -depleted medium, 
including only norepinephrine, retinoic acid, alongside the standard L-glutamine and 
penicillin/streptomycin can be used to maintain consistent contractility in HL-1 cells without 





Basal Medium NE RA Additional Supplements 
Claycomb Media ✓ ✓ 10% FCS 
Claycomb Media ✓ ✓ 1% FCS 
Claycomb Media ✓ ✓ None 
DMEM high glucose Media ✓ ✓ None 
Advanced DMEM Media (Thermo-Fisher) ✓ ✓ None 






















Figure 4.9 Inhibition of HL-1 proliferation is associated with improved contractility. HL-1 
cells were grown in an xCELLigence Cardio E-plate in complete Claycomb medium until 
confluency was attained, thereafter exposed to various growth factor-depleted media 
formulations. HL-1 cells exposed to growth factor-depleted media formulations resulted in 
improved contractility at plateau resulting in stabilised contractility over time. Data shows 
normalised CI variations (A) and representative impedance contractility traces(B), typical of 
at least 8 separate determinations. C. Illustrates continuous beat rate changes over 120 hours 






4.4  Growth supplement depleted medium does not alter the bioenergetic 
profile of HL-1 cells  
 
To maximise HL-1 contractility at confluency, the study described in section 3.2.2. identified 
standard DMEM medium supplemented with only norepinephrine and retinoic acid as 
effective for maintenance of viability and contractility. However, to ascertain whether 
omission of the other factors from the growth media had an effect upon cellular energetics or 
introduced cellular stress, mitochondrial function of HL-1 cells in these growth media were 
evaluated using Seahorse XF analysis (defined in section 2.6). Following initial growth in 
complete Claycomb media and establishment of cell confluency and a functional syncytia, the 
media was either retained as complete Claycomb media or changed to HL-1 optimised DMEM 
medium (devoid of FCS and supplemented with only norepinephrine and retinoic acid) for 48 
hours. Mitochondrial function and respiration were then assessed by modulation of 
complexes in the Electron Transport Chain (ETC) by the consecutive addition of specific 
compounds, and the subsequent assessment of Oxygen Consumption Rate (OCR), as detailed 
in section 2.6. The sequence of added compounds is listed in table 2.4 and included:  
oligomycin as a mitochondrial complex V inhibitor, FCCP as a proton uncoupler, rotenone and 
antimycin-A as inhibitors of complex I and complex III respectively. In both media, addition of 
the complex V inhibitor, oligomycin, promoted ATP synthase inhibition and resulted in an 
expected decrease in OCR from baseline level. Subsequent addition of the proton uncoupler, 
FCCP, resulted in the expected increase of OCR above baseline level due to the proton 
uncoupling mechanisms that allow mitochondrial membrane permeabilization to protons, 
indicative of the maximum respiratory capacity of HL-1 cells. Final addition of the complex I 
and III inhibitors, rotenone and antimycin-A, decreased the OCR below baseline level, as 
expected due to the inhibition of the respiratory chain. Additionally, no differences were 
observed in basal rate, proton leak and ATP production rates (Figure 4.11A and4.11B). 
Together this confirms that there was no significant difference in HL-1 bioenergetics between 
those incubated in the DMEM formulation as opposed to complete Claycomb media (figures 
4.10 and 4.11), further supporting the use of the modified DMEM media for assessment of 













































Figure 4.10 Exposure to complete Claycomb and modified DMEM media formulations does 
not affect mitochondrial oxygen consumption rate of HL-1 monolayer cultures. HL-1 cells 
were grown to functional confluency and subsequently exposed to different media conditions 
A. complete commercial Claycomb medium and B. modified DMEM medium for 48 h prior to 
testing. OCR was measured using a Seahorse analyser. Data shows OCR measurements over 
time in response to electron transport chain modulators. Arrows indicate injection of electron 
transport chain complex modulators, oligomycin, FCCP, rotenone/antimycin A in order of 
injection. Data are mean ±SD of at least 10 separate determinations from the same 







Figure 4.11 Exposure to complete Claycomb and modified DMEM media formulations does 
not alter the bioenergetic profile of HL-1 cells. HL-1 cells were grown to functional confluency 
and subsequently exposed to different media conditions A. complete commercial Claycomb 
medium and B. modified DMEM medium for 48 h prior to testing. Data shows comparable rates 
of basal and spare respiratory capacity, proton leak and ATP production. Data are mean ±SD of 



















































4.5 Implications of norepinephrine supplementation upon HL-1 cell 
bioenergetics and contractility 
 
The inclusion of norepinephrine in growth media is established as a necessity for maintenance 
of HL-1 contractility in monolayer culture (Claycomb et al. 1998). However, norepinephrine 
acts as a α1/α2-adrenergic agonist and as such activates functional signalling in HL-1 cells, and 
therefore may interfere with subsequent analyses of drugs interacting with this pathway, with 
implications for determination of drug-induced cardiotoxicity. Consequently, the effects of 
norepinephrine upon HL-1 cellular bioenergetics and spontaneous contractility were 



















4.5.1 Norepinephrine-supplemented media formulations do not alter the HL-1 basal 
bioenergetic profile 
 
The analysis of mitochondrial stress tests reported in figure 4.12 shows OCR fluctuations in 
response to known electron transport chain complex modulators oligomycin, FCCP, and 
rotenone/antimycin A. Confluent cells that were not supplemented with norepinephrine 
exhibited a similar respiration profile compared to confluent cells that were supplemented 
with norepinephrine, thus corroborating the fact that the bioenergetic profile of HL-1 cells 
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Figure 4.12 The presence or absence of norepinephrine as a medium supplement for 
confluent HL-1 cells does not alter cellular bioenergetic profile. HL-1 cells were grown to 
functional confluency and subsequently exposed to media formulations supplemented with 
and without norepinephrine for 48 hours prior to testing. Data shows OCR measurements over 
time in response to electron transport chain modulators. Arrows indicate injection of electron 
transport chain complex modulators, oligomycin, FCCP, rotenone/antimycin A in order of 
injection. Data are mean ±SD of at least 10 separate determinations from the same experiment, 




4.5.2 Norepinephrine-supplemented media formulations are essential for the 
maintenance of HL-1 synchronous contractility 
 
Following confirmation that the presence or absence of norepinephrine does not alter HL-1 
mitochondrial respiration, the effects of norepinephrine upon HL-1 baseline contractility was 
carried out. HL-1 monolayers were grown to contractile confluency in the xCELLigence Cardio 
system, and subsequently exposed to media formulations with or without norepinephrine. 
Contractility baseline readings were monitored 24 hours post media substitution. Data 
presented in figure 4.13 demonstrates that HL-1 cells exposed to norepinephrine-depleted 
medium exhibited an unstable baseline contractility pattern (figure 4.13). Conversely, HL-1 
cells in media supplemented with norepinephrine achieved a stable and synchronised 
contractile pattern, indicating the importance of norepinephrine for maintenance of cell-cell 
interactions and functional contractility. This study therefore suggests that norepinephrine 
depletion leads to altered cell-cell interactions within HL-1 syncytia, possibly due to 
disturbances in AP conduction. 
Figure 4.13 Medium supplementation with norepinephrine leads to improved stabilisation 
of HL-1 baseline contractility. HL-1 cells kept in norepinephrine supplemented medium 
achieved stable contractility, while norepinephrine depleted HL-1 cells displayed an uneven 
and erratic baseline contractility pattern. Data are the distribution of beat-rate at baseline of 




4.6 Implications of norepinephrine supplementation upon response of HL-1 to 
cardioactive agents 
 
The inclusion of norepinephrine in growth media is established as a necessity for maintenance 
of HL-1 contractility in monolayer culture (section 4.5). However, norepinephrine acts as a 
α1/α2-adrenergic agonist and as such may interfere with subsequent analyses of drugs 
interacting with this pathway, with implications for determination of drug-induced 
cardiotoxicity. To address this concern, the effects of a known panel of cardioactive agents on 
HL-1 contractility in the presence or absence of norepinephrine using the xCELLigence Cardio 
system were evaluated. 
 
4.6.1 Norepinephrine-supplemented media has minimal effect upon impedance 
determination of the drug-induced effects of cardioactive agents 
 
Norepinephrine acts as a positive chronotropic stimulant via its affinity to cardiomyocyte 
adrenergic receptors, with potential implications for impeding detection of cardioactive 
compounds with comparable properties and targets; this is particularly evident with the drug 
isoproterenol, a norepinephrine analogue. In order to appraise this issue, the effects of a panel 
of cardioactive agents (table 4.4, including isoproterenol) upon confluent contractile HL-1 cells 
were assessed in the presence and absence of norepinephrine. For these studies, once 
satisfactory cell growth and stable contractility were achieved, cells were exposed to the 
growth-factor depleted DMEM medium formulation with or without norepinephrine 
supplementation. A panel of known cardioactive agents (table 4.4) was then evaluated 
through the assessment of contractility parameters.  
The study described in section 4.5.2 highlighted the inability of norepinephrine-free HL-1 cells 
to achieve a stable contractility baseline. This finding was further confirmed in this study, 
where only a small proportion of norepinephrine-free HL-1 plate wells showed a measurable 
impedance contractility waveform; selected representative contractility waveforms are 
shown in figure 4.14 A, where baseline and 2 hours post-treatment traces are compared. 




 In the presence and absence of norepinephrine supplementation, isoproterenol was still able 
to elicit an increase in contractility beat-rate. Exposure to the β-adrenoceptor antagonist 
Carvedilol should theoretically counteract the effect of norepinephrine, an activity evident in 
this study with a decrease in beat-rate only observed in the absence of norepinephrine. In the 
case of the calcium channel blocker verapamil, a non-significant change in beat-rate was 
observed in both the presence and absence of norepinephrine (figure 4.14). Taken together, 
this study indicates that media supplementation with norepinephrine has little effect upon 
detectability of cardioactive agents. While the absence of norepinephrine in the growth 
factor-depleted DMEM medium formulation seemed to elicit more physiologically relevant 
effects in HL-1 contractility parameters in response to specific agents, the overall functionality 
and stability of HL-1 contractility was compromised as demonstrated in the baseline readings. 
For this reason, norepinephrine exclusion from media formulations was deemed 


















Table 4-4 Chemical structures of known cardioactive agents that may interfere with drug-
































Figure 4.14 Norepinephrine-supplemented HL-1 medium stabilises baseline contractility, 
and exerts little effect upon detectability of cardioactive agents.  
HL-1 cells were grown to contractility on the xCELLigence Cardio system and exposed to a set 
of known cardioactive agents in the presence or absence of norepinephrine. Data shows A). 
representative raw impedance traces of contractility at baseline and 2h post compound 
exposure, and B). beat-rate expressed as beat/minute ±SD, corrected for vehicle control. 





















4.7 HL-1 cell line demonstrates consistent responses to known cardioactive 
and antiarrhythmic agents 
 
In order to establish the suitability of the HL-1 cell line model for the detection of drug-induced 
functional and structural effects, a panel of known cardioactive agents (Table 4.4) was 
screened using the xCELLigence Cardio system.  
For these studies, once stable contractility was detected, medium was substituted with the 
growth factor-depleted DMEM medium formulation supplemented with norepinephrine, 
retinoic acid, l-glutamine and penicillin/streptomycin, and contractility was monitored for 24 
hours every 30 minutes thereafter. Spontaneous HL-1 activity was recorded and assessed for 
each experimental batch in order to detect and exclude wells displaying spontaneous beat 
rhythm irregularities prior to compound addition with compounds. To validate different 
batches of HL-1 cells, the cells were screened against a panel of compounds with well-defined 
cardioactive effects (Table 4-5). Analysed parameters included CI variations, beat rate, and cell 
index (impedance) beat amplitude. 
The class I antiarrhythmic agents quinidine, lidocaine and propafenone elicited consistent 
detectable effects in HL-1 cells. Quinidine induced a transient decrease in beat rate, as 
expected due to its effects on AP prolongation by Na+ channel blockade, resulting in a 60% 
total decrease in beat rate within 24 hours post compound addition. Additionally, quinidine 
resulted in a transient 20% decrease in CI beat amplitude (BA) within 6 hours post compound 
addition. Similarly, lidocaine induced a marked decrease in beat rate, resulting in a 40% 
decrease 1 hour post compound addition, and a concomitant 20% decrease in BA 6 hours post 
compound addition. Propafenone exerted a 45% decrease in beat rate, and a 20% decrease in 
BA 1 hour post compound addition. 
 Exposure of contractile HL-1 cells to either of the class II β-adrenergic blockers, Metoprolol 
and Carvedilol, did not result in any detectable effects upon HL-1 contractility and CI 
parameters. Conversely, exposure to the β-adrenoceptor agonist isoproterenol induced a 
detectable effect on HL-1 contractility parameters, causing an 82% increase in beat rate 0.5 




Exposure to the non-selective potassium channel blocker amiodarone did not exert a 
detectable effect in HL-1 contractility parameters. On the contrary, the experimental selective 
potassium hERG channel blocker E-4031 elicited an expected marked response in contractile 
parameters, with beat rate decreasing by 74% within 0.5 hours post compound addition.  Beat 
amplitude was decreased 0.5 hours post compound addition, and increased 6 hours post 
compound addition. 
The class IV antiarrhythmic compound verapamil induced detectable effects on HL-1 
contractility. Verapamil however exerted an unexpected transient increase in beat rate by 
50% 0.5 hours post compound addition, therefore inducing a diametric effect. Beat amplitude 
was temporarily decreased by 24% 1 hour post compound addition. 
The structural cardiotoxic anthracycline doxorubicin induced an expected significant (p<0.001) 
initial increase in beat rate, followed by a steady decrease of the parameter within 24 hours 
post compound addition. Similarly, changes in beat amplitude resulted in an acute temporary 
increase of the parameter by 250%, before undergoing a steady decline and contractility arrest 
within 24 hours post compound addition. As predicted, doxorubicin induced a significant 
(p<0.001) decrease in CI, inducing a 66% decrease of the parameter within 24 hours. 
Overall, these results demonstrate that the HL-1 cell line steadily responds to a wide panel of 
functional and structural cardioactive agents. This study therefore serves as proof of concept 











Table 4-5 Known cardioactive agent effects in HL-1 cells vs effects detected using 
impedance-based technology. All parameters in this table are reported as an increase (↑) a 
decrease (↓) or unaffected (-). 
 
Compound Mechanism Expected effect 
Detectable effect in 
HL-1 cell line using 
xCELLigence Cardio 
Class I antiarrhythmic agents: Voltage-gated Sodium Channel Blockade 
Quinidine 
Class Ia: Nav1.5 open 
state inhibitor with rapid dissociation 





Class Ib: Nav1.5 open 






Class Ic: Nav1.5 inactivated 





Class II antiarrhythmic agents:  Autonomic inhibitors and activators 












Class III antiarrhythmic agents: Potassium channel blockers 








Class IV antiarrhythmic agents: Calcium channel blockers 

















































Figure 4.15 Quinidine induces contractility changes in HL-1 cells. HL-1 cells were grown to 
contractility on the xCELLigence Cardio system and exposed to 1µM quinidine for 24 hours. 
Beat rate was significantly decreased (p<0.001) by 60 % within 24 h. CI beat amplitude was 
transiently affected showing a 20% decrease 1 h post dosing and restored to baseline levels 
at 24 h post dosing. Impedance cell index was unaffected. Data are normalised to baseline 
and vehicle control (∆∆), and are the average ±SD of at least 3 separate determinations. 
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Figure 4.16 Lidocaine induces contractility changes in HL-1 cells. HL-1 cells were grown to 
contractility on the xCELLigence Cardio system and exposed to 0.5µM lidocaine for 24 hours. 
Beat rate was significantly decreased (p<0.001) by 40 % within 24 h. CI beat amplitude was 
transiently affected showing a 20% decrease 1 h post dosing and restored to baseline levels at 
24 h post dosing. Impedance cell index was unaffected. Data are normalised to baseline and 
vehicle control (∆∆), and are the average ±SD of at least 3 separate determinations. Tested by 










































































































Figure 4.17 Propafenone induces contractility changes in HL-1 cells. HL-1 cells were grown 
to contractility on the xCELLigence Cardio system and exposed to 1µM propafenone for 24 
hours. Beat rate was significantly decreased (p<0.001) by 40 % within 24 h. CI beat amplitude 
was affected showing a 20% decrease within 1 h and a further decrease 24 h post drug 
addition. Impedance cell index was unaffected. Data are normalised to baseline and vehicle 
control (∆∆), and are the average ±SD of at least 3 separate determinations. Tested by ANOVA 


















































































Figure 4.18 Metoprolol does not induce detectable contractility changes in HL-1 cells. HL-1 
cells were grown to contractility on the xCELLigence Cardio system and exposed to 1µM 
metoprolol for 24 hours. Beat rate, CI beat amplitude and. impedance cell index were 
unaffected. Data are normalised to baseline and vehicle control (∆∆), and are the average 















































































Figure 4.19 Carvedilol does not induce detectable contractility changes in HL-1 cells. HL-1 
cells were grown to contractility on the xCELLigence Cardio system and exposed to 1µM 
carvedilol for 24 hours. Beat rate, CI beat amplitude and impedance cell index were 
unaffected. Data are normalised to baseline and vehicle control (∆∆), and are the average 




























































Isoproterenol  100 nM
Figure 4.20 Isoproterenol induces contractility changes in HL-1 cells. HL-1 cells were grown 
to contractility on the xCELLigence Cardio system and exposed to 100nM isoproterenol for 24 
hours. Beat rate was significantly increased (p<0.001) by 82 % within 0.5 h. CI beat amplitude 
was affected showing a 60% increase 1 h post drug addition. Impedance cell index was 
unaffected. Data are normalised to baseline and vehicle control (∆∆), and are the average ±SD 













































































Figure 4.21 Amiodarone does not induce detectable contractility changes in HL-1 cells. . HL-
1 cells were grown to contractility on the xCELLigence Cardio system and exposed to 1µM 
amiodarone for 24 hours. Beat rate, CI beat amplitude and impedance cell index were 
unaffected. Data are normalised to baseline and vehicle control (∆∆), and are the average 















































































Figure 4.22 E-4031 induces contractility changes in HL-1 cells. HL-1 cells were grown to 
contractility on the xCELLigence Cardio system and exposed to 50nM E-4031 for 24 hours. Beat 
rate was significantly decreased (p<0.001) by 84 % within 1 h. CI beat amplitude was affected 
showing an 82% decrease 0.5h post drug addition. Impedance cell index was unaffected. Data 
are normalised to baseline and vehicle control (∆∆), and are the average ±SD of at least 3 




















































Figure 4.23 Verapamil induces contractility changes in HL-1 cells.  HL-1 cells were grown to 
contractility on the xCELLigence Cardio system and exposed to 0.1µM verapamil for 24 hours. 
Beat rate was significantly increased (p<0.001) by 50 % within 0.5 h. CI beat amplitude was 
affected showing a 24% decrease 1h post dosing. Impedance cell index was unaffected. Data 
are normalised to baseline and vehicle control (∆∆), and are the average ±SD of at least 3 




































































































Figure 4.24 Doxorubicin induces contractility changes in HL-1 cells.  HL-1 cells were grown 
to contractility on the xCELLigence Cardio system and exposed to 1µM doxorubicin for 24 
hours. Beat rate was significantly increased (p<0.001) by 100 % within 6 h. CI beat amplitude 
was affected showing a 250% increase (p<0.001) 1h post drug addition. Impedance cell index 
was decreased by 66% (p<0.001) within 24 h. Data are normalised to baseline and vehicle 
control (∆∆), and are the average ±SD of at least 3 separate determinations. Tested by ANOVA 






4.8 Pan-HDAC inhibition induces perturbations in functional, structural and 
viability parameters in the HL-1 murine atrial cell line 
 
 Previous studies reported in section 3.3 indicated that pan-HDAC inhibition at sub-clinically 
relevant concentrations induced proarrhythmic events and permanent contractility changes 
in a hiPSC-CM model. Following validation of the HL-1 cells as a suitable model for the 
detection of functional and structural changes in this study, the effects of the pan-HDAC 
inhibitors SAHA and TSA were evaluated in this model using the xCELLigence Cardio system, 
with a focus on sub-clinical concentrations (methods described in section 2.7). Impedance cell 
index (CI) beat rate and beat amplitude changes were evaluated with the aim of detecting 
acute and late-onset cardiotoxicity.  
SAHA at both 600 nM and 200 nM induced a marked 110% increase in beat rate 12 hours post 
drug addition, before steadily decreasing and resulting in complete contractility arrest 100 
hours after drug exposure. HL-1 cells exposed to 50 nM SAHA maintained a stable beat rate 
until 105 hours after drug addition, before displaying an abrupt decline leading to total 
cessation of contractility by 120 hours (Figure 4.25 A). Contractility was not restored upon 
fresh media supplementation, thus indicating the occurrence of a permanent damage. 
Similarly to SAHA, TSA resulted in contractility arrest at all tested concentrations (1 µM, 200 
nM and 50 nM), displaying functional cardiotoxicity in a dose-dependent manner (Figure 4.25 
B). TSA induced significant (p < 0.001) beat rate changes 5 hours post drug exposure, with 
1µM TSA resulting in a 55% decrease, in contrast to 200 nM which resulted in a 46% increase 
in beat rate. Exposure to 50 nM TSA resulted in a delayed effect upon beat rate of the HL-1 
cells, presenting as an initial 26% increase after 12 hours exposure, followed by a steady 
decline within 24 hours (Figure 4.25 B). Contractile activity did not resume upon fresh media 
supplementation. 
At the higher concentrations of SAHA and TSA (600 nM and 1 µM, respectively) a positive 
inotropic effect upon cellular beat amplitude was detected (p < 0.05) (Figure 4.26 A and 4.26 
B). However, at the lower drug concentrations no significant inotropic effect upon beat 
amplitude was observed, and a steady reduction in the parameter was recorded, as reflected 




Remarkable changes were observed in cell index (CI) in the presence of both SAHA and TSA. 
SAHA induced a dose-dependent CI decrease, resulting in a maximal decrease of 34%, 52% 
and 69% at 48 hours for 50 nM, 200 nM and 600 nM, respectively (Figure 4.27 A). These CI 
changes remained stably decreased, albeit showing a marginal restoration towards baseline 
levels between 72-84 hours after drug addition. Upon compound removal, CI changes 
remained unaffected and were not restored to baseline levels. This decline in Cl is indicative 
of either cell death/detachment, cellular hypotrophy, or a morphological change. To 
determine whether it was attributed to cellular death/detachment, a parallel MTT assay was 
performed alongside the xCELLigence assay. This showed that HL-1 cell viability and thus cell 
number were not diminished at any of the SAHA concentrations evaluated, coinciding with 
the decline in Cl values, and therefore the changes were a result of structural modifications of 
cellular/syncytial morphology. 
In a similar fashion to SAHA, TSA also induced a decrease in CI following drug addition (Figure 
4.27 C). Effects with 1 µM TSA were noticeable as early as 1 hour post compound addition and 
exposure to 200 nM TSA resulted in a significant (p < 0.001) CI decrease culminating 12 hours 
after drug addition. In the case of the lower 50 nM TSA concentration, a non-significant decline 
in Cl was observed by 24 hours after drug exposure. As with SAHA, removal of TSA did not 
affect CI levels, which remained at their reduced levels and did not return to baseline levels 
indicating the occurrence a permanent change. Assessment of drug-induced cytotoxicity by 
the MTT assay indicated a significant effect with 1 µM, supporting the drop in Cl being a 
consequence of primarily cell death/detachment (figure 4.27D). On the contrary, no 
cytotoxicity was observed with TSA concentrations of 200 nM or 50 nM (figure 4.27D), and 
therefore any changes in CI can also be plausibly linked to changes in cell morphology and 
structural cardiotoxicity. 
To further confirm that the effects of pan-HDACi at sub-cytotoxic concentrations were 
dependent on structural changes, and not on cellular death or reduction in cellular metabolic 
activity, manual cell counts were performed to ascertain that cell numbers in treated and 
untreated cells remained similar. Results shown in figure 4.28A and 4.28B demonstrate that 
cell numbers were unaffected by sub-clinical and sub-cytotoxic concentrations of SAHA and 
TSA, thus further corroborating the conclusion that changes in CI are dependent on structural 












Figure 4.25 Pan-HDACis induce time-dependent changes in beat rate at clinical and sub-
clinical concentrations in HL-1 cells. HL-1 cells were exposed to SAHA and TSA at a range of 
concentrations for 120 h. A. SAHA induced significant beat rate changes starting with an 
increase 12 h post addition at concentrations between 200 nM and 600 nM  before a late-
onset contractility arrest within 48 h post exposure B. TSA induced significant beat rate 
changes starting from 5 h post compound addition at concentrations between 1 µM and 50 
nM, starting with an initial increase and followed by contractility arrest in a time-dependent 
manner. Data are the average ±SD of at least 3 separate determinations, and are normalised 
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Figure 4.26 Pan-HDACis induce time-dependent changes in beat amplitude at clinical and 
sub-clinical concentrations in HL-1 cells. HL-1 cells were exposed to SAHA and TSA at a range 
of concentrations for 120 h. A. SAHA induced significant beat amplitude changes starting 
from 12 h post addition at concentrations between 600nM and 50nM in a time-dependent 
manner. B. TSA induced significant beat amplitude changes starting from 5 h post compound 
addition at concentrations between 1 µM and 50 nM in a time-dependent manner. Data are 
the average ±SD of at least 3 separate determinations, and are normalised to baseline and 
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Figure 4.27 Pan-HDACIs induce dose and time-dependent permanent changes in cell index 
and viability at clinical and subclinical concentrations in HL-1 cells. HL-1 cells were exposed 
to SAHA and TSA at a range of concentrations for 120 h. A. SAHA induced a significant 
decrease in CI at all tested concentrations starting 12 h post compound addition. B. MTT 
assays did not evidence any reduction in cell viability following SAHA addition. C. TSA induced 
a significant decrease in CI starting 12 h post compound addition. D. MTT assays did not 
evidence any reduction in cell viability at 200 nM and 50nM TSA concentrations. Data are the 













































Figure 4.28 Pan-HDACIs at sub-cytotoxic concentrations do not affect cell viability. 
Functional HL-1 cells were exposed to SAHA and TSA at a range of concentrations and 
counted using a haemocytometer after 6, 24 and 48 h compound exposure. A. sub-clinical 
concentrations of SAHA did not affect average cell numbers. B. TSA at sub-cytotoxic 
concentrations did not affect average cell numbers. Data are normalised to time-matched 
vehicle control and are the average ±SE of at least 3 different experiments. Tested by ANOVA 





























































































4.9 Determination of pan-HDACI pharmacological targets in HL-1 cells 
 
Following the confirmation that pan-HDACI compounds induce functional and structural 
alterations in HL-1 cells at sub-clinical and non-cytotoxic concentrations, a study was designed 
to ascertain whether these drugs induced their reported pharmacological activity in these cells 
at these concentrations. Specifically, the protein acetylation of two main pan-HDACI 
molecular targets was assessed (methodology detailed in section 2.8). Acetylation of histone 
H4, as a primary HDACI pharmacological target was assessed in HL-1 cells. Additionally, the 
HDACI-mediated inhibition of HDAC6 α-tubulin deacetylation was assessed. Given that α-
tubulin is a protein found in the cytoskeleton, where it has fundamental roles in maintaining 
cellular structural features, an investigation into the HDACI-induced effects upon α-tubulin 
acetylation were hypothesised to define potential mechanisms of HDACI-induced structural 
cardiotoxicity. 
Treatment of HL-1 cells with 1 µM TSA, shown to be cytotoxic, caused an increase in both α-
tubulin and histone H4 acetylation levels in a time-dependent manner. Conversely, no change 
in acetylation patterns was observed with the non-cytotoxic 200 nM concentration of TSA, 
suggesting that TSA concentrations ≤ 200 nM are not-pharmacologically active in this cell type 
(Figure 4.29B). As SAHA is an analogue of TSA, with lower pharmacological activity, it is 
assumed this is also the case for this drug. Overall, these findings implicate that any functional 
or structural effects upon HL-1 cells evidenced with sub-cytotoxic pan-HDACi concentrations 
are unlikely to be a result of the reported pharmacological mechanism of action. It is therefore 
likely that the effects of sub-pharmacologically active pan-HDACI concentrations could be 
















Figure 4.29 Determination of pan-HDACi pharmacological targets in HL-1 cells. Western Blot 
analysis of HL-1 whole protein extracts assessing levels of acetylated α tubulin (55 kDa) and 
acetylated histone H4 (10 kDa) following treatment with A. 1µM and B. 200 nM 
concentrations of Pan-HDACi TSA. Each lane contained 20µg protein/lane. Results are 
















In order to elucidate potential additional mechanisms underpinning HDACI-induced 
cardiotoxicity, the effects of the pan-HDACI TSA on HL-1 metabolic respiration were assessed 
using Seahorse XF technology (methods detailed in section 2.6). The mitochondrial stress test 
results reported in figure 4.30A indicate that treatment with 1 µM TSA induced a significant 
(p<0.05) acute increase in HL-1 spare respiratory capacity, observable upon oligomycin and 
subsequent FCCP exposure, compared to vehicle treated cells. Remarkably, TSA treated cells 
displayed a 200% increased spare respiratory capacity under stressed conditions, leading to 
an overall 400 pmol/min increase (from 200 to 600 pmol/min) in OCR compared to 
endogenous OCR values. 
Overall, these results suggest that HDACi-mediated bioenergetic changes could alter 

































Figure 4.30 Treatment with pan-HDACi increases spare respiratory capacity in HL-1 cells. 
HL-1 cells were grown to functional confluency before being exposed to 1µM TSA. Data 
shows A. Oxygen consumption rate (OCR) measurements over time in response to electron 
transport chain modulators. Arrows indicate injection of electron transport chain complex 
modulators, oligomycin, FCCP, rotenone/antimycin A in order of injection. And B. pmol/min 
changes in OCR at baseline and stressed conditions in treated cells. Data are mean ±SD of at 
least 10 separate determinations from the same experiment, typical of 3 separate 
experiments. 
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4.11 Selective HDAC inhibition elicits functional and structural cardiotoxicity in 
HL-1 cells 
 
To define whether HDACi-induced cardiotoxicity could be attributed to the inhibition of a 
specific sub-class of HDACs, thus confirming the findings observed in the hiPSC-CM model 
(chapter 3.4), an analogous investigation into the effects of selective HDACi in HL-1 cells was 
carried out using the xCELLigence Cardio system. Measured parameters included beat rate, 
beat amplitude and cell index.  
 
4.11.1 Class I selective HDACi induces changes in HL-1 cardiomyocyte functionality 
 
The class I selective HDACI MS-275 (Entinostat) induced permanent contractility changes in 
HL-1 cells. At clinically relevant concentrations (1.2µM and 0.5 µM) complete loss of 
contractility within 48 hours post compound addition was observed (Figure 4.31). Similarly to 
the effect induced by pan-HDACIs, MS-275 induced a significant (p < 0.001) increase in beat 
rate prior to contractility arrest. Upon compound washout, contractility did not resume. Beat 
amplitude was not affected until 12 hours post compound addition, where a constant decline 
in the parameter was initiated, decreasing by 63% and 56 % after exposure to 1.2µM and 0.5 
µM, respectively. MS-275 therefore induced acute functional cardiotoxicity in HL-1 cells. 
A significant (p<0.001) change in CI was observed starting 24 hours post MS-275 addition, at 
both tested concentrations of 1.2µM and 0.5 µM, resulting in a total 44% and 36% CI decrease, 
respectively (Figure 4.32). Upon compound removal, CI values were not restored to baseline 
values. Assessment of cellular viability by the MTT assay however showed no significant 
cytotoxicity, thus supporting the conclusion that class I HDAC selective inhibition could 

















Figure 4.31 MS-275 class I inhibitor induces changes in contractility parameters at clinically-
relevant concentrations in HL-1 cells. HL-1 cells were exposed to MS-275 at different 
concentrations for 120 h. A. MS-275 induced a significant decrease in beat rate and B. Beat 
amplitude Data are normalised to baseline and vehicle control (∆∆), and are the average ±SD 
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Figure 4.32 MS-275 class I inhibitor induces permanent changes in cell index at clinically-
relevant concentrations in HL-1 cells. HL-1 cells were exposed to MS-275 at different 
concentrations for 120 h. A. MS-275 induced a significant decrease in CI starting 24 post 
compound addition. Data are normalised to baseline and vehicle control (∆∆) B. MTT assays 
did not evidence a significant decrease in cell viability. Data are normalised to control and are 























4.11.2 Class IIb selective HDACi induces temporary changes in HL-1 cardiomyocyte 
functionality  
 
The class IIb selective HDACi tubacin induced transient contractility changes in HL-1 cells. Both 
tested concentrations of 5 µM and 1 µM resulted in a temporary acute increase in beat rate 
within 6 hours post compound addition, before returning to baseline levels within 12 hours. 
Changes in impedance beat amplitude were only recorded with the use of 5 µM tubacin, 
where an increase of the parameter was observed between 1 and 12 hours post compound 
addition. No significant changes of the parameter were recorded following treatment with 1 
µM tubacin. 
A non-significant decrease in CI was observed with both tested concentrations, resulting in a 
total 19 % decrease of the parameter 72 hours post compound addition. 
Overall, these results suggests that class IIb-selective HDAC inhibition are not associated with 
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Figure 4.33 Tubacin class IIb inhibitor does not induce major changes in contractility 
parameters in HL-1 cells. HL-1 cells were exposed to tubacin at different concentrations for 
120 h. A. Tubacin induce a transient beat rate changes in HL1 cells by 20% 6 h post 
compound addition. B. Tubacin did not induce significant beat amplitude changes in HL-1 
cells. Data are normalised to baseline and vehicle control (∆∆) and are the average ±SD of 
at least 3 separate determinations typical of 3 different experiments. Tested by ANOVA and 

























































Figure 4.34 Tubacin class IIb inhibitor does not induce significant changes in viability 
parameters in HL-1 cells. HL-1 cells were exposed to tubacin at different concentrations for 
120 h. A. Tubacin did not induce significant variations in CI. Data are normalised to baseline 
and vehicle control (∆∆) and are the average ±SD of at least 3 separate experiments B. MTT 
assays did not evidence a significant reduction in cell viability. Data are normalised to control 
and are the average ±SD of at least 3 separate determinations. Tested by ANOVA and 







Current methods used in preclinical cardiotoxicity screening involve in vivo models 
complemented by in-vitro cell models. Current cell models are limited by a lack of capacity 
for expansion and finite lifespan in culture, high cost and requirements for complex culture 
conditions, poor representation of the cardiac phenotype, or focus on specific cardiac ion 
channels or molecular pathways. As such these current models generally provide limited 
insights into toxicological investigations (Ando et al. 2017; Obergrussberger et al. 2016). 
The availability of an expandable and reproducible source of cardiomyocytes with 
applicability for screening of compounds for cardiotoxicity potential would undoubtedly 
improve this area. However, attempts to create fully functional cardiac immortalised cell 
lines with applicability (and compatibility) for evaluation of mechanistic cardiotoxicity 
have not been successful to date. The HL-1 atrial murine-derived cell line is unique in that 
it remains the only expandable in-vitro model that is cardiac in origin, retains a cardiac 
phenotype, and an ability for functional contractility in culture (Claycomb et al. 1998). The 
aim of this chapter was to assess and characterise the HL-1 cell line in terms of its utility 
as a model for evaluation of drug-induced cardiotoxicity and its potential for inclusion in 
non-clinical studies for assessment of cardiac liabilities. 
The initial stage of this study focused on defining the intrinsic growth properties and native 
contractility characteristics of the HL-1 cell line. In addition to elucidating culture and 
growth parameters, this study also uniquely utilised impedance-based technologies, 
specifically the xCELLigence Cardio real-time cell analysis (RTCA) system, to non-invasively 
and continuously evaluate growth kinetics and in-vitro contractility parameters of the Hl-
1 cell line. Previous studies had reported the HL-1 model to be heterogeneous in terms of 
its contractile phenotype, particularly a lack or presence of contractility in sub-clones of 
the HL-1 cell line despite expression of specific ion channel and cardiac markers (Dias et 
al. 2014). In this study, HL-1 cells were shown to consistently retain the ability for 
contractility, albeit asynchronously and differentially across the culture vessel, suggesting 
that previous studies involving selective cloning of contractile sub-populations may be 
somewhat ambiguous and misleading in this regard and assumptive of uniform clonal 




time-limited and strictly dependent on regular media supplementation, only displaying 
consistent rhythmicity for up to 4 hours after each media change. This factor of HL-1 cell 
contractility had not been incorporated into earlier reported studies of this cell line (Eimre 
et al. 2008; Dias et al. 2014). Furthermore, an additional hindrance to HL-1 contractility is 
the persistent proliferative nature of this immortalised cell line (section 4.2). Based on 
these findings, it is perhaps not surprising in hindsight that most previously reported HL-1 
based studies addressing contractile effects were restricted to either single endpoint 
assays or assessment of short-term acute electrophysiological effects, a consequence of a 
lack of longevity or appreciation of contractility in-vitro (Wiersma et al. 2019; Z. Dong et 
al. 2017; Darpo et al. 2014; White, Constantin, and Claycomb 2004). Consequently, the 
next aim of this phase of the study was focused toward utilisation for this cell line for acute 
and long-term cardiotoxicity evaluations. The objective being to develop a novel 
methodology to improve the HL-1 contractility timespan, and to optimise the use of this 
model on the xCELLigence system. Several studies focused on culture of cardiomyocytes 
and their maintenance in-vitro have demonstrated the requirement of specific media 
supplements for maintenance of a cardiac phenotype, albeit these primary cell models are 
limited by their post-mitotic non-proliferative nature for longer-term evaluations 
(Callaghan et al. 2020; Fiegle, Volk, and Seidel 2020; Tomsits et al. 2020). Similarly, media 
for maintenance of stem-cell derived cardiomyocytes is also highly dependent on a panel 
of supplements and other biological factors (Correia et al. 2017). With respect to HL-1 cells, 
their in vitro culture was established through the development of a specialised media 
termed ‘Claycomb media’ supplemented with a series of growth factors and supplements 
(Claycomb et al. 1998). However, the derivation of this media was focused on growth and 
survival of this immortalised cell line, alongside maintenance of a defined set of cardiac-
specific phenotypic parameters, rather than establishment of consistent contractility and 
longer-term studies cardiac-selective effects (Claycomb et al. 1998). An important 
approach was thus to deconstruct the Claycomb media to gain an insight into the role and 
importance of media components towards growth, maintenance and contractility of the 
HL-1 cell line. The outcome of this investigation demonstrates that although most included 
factors are required for growth and maintenance of this cell line, inclusion of specific 
factors are crucial to establishment and continuation of contractility, particularly 




shown to be essential for the expression of Cav1.2 and CACNA1C genes during 
cardiomyogenesis, thus regulating the presence of L-type voltage-dependent calcium 
channels (Lehmann et al. 2013). Physiologically norepinephrine is released by sympathetic 
neurons wherein it activates beta-1 adrenoceptors on cardiac myocytes to facilitate 
chronotropic, inotropic and lusitropic effects upon the heart. This is counterbalanced by 
the greater parasympathetic effects mediated at the sinoatrial and atrioventricular node 
by acetylcholine to cause negative chronotropy and regulate cardiac contraction (Gordan, 
Gwathmey, and Xie 2015). However, cardiac cells cultured in-vitro  lack innervation and 
the majority do not exhibit autonomous pacemaker capability, therefore relying on 
norepinephrine supplementation to promote contractility. The observations in this study 
thereby not only corroborate a requirement of norepinephrine for the correct formation 
of HL-1 syncytial structures, but evidence that continuous supplementation with 
norepinephrine is decisive in the stabilisation of HL-1 contractility, without impacting cell 
viability and bioenergetics. Retinoic acid plays multiple roles during heart development 
and is an important factor in subtype differentiation of cardiomyocytes, particularly 
promotion of atrial-like or sinoatrial-like differentiation (Stefanovic and Zaffran 2017; 
Protze et al. 2017). Furthermore, exposure of stem-cell derived cardiomyocytes to retinoic 
acid promotes their electrophysiological maturation and calcium handling (Gassanov et al. 
2008). It is not unconceivable to expect a similar effect occurs with the HL-1 cell model. 
Consequently, both norepinephrine and retinoic acid were therefore identified as 
essential components for the long-term maintenance of HL-1 functionality. 
One of the aforementioned issues that impact the timespan of HL-1 contractility was 
attributed to the immortalised nature of these cells, as observed in the xCELLigence 
studies, with cellular proliferation progressing in spite of the formation of functional 
syncytial structures in HL-1 cells. In this regard, effort was focused on identification of a 
media formulation unsupportive of cellular proliferation once cellular confluency was 
obtained, whilst simultaneously preserving syncytial integrity. Unsurprisingly, HL-1 cells do 
not achieve successful proliferation when seeded in growth factor-depleted media 
formulations. Nevertheless, HL-1 cells that are initially grown in fully supplemented 
Claycomb formulations until syncytial formation, and only thereafter depleted of growth 




lacking support factors for proliferative growth. Several supplements found in Claycomb 
media formulations, including cholesterol, oleic and linoleic acids, were reported to play a 
critical role in the formation of cardiomyocyte cellular membranes, cell-cell interaction 
and assembly of mitochondrial complex subunits (Maekawa et al. 2019; Haque et al. 2016). 
Therefore, after ensuring the successful formation of HL-1 syncytial structures using 
complete Claycomb media formulations, depletion of selected supplements including 
growth factors, cholesterol, oleic and linoleic acids allowed cessation of further cellular 
proliferation, and led to a functional improvement of the existing HL-1 monolayers without 
hampering viability and metabolic functionality (sections 4.3 and 4.4). Consequently, these 
studies allowed to design a novel optimised protocol for long-term HL-1 studies, whereby 
cells are initially plated and grown to functionality, and thereupon maintained in growth-
factor depleted medium, with the addition of norepinephrine and retinoic acid, with 
twelve-hourly media changes for up to 120 hours. 
After the establishment of a novel effective protocol for the use of HL-1 cells on the 
xCELLigence RTCA systems, the second phase of the study was dedicated to the validation 
of the HL-1 model for its use in nonclinical cardiotoxicity studies. Initially this involved 
evaluation of the effects of a panel of known cardioactive agents upon HL-1 cells using the 
xCELLigence Cardio RTCA system. The HL-1 model consistently and reproducibly 
responded to the majority of tested cardioactive agents, demonstrating for the first time 
that the analysis of impedance functional parameters can successfully detect arrhythmic 
and proarrhythmic effects in this model. Early investigations reported by Claycomb et al 
indicated the presence of functional ion channels in HL-1 cells, describing the expression 
of fully functional IKr currents, INa and L-type calcium currents (Claycomb et al. 1998; White, 
Constantin, and Claycomb 2004). Further studies supported this through the ability of HL-
1 cells to respond to specific ion channel interactive agents using various 
electrophysiological techniques, including manual and automated patch clamping (White, 
Constantin, and Claycomb 2004; Toyoda et al. 2010; Kammonen et al. 2017). In particular, 
potassium channel blocker compounds E-4031 and dofetilide were reported to elicit 
strong responses by successful blockade of HL-1 endogenous Ikr currents (Toyoda et al. 
2010). Conversely, the sodium channel blocker lidocaine and the β-adrenergic agonist 




(Kammonen et al. 2017). In the study presented herein, Ikr blockade with E-4031 resulted 
in a marked effect on beat rate and beat amplitude impedance parameters, agreeing with 
the previously reported electrophysiological endpoint studies. On the contrary, the non-
selective potassium channel blocker amiodarone did not elicit detectable effects on 
impedance parameters; recent studies on beat rate variability in a murine embryonic stem 
cell-derived cardiomyocyte model have documented a similar response to amiodarone, 
whereby no detectable variations in beat parameters were recorded (Niehoff et al. 2016). 
Even though amiodarone is classified as a class III antiarrhythmic compound, its effects are 
notoriously complex and can affect a wide array of mechanisms: amiodarone was in fact 
shown to elicit structural effects, as well as sodium and calcium current blockade in a rate-
dependent manner (Riedel et al. 2014). The resulting competing effects could therefore 
underpin the undetected response to this compound in HL-1 cells. Relevant cardioactive 
effects via voltage-gated sodium channel blockade were consistently achieved, with 
significant effects on beat rate and beat amplitude impedance readings (figures 4.15, 4.16 
and 4.17). Exposure of the HL-1 cells to the calcium channel blocker verapamil also induced 
a significant response, which rather than the expected bradycardic response observed in 
vivo was the converse, and resulted in an increase in beat rate. This effect is not exclusive 
to this model but is also observed in hiPSC-CM models (Zeng et al. 2019). This paradoxical 
response of hiPSC-CMs to verapamil and other calcium channel blockers was confirmed as 
being the net effects of other cardiac ion currents, with action potentials of hiPSC-CMs 
shown to be sodium channel driven (Zeng et al. 2019). By reducing sodium channel 
availability in hiPSC-CMs, such as via modulation of potassium ion levels in growth media, 
the response to calcium channel blockers was reversed, reflecting the bradycardic effect 
observed in vivo and clinically (Zeng et al. 2019). This has implications for safety 
assessment of drug candidates with multiple effects, including calcium channel inhibition, 
wherein results in vitro may contrast the actual in vivo response and thus a misleading 
result. Therefore, adaption of the monovalent concentrations of growth media may be 
required to address this issue. It remains to be determined whether further configuration 
of Claycomb media would also circumvent this issue in HL-1 cells. 
Overall, the detection of functional effects through the use of impedance-based systems 




While HL-1 cells retain atrial characteristics, they have the advantage of expressing native 
forms of various ionic currents (Claycomb et al. 1998); this study proves that HL-1 
monolayers can therefore be useful not only for the investigation of atrial-linked 
dysfunctions, such as atrial fibrillation, but also for the detection of more general aspects 
of functional early cardiotoxicity studies.  
Following the successful validation of the HL-1 model for use in cardiotoxicity studies, this 
model was applied to the evaluation of cardiotoxic potential of the epigenetic modulating 
histone deacetylase (HDAC) inhibitor class of drug, implicated as a therapeutic approach 
for a range of conditions (Gryder, Sodji, and Oyelere 2012b; Lopez et al. 2016). Exposure 
of HL-1 cells to clinically relevant concentrations the pan HDAC inhibitors, SAHA and TSA, 
caused consistent functional changes. Marked increases in beat rate and beat amplitude 
parameters were elicited with both compounds, followed by a complete cessation of 
contractility by 100 hours after drug addition. These findings are in agreement with those 
obtained with hiPSC-CMs (Chapter 3), where a marked decrease in contractility was 
observed by approximately 48 hours post compound addition. These effects mirror the 
detection of delayed cardiac dysrhythmias, including atrial fibrillation, in clinical studies 
(Kopljar et al. 2016; Subramanian et al. 2010). Importantly, detection of these functional 
abnormalities several hours after drug exposure in the HL-1 model offers a distinct 
advantage over the majority of current preclinical cardiac screening methodologies which 
often focus on acute (≤ 1 hour) effects. These observations thereby support the utility of 
the HL-1 model as a screening tool for drug-induced functional cardiac disturbances. 
Alongside identification of effects upon cardiomyocyte contractility, these studies also 
indicated effects upon cardiomyocyte structure or morphology following exposure to the 
pan-HDACi SAHA. Of note is the fact that decreases in cell index were recorded even at 
drug concentrations below those that induced cytotoxicity. A lack of loss of cellular 
viability coupled to maintenance of cell number, alongside these declines in cell index, 
strongly implicated these changes were imputable to structural cardiomyocyte changes. 
This effect of pan-HDACi upon cardiac cells is supported by a recent study using hipSC-CMs 
in-vitro which showed transcriptional changes induced by these compounds were 
associated with structural cardiac changes (Kopljar et al. 2016). Moreover, several recent 




heart failure, primarily involving the reversal of cardiac hypertrophy (McKinsey 2012; 
Wallner et al. 2020). This implicates that HDACi additionally cause structural changes in 
cardiomyocytes, involving cellular hypotrophy or atrophy, although it remains to be 
determined whether these effects are mirrored in toxicity of these drugs in the clinic.  
The investigation into pan-HDACi pharmacological activity in HL-1 cells revealed that both 
functional changes in contractility, as well as structural/morphological changes reflected 
in CI changes, were elicited at HDACi concentrations that did not initiate histone 
acetylation. This finding implicates that HDACi-mediated cardiotoxicity could depend on 
additional secondary pharmacology effects. Several studies have linked the involvement 
of class I HDACs with mitochondrial alteration in cardiomyocytes (Herr et al. 2018; Lkhagva 
et al. 2018). Additionally, recent studies have observed that treatment with pan-HDACis is 
correlated with an improvement of mitochondrial bioenergetics, particularly when 
investigated in relation to cardiac oxidative stress dysfunctions as well as ischemia-
reperfusion myocardial injuries (Lkhagva et al. 2018; Wallner et al. 2020). In this study, 
pan-HDAC inhibition resulted in significant changes in mitochondrial respiration, with a 
marked augmentation of spare respiratory capacity levels of HL-1 cells, therefore 
confirming the contribution of HDACi activity to mitochondrial impairment. While the 
improvement of mitochondrial oxygen consumption rate (with the subsequent increase in 
respiratory capacity levels) can be considered as a potentially cardioprotective effect in a 
pathological context, this study suggests that further elucidation of the interplay between 
HDACi and cardiac mitochondria is needed to determine possible cardiotoxic 
consequences associated with the use of this class of compounds. 
The selective inhibition of HDAC sub-classes provided an additional insight into the 
mechanisms of HDACi-mediated effects on cardiomyocytes. Similar to the effects 
observed with the use of pan-HDACis SAHA and TSA, the class I selective inhibitor MS-275 
resulted in delayed functional and structural alterations in HL-1 cells. Remarkably, the 
delayed onset of functional perturbations was concomitant with perturbations in CI that 
were not associated with decreased cellular viability, and thus indicative of morphological 
changes even at sub-clinical concentrations. Conversely, the class IIb inhibitor tubacin did 
not induce major detectable changes in either functional or structural parameters. These 




by class I HDAC selective inhibition, but not class IIb. There may be an involvement for 
class IIa in these effects, but based on the fact they show little HDAC enzymatic activity 
and inhibitory response to SAHA or TSA, this is unlikely (Bü et al. 2013). The involvement 
of class I HDAC inhibition with structural cardiac alterations has been well documented in 
literature: class I HDAC inhibition has in fact been shown to blunt cardiac pathological 
hypertrophy by epigenetic modifications that suppress a cell growth-associated gene 
through the mTOR pathway (Morales et al. 2016). However, further investigations are 
needed to understand whether class I HDACi induces cardiomyocyte perturbations at sub-
pharmacologically active levels, or whether HDACi-mediated cardiotoxicity is due to an 

























5 Characterisation of the AC10 human ventricular cell line for 
































At present, effective approaches for in-vitro preclinical detection of structural cardiac 
liabilities are lagging, leading to most drug-induced structural perturbations either being 
detected at late-stage project phases during final trials, or post-marketing, usually manifesting 
in the clinic as a result of latent late-onset effects (Schwach, Slaats, and Passier 2020; J. Dong 
and Chen 2018). Currently, hiPSC-CMs are considered the most relevant in-vitro model used 
for preclinical cardiotoxicity screening applications. However, several limitations still remain 
unresolved with this model, as detailed in chapter 3. Two major limitations include I) the 
reliability for detection of structural liabilities, and II) high maintenance and experimental cost. 
The availability of cost-effective and representative models that could aid in the detection of 
structural cardiotoxicity at the early stages of drug development, would therefore offer 
important improvements in this area. Due to their simplicity and ease of use, the AC10 and 
AC16 human-derived ventricular cardiomyocyte cell lines could represent an accessible and 
pragmatic candidate model for this purpose. 
The AC cell lines are derived from the fusion of SV40 transformed immortalised human 
fibroblasts with primary human cardiomyocytes (Davidson et al. 2005). The resulting 
immortalised AC cell lines (AC1, AC10, AC12 and AC16) retain a cardiac phenotype, albeit 
remaining in a pre-contractile state (Davidson et al. 2005). AC cell lines express relevant 
cardiac features, displaying tropomyosin protein structures, as well as expressing cardiac 
troponin I and troponin C (Figure 5.1, Rockley 2018). Additionally, AC10 cells exhibit 
expression of the cardiac transcription factor NKX2.5, as well as the presence of alpha-actinin 
in a non-striated fashion, confirming the unique pre-contractile phenotype of these cells 
(Figure 5.1). Since their development, the AC16 and AC10 cell lines have been used for 
developmental studies of the human heart, evaluation of myocardial cell injury, post-
ischaemia cardiac remodelling, and molecular studies of myocardial inflammatory responses, 
fibrosis and cardiomyopathies (Ontoria-Oviedo et al. 2018; Hirai et al. 2020; Wen et al. 2020; 
Yuan et al. 2016). Therefore, despite their inability to form functional syncytia, they could 
provide a simple and cost-effective model for the mechanistic early detection of structural 
























Figure 5.1 AC10 cells retain cardiac phenotype features. AC10 are a human ventricular-
derived cell line that shows different levels of expression of cardiac markers: tropomyosin, 
cardiac troponin I, cardiac troponin C, cardiac transcription factor NKX2.5, alpha actinin. 
(Image courtesy of Dr Richardson and Dr Rockley) 
 
Figure 5.2 AC10 cells retain cardiac phenotype features. AC10 are a human ventricular-
derived cell line that shows different levels of expression of cardiac markers: tropomyosin, 
cardiac troponin I, cardiac troponin C, cardiac transcription factor NKX2.5, alpha actinin. 
(Image courtesy of Dr Richardson and Dr Rockley) 
 
Figure 5.3 MTT assay as a quantitative method to assess AC10 cell viability over time. A. 
MTT assay to assess AC10 cell growth and survival over time. B. relationship between cell 
number and MTT colorimetric absorbance values at 550 nm.  Data are the mean and SEM of 
at least 3 independent experiments. 
 
 
Figure 5.4 Growth kinetics of AC10 cells plated at different seeding densities. AC10 cells 
were plated on an xCELLigence DP E-plate at different densities and monitored over time. 
Impedance plateau was attained at different timepoints post seeding. Data are the mean ±SD 
of at least 4 different determinations from separate experiments. 
 
Figure 5.5 Growth kinetics of AC10 cells plated at different seeding densities. AC10 cells 
were plated on an xCELLigence DP E-plate at different densities and monitored over time. 
Impedance plateau was attained at different timepoints post seeding. Data are the mean ±SD 
of at least 4 different determinations from separate experiments. 
 
Figure 5.6 Doxorubicin induces characteristic hypertrophic changes in AC10 cells. AC10 cells 
were exposed to doxorubicin at a range of concentrations for 72 h. A. Doxorubicin induced a 




5.1.1 Use and relevance of three-dimensional modelling in preclinical cardiotoxicity 
 
The optimisation and use of three-dimensional in-vitro culture techniques has gained 
increasing momentum in recent years. The use of spheroids and organoids is particularly 
appealing for use in in-vitro drug safety screening, as three-dimensional models have the 
potential of providing better in-vivo-like and physiologically relevant tissues, thus providing 
enhanced predictivity profiles compared to two-dimensional platforms (Wrzesinski et al. 
2014).  Such is the case of various hepatic 3D models derived from hepatocyte cell lines, which 
have been successfully established and implemented for drug safety and toxicology 
applications (Gaskell et al. 2016; Kyffin et al. 2019). 
Cardiac spheroids have recently been established, utilising hiPSC-CMs in co-culture with 
primary cardiac fibroblasts and cardiac endothelial cells (Ravenscroft et al. 2016). This 
particular triculture combination of cell lineages, representative of the adult human cardiac 
composition, has enabled the generation of reproducible and contractile cardiac 3D models 
which demonstrated good predictivity against acute functional cardiotoxicants (Tomlinson et 
al. 2019; Ravenscroft et al. 2016). Furthermore, 3D cultured hiPSC-CMs have been shown to 
enhance non-myocyte cell functionality, as well as enhance overall microtissue maturity 
(Ravenscroft et al. 2016).  
The utility of cardiomyocyte cell lines, including the AC10 cell line, has not been assessed for 
use in 3D scaffold free microtissue applications. Given the remarkable advantages of 3D 
microtissues in terms of improvement of CM functionality, phenotype maturation and 
prolonged culturing lifespan, the AC10 cardiomyocyte cell line could provide a more 
accessible, scalable and cost-effective model for acute and sub-acute structural cardiotoxicity 










5.1.2 Aims and Objectives 
 
The AC10 cardiomyocyte cell line provides a readily expandable source of cells that retain 
several relevant cardiac markers. The use of this cell line paired with high-throughput and 
advanced culture technologies for early preclinical cardiotoxicity screening has not been fully 
explored to date. For this reason, a set of studies is hereby described with the aim to 
characterise the AC10 cell line for use in structural toxicology applications through the 
following objectives. 
1) Assess the suitability of the AC10 human ventricular cell line for preclinical cardiotoxicity 
studies in two-dimensional monolayers 
(a) Assess the utility of the AC10 cell line in combination with xCELLigence RTCA 
impedance systems 
2) Evaluate and characterise the suitability of AC10 cells for preclinical cardiotoxicity studies 
in three-dimensional spheroid cultures 
3) Evaluate the utility of the AC10 model in the detection of structural cardiotoxicity induced 
by the HDACi class of drugs. 
(a) Assess the ability of AC10 cells to detect structural cardiotoxicity in 2D 
platforms using impedance-based systems. 















5.2 AC10 cell line characterisation for structural cardiotoxicity studies 
 
5.2.1 AC10 cell line characterisation of growth kinetics for studies in two-dimensional 
cultures 
 
To optimise a protocol for AC10 cell cardiotoxicity using two-dimensional platforms, cellular 
proliferative and kinetic characteristics were assessed. A set of studies combining the use of 
xCELLigence DP16 system and MTT assays were designed to gain an insight into the optimal 
seeding densities of AC10 cells required for cardiotoxicity detection experiments using these 
methodologies. 
To determine the limitations of the MTT assay for cellular quantitative purposes of AC10 cells, 
an investigation into the relationship between manually determined cell number and 
detectable absorbance was carried out, in cells cultured in a 96-well plate. The lower and 
upper absorbance detection thresholds, whereby cell numbers were either insufficient to 
allow a quantifiable MTT formazan crystal reduction or were too elevated leading to 
colourimetric saturation were determined (Figure 5.2). Specifically, the lower detection limit 
was identified as ≤ 1 X 103 cell/mL and the upper detection limit was identified as ≥ 1 x 105 
cell/mL. A linear relationship between cell number and detection by the MTT assay was 
therefore confirmed for AC10 cells within these identified limits (1 X 103 - 1 x 105 cell/mL). 
In terms of determination of cellular responses using the xCELLigence methodologies, AC10 
cells were plated on a DP16 E-Plate at a range of seeding densities, and cell index was 
monitored over time (method, section 2.7.1). Specific growth and kinetics parameters were 
identified for each initial seeding density, allowing to identify the optimal cell growth stage in 
relation to impedance values (Figure 5.3). Since AC10 cells do not form contractile syncytia, a 
suitable initial seeding density necessary to attain a stable cellular monolayer was 
extrapolated from the impedance traces. For subsequent cytotoxicity studies combined with 
the xCELLigence DP16 system, an initial seeding density between 1 x 105 and 2 x 105 cells/mL 
was deemed optimal, as it allowed AC10 cells to reach a stable impedance value within 36 
hours post-seeding. The impedance cell index values further suggest that a confluent cellular 
monolayer was achieved and sustained for ≥48 hours post plateau, demonstrating suitability 




To confirm viability of AC10 cells during assessment by xCELLigence, cells were plated at a 
range of seeding densities, with cell viability subsequently evaluated using the MTT assay 
(methodology described in section 2.5.1) (figure 5.2A). A steady increase in absorbance was 
detected with AC10 cells plated at initial seeding densities between 1 x 103 and 1 x 105 cell/mL, 
demonstrating successful survival of AC10 cell monolayers over the course of 96 hours. On the 
contrary, cells plated at initial seeding densities between 1 X 102 and 1 X 103 did not determine 
a detectable increase in absorbance over time, in agreement with the previously defined 
limitations of the MTT assay stated above. 
 
Overall, these experiments allowed to validate the use of MTT assays for AC10 quantitative 













































































Figure 5.2 MTT assay as a quantitative method to assess AC10 cell viability over time. A. 
MTT assay to assess AC10 cell growth and survival over time. B. relationship between cell 
number and MTT colorimetric absorbance values at 550 nm.  Data are the mean and SEM of 
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Figure 5.3 Growth kinetics of AC10 cells plated at different seeding densities. AC10 cells 
were plated on an xCELLigence DP E-plate at different densities and monitored over time. 
Impedance plateau was attained at different timepoints post seeding. Data are the mean ±SD 








Figure 5.11 Internal structure of AC10 monoculture and triculture spheroids. Spheroids 
were cultured on ULA plates for 14 days, fixed and stained with anti-cardiac troponin I (green) 
, Hoechst to stain the cell nuclei (blue), phalloidin to stain cytoskeletal structures (red) and 
anti CD31  antibody to stain endothelial cells (white; yellow arrow shows primitive vessel-like 
endothelial cell aggregation). Images are maximum intensity projections representative of a 
mid-section of each spheroid, typical of at least 3 different spheroids. A. Monoculture AC10: 
20x magnification, scale bar is 50 µm B. Triculture AC10: 40x magnification with oil 
immersion, scale bar is 20 µm. 
 
Figure 5.12 Internal structure of AC10 monoculture and triculture spheroids. Spheroids 
were cultured on ULA plates for 14 days, fixed and stained with anti-cardiac troponin I (green) 
, Hoechst to stain the cell nuclei (blue), phalloidin to stain cytoskeletal structures (red) and 




5.2.2 AC10 cell line characterisation for structural cardiotoxicity studies in two-
dimensional cultures 
 
To assess the suitability of the AC10 cell line for the detection of drug induced structural 
perturbations, effects of the known structural cardiotoxicant doxorubicin were assessed using 
the xCELLigence DP system. For this study, AC10 cells were plated and monitored on a 
xCELLigence DP E-plate until confluency and cell index plateau were achieved, and 
subsequently doxorubicin was added at a range of concentrations.  
Doxorubicin induced a significant (P<0.05) increase in cell index 24 hours post compound 
addition at 100 nM and 50 nM concentrations, suggesting AC10 cells underwent an acute 
hypertrophic morphological change (Figure 5.4A and 5.4B). Doxorubicin induced a steady 




















Figure 5.4 Doxorubicin induces characteristic hypertrophic changes in AC10 cells. AC10 cells 
were exposed to doxorubicin at a range of concentrations for 72 h. A. Doxorubicin induced a 
transient increase in cell index at concentrations between 50 nM and 100 nM, and a decrease 
in cell index at 1 µM. B. Cell index changes 24 h post compound addition, * = p<0.05. 
Impedance data are normalised to time-matched vehicle control and baseline values (∆∆%) 
and are the average ±SEM of at least 3 different experiments. Tested by ANOVA with 
Bonferroni post hoc modifications. 
 
Figure 5.15 Doxorubicin induces characteristic hypertrophic changes in AC10 cells. AC10 
cells were exposed to doxorubicin at a range of concentrations for 72 h. A. Doxorubicin 
induced a transient increase in cell index at concentrations between 50 nM and 100 nM, and 










5.2.3 AC10 cell line characterisation for structural studies in three-dimensional 
cultures 
 
Following the characterisation of growth and kinetics of the AC10 cell line model, and the 
confirmation of its suitability for the detection of structural liabilities using standard two-
dimensional cultures, it was hypothesised that AC10 cells could be utilised in three-
dimensional cultures. Within these studies, AC10 cells were used for the first time to establish 
single-lineage spheroid monocultures, as well as multi-lineage spheroid tricultures comprising 
human primary cardiac fibroblast and human primary cardiac endothelial cells (methodology 
described in section 2.4). Firstly, AC10 cells were assessed to characterise their ability to 
successfully aggregate into viable 3D structures. Next, the newly formed spheroids were 
monitored to assess overall growth and size over time (figure 5.5A). Both monoculture and 
triculture spheroids appeared spherical in shape, maintaining this feature over time. 
Monoculture and triculture spheroids reached their maximum size within approximately 20 
days post plating, with a maximum diameter of 540 ± 90 µm for monoculture spheroids, and 
a maximum diameter of 700 ±88 µm for triculture spheroids. Following this timepoint, 
spheroids displayed structural instability likely due to continuous cellular proliferation, 
subsequently leading to the formation of an unviable hypoxic core. Interestingly, despite an 
equal initial cellular number used, AC10 monoculture spheroids remained smaller in size 
compared to triculture spheroids.  
Immunofluorescent staining was used to investigate structural features in both monoculture 
and triculture spheroids (figure 5.6 A and B). For these studies, spheroids cultured for 14 days 
were fixed, stained and mounted onto microscope slides according to the methodology 
described in section 2.10. Both monoculture and triculture spheroids were shown to retain 
the expression of cardiac troponin I (cTnI), albeit cTnI staining did not evidence the formation 
of a syncytium-like cellular organisation. In tricultures, staining with phalloidin evidenced a 
network of f-actin filaments, allowing to assess the internal cytoskeletal organisation 
throughout the spheroids. Staining for the platelet endothelial cell adhesion molecule CD31 
was used to locate cardiac endothelial cells within the spheroids, highlighting clustering of 
endothelial cells in one physical location within the spheroid in a potential effort to form minor 




function of these structures. Hoechst stain was used to identify cell nuclei throughout the 
spheroids. 
Overall, these studies demonstrate that AC10 cells can be used to successfully construct 3D 
spheroids, both using a monoculture and a triculture approach. These studies also allowed to 
identify the optimal experimental timeframe for AC10 spheroid studies: to avoid loss of 
structural stability and other non-drug dependent disturbances, AC10 spheroids were used 14 




















Figure 5.5. AC10 cells form viable monoculture and triculture spheroids. A. Growth curves 
of AC10 monoculture and triculture spheroids cultured in ultra low adhesion plates. Data is 
the average size in µm ±SD of at least three separate spheroids, imaged using  brightfield 
microscopy. B. Representative brightfield images illustrating spheroid size, growth and 














Figure 5.6. Internal structure of AC10 monoculture and triculture spheroids. Spheroids were cultured on ULA plates for 14 days, fixed and stained 
with anti-cardiac troponin I (green), Hoechst to stain the cell nuclei (blue), phalloidin to stain cytoskeletal structures (red) and anti CD31  antibody to 
stain endothelial cells (white; yellow arrow shows primitive vessel-like endothelial cell aggregation). Images are maximum intensity projections 
representative of a mid-section of each spheroid, typical of at least 3 different spheroids. A. Monoculture AC10: 20x magnification, scale bar is 50 µm 
B. Triculture AC10: 40x magnification with oil immersion, scale bar is 20 µm. 
 
Figure 5.16 Internal structure of AC10 monoculture and triculture spheroids. Spheroids were cultured on ULA plates for 14 days, fixed and stained 
with anti-cardiac troponin I (green) , Hoechst to stain the cell nuclei (blue), phalloidin to stain cytoskeletal structures (red) and anti CD31  
antibody to stain endothelial cells (white; yellow arrow shows primitive vessel-like endothelial cell aggregation). Images are maximum intensity 












5.3 HDACi induce structural cardiotoxic changes in AC10 cells 
 
5.3.1 Pan-HDACi induce structural changes in 2D AC10 cell line monolayer 
 
Previous studies described in chapters 3 and 4 confirmed that pan-HDACi induced functional 
alterations in hiPSC and HL-1 two-dimensional cell models, in addition to significant structural 
and metabolic cardiomyocyte changes in the HL-1 model. Consequently, the effects of the 
pan-HDACi SAHA and TSA were evaluated in AC10 cells, particularly focusing on the detection 
of structural and morphological cellular alterations. For these studies, AC10 cells were initially 
assessed for cell index changes in response to pan-HDACi exposure using the xCELLigence DP 
system. 
In line with previous studies using the HL-1 model, the pan-HDACI SAHA and TSA induced a 
significant (p<0.05) drop in cell index within 24 hours post compound addition at 
concentrations between 5µM and 200 nM for SAHA , and between 3 µM and 200 nM for TSA.  
The decrease in cell index at higher compound concentrations (5 - 1.2 µM SAHA and 3 – 1 µM 
TSA) was attributed to pan-HDACi-induced cytotoxicity as demonstrated by relevant MTT 
assays, identifying  IC50 values in AC10 cells at 1.82 ± 0.4 µM for SAHA (Figure 5.7 B) and 1.67 
± 0.5 µM for TSA (Figure 5.8B). Remarkably, the significant decrease in cell index was 
observable at concentrations below the cytotoxic threshold. To investigate whether these 
effects were dependent on structural changes, and not on cellular death or effects on cellular 
metabolic activity, manual cell counts were performed. Data indicated that cell numbers in 
AC10 cells treated with sub-cytotoxic concentrations of pan-HDACI SAHA and TSA remained 
unaltered, suggesting that the observed effects on cell index were dependent on cellular 
morphological alterations (Figures 5.7 C and 5.8C). 
Further studies using brightfield microscopy on non-confluent pan-HDACi-treated AC10 cells 
evidenced a drastic and irreversible change in cellular appearance and morphology following 
pan-HDACi exposure (Figure 5.9A and 5.9B). In these studies, non-confluent AC10 cells were 
exposed to a single 200 nM sub-cytotoxic concentration of TSA for 24 hours, before 




a fibroblast-like cellular structure typical of AC10 cells to a more elongated and stretched 
appearance (Figure 5.9). From these results it is plausible to assume that any reduction in 
impedance cell index, recorded after exposure to sub-cytotoxic pan-HDACi concentrations, is 
a direct consequence of hypotrophic morphological changes, which would result in a reduced 
E-plate electrode surface-to-cell contact ratio. Additionally, cells did not resume their original 
morphology upon compound removal, demonstrating the occurrence of a permanent 
morphological change. 
Taken together, these results confirm that morphological changes in AC10 cells are associated 
with sub-cytotoxic pan-HDACi exposure, and are also in line with the impedance cell index 





























































Figure 5.7 Pan-HDACIs induce changes in cell index and viability at toxic and sub-toxic 
concentrations in AC10 cells. AC10 cells were exposed to SAHA at a range of concentrations 
for 72 h. A. SAHA induced a significant decrease in CI at concentrations between 5 µM and 
200 nM starting 12 h post compound addition. B. MTT assays did not evidence any reduction 
in cell viability following SAHA addition at concentrations between 200 and 500 nM. C. sub-
clinical concentrations of SAHA did not affect average cell numbers. Impedance data are 
normalised to time-matched vehicle control and baseline values (∆∆%) and are the average 
±SE of at least 3 different experiments. Cell counts and MTTs are normalised to vehicle control 




Figure 5.19 Pan-HDACIs induce changes in cell index and viability at toxic and sub-toxic 






































































































Figure  5.8 Pan-HDACIs induce changes in cell index and viability at clinical and subclinical 
concentrations in AC10 cells. AC10 cells were exposed to TSA at a range of concentrations for 
72 h. TSA induced a significant decrease in CI at concentrations between 3 µM and 200 nM 
starting 12 h post compound addition. B. MTT assays did not evidence any significant 
reduction in cell viability following TSA addition at concentrations between 200 and 500 nM. 
C. Sub-cytotoxic concentrations of TSA did not affect average cell numbers Impedance data 
are normalised to time-matched vehicle control and baseline values (∆∆%) and are the 
average ±SE of at least 3 different experiments. Cell counts and MTTs are normalised to 
vehicle control and are typical of at least 3 separate experiments. Tested by ANOVA with 






























Figure 5.9 Pan-HDACi induce cellular structural remodelling at sub-cytotoxic concentrations 
in AC10 cells. AC10 cells were exposed to 200 nM TSA for 24 h and imaged under phase 
contrast microscopy (magnification 20X).A. Typical AC10 cell morphology after exposure to 
vehicle DMSO. B. TSA induced elongation and structural remodelling of AC10 cells without 
affecting cellular integrity and viability Images are representative of at least 4 different 
separate experiments. Enhanced contrast (right) was used to highlight cell surface and 
morphological features. 
 
Figure 5.28 Pan-HDACi induce cellular structural remodelling at sub-cytotoxic 
concentrations in AC10 cells. AC10 cells were exposed to 200 nM TSA for 24 h and imaged 
under phase contrast microscopy (magnification 20X).A. Typical AC10 cell morphology after 
exposure to vehicle DMSO. B. TSA iFigure 5.29 Class I selective inhibitor, but not class IIb, 
induced a transient decrease in cell index in AC10 cells. . AC10 cells were exposed to MS-
275 and tubacin for 72 h. A. MS-275 induced a transient decrease in cell index following 
exposure to 1 µM but not 200 nM. A concentration of ≤ 1 µM did not induce cytotoxicity. B. 
Tubacin at 5 µM did not induce detectable changes in cell index and did not induce 
cytotoxicity. Impedance data are normalised to time-matched vehicle control and baseline 
values (∆∆%) and are the average ±SE of at least 3 different experiments. MTTs are 
normalised to vehicle control and are typical of at least 3 separate experiments. Tested by 
ANOVA with Bonferroni post-hoc modifications. 
 
 
Figure 5.30 Class I selective inhibitor, but not class IIb, induced a transient decrease in cell 
index in AC10 cells. . AC10 cells were exposed to MS-275 and tubacin for 72 h. A. MS-275 
induced a transient decrease in cell index following exposure to 1 µM but not 200 nM. A 
concentration of ≤ 1 µM did not induce cytotoxicity. B. Tubacin at 5 µM did not induce 
TSA 200 nM 
 













5.3.2 Determination of HDACI pharmacological targets in AC10 cells 
 
After confirming that pan-HDACi induced morphological alterations in AC10 cells at sub-
clinical and sub-cytotoxic concentrations, studies were carried out to gain mechanistic insight 
into the pharmacological activity of SAHA and TSA in the AC10 model. As in the analogous 
studies reported in section 4.9, two primary HDACi targets were assessed in AC10 whole 
protein lysates following exposure to various pan-HDACi concentrations (methodology 
described in section 2.8). Acetylation of histone H4 and α-tubulin were therefore assessed in 
response to TSA and SAHA (figure 5.10 and 5.11). 
Treatment with the cytotoxic 1.2 µM concentration of SAHA resulted in an increase in both 
histone H4 and α-tubulin acetylation levels. However, exposure to sub-cytotoxic 
concentrations of SAHA ≤ 200 nM did not change protein acetylation levels (figure 5.10).  
A similar effect was observed following exposure to TSA: the cytotoxic 1 µM concentration 
elicited marked acetylation of both α-tubulin and histone H4 in a time-dependent manner. 
Conversely, no change in acetylation was observed following exposure to the non-cytotoxic 
200 nM concentration of TSA. 
Together, these observations suggest that any structural effects induced following sub-
cytotoxic exposure to pan-HDACi are likely to be attributed to secondary pharmacology effects 
rather than main HDACi pharmacological targets. These results therefore further corroborate 




















Figure 5.10 Determination of pan-HDACi pharmacological targets in AC10 cells. Western Blot 
analysis of AC10 whole protein extracts assessing levels of acetylated α tubulin (55 kDa) and 
acetylated histone H4 (10 kDa) following treatment with A. 1µM and B. 200 nM 
concentrations of Pan-HDACi TSA. Each lane contained 20µg protein/lane. Results are 
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Figure 5.11 Determination of pan-HDACi pharmacological targets in AC10 cells. Western 
Blot analysis of AC10 whole protein extracts assessing levels of acetylated α tubulin (55 kDa) 
and acetylated histone H4 (10 kDa) following treatment with A. 1µM and B. 200 and 300 nM 
concentrations of Pan-HDACi SAHA. Each lane contained 20µg protein/lane. Results are 
representative of one typical experiment of at least 3 separate experiments 
 
 
Figure 5.31 Determination of pan-HDACi pharmacological targets in AC10 cells. Western 



















5.3.3 Sub-selective class I HDAC inhibition, but not class IIb, is associated with 
structural alterations in AC10 cell monolayers 
 
To confirm whether HDACi-induced structural changes could be attributed to selective HDAC 
inhibition in AC10 cells, an investigation into the effects of class I and IIb HDAC selective 
inhibitors was carried out. For these studies, AC10 cells were grown to confluency in a 
xCELLigence DP E-plate, and subsequently exposed to class I HDACi MS-275 and class IIb HDACi 
tubacin. 
Results indicate that class I selective inhibitor, but not class IIb, induced a decrease in cell index 
(figure 5.12A and 5.12B). Specifically, MS-275 induced a significant (p<0.05) decrease in cell 
index by 31% 24 hours post compound addition at the cytotoxic concentration of 1 µM. No 
decrease in cell index was however recorded following exposure to 200 nM MS-275. 
Class IIb selective inhibitor tubacin did not induce detectable changes in cell index even at the 
highest tested concentrations (figure 5.12B). 
Overall, these results confirm that class I, but not class IIb, is partly implicated in HDACi-
induced cardiotoxicity. Lastly, these results are consistent with the structural effects observed 
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Figure 5.12 Class I selective inhibitor, but not class IIb, induced a transient decrease in cell 
index in AC10 cells. AC10 cells were exposed to MS-275 and tubacin for 72 h. A. MS-275 
induced a transient decrease in cell index following exposure to 1 µM but not 200 nM. A 
concentration of ≤ 1 µM did not induce cytotoxicity. B. Tubacin at 5 µM did not induce 
detectable changes in cell index and did not induce cytotoxicity. Impedance data are 
normalised to time-matched vehicle control and baseline values (∆∆%) and are the average ±SE 
of at least 3 different experiments. MTTs are normalised to vehicle control and are typical of at 
least 3 separate experiments. Tested by ANOVA with Bonferroni post-hoc modifications. 
 
 
Figure 5.41 Class I selective inhibitor, but not class IIb, induced a transient decrease in cell 
index in AC10 cells. . AC10 cells were exposed to MS-275 and tubacin for 72 h. A. MS-275 
induced a transient decrease in cell index following exposure to 1 µM but not 200 nM. A 
concentration of ≤ 1 µM did not induce cytotoxicity. B. Tubacin at 5 µM did not induce 
detectable changes in cell index and did not induce cytotoxicity. Impedance data are 
normalised to time-matched vehicle control and baseline values (∆∆%) and are the average ±SE 










5.3.4 Pan-HDACi induce structural changes in AC10 spheroids 
 
Studies on AC10 cell monolayers confirmed that pan-HDACi induce structural and 
morphological changes. AC10 monoculture and triculture spheroids were therefore used to 
assess pan-HDACi structural effects in a three-dimensional microenvironment. The first phase 
of these studies was designed to assess chemosensitivity and viability of 3D AC10 structures 
against HDACi compounds using ATP viability assays. Next, studies were focused on the 
identification of structural perturbations using a combination of bioimaging techniques, 
assessing whole-spheroid morphological features as well as internal structural alterations. 
 
5.3.4.1 AC10 spheroids demonstrate enhanced sensitivity to pan-HDACi 
 
Chemosensitivity of monoculture and triculture spheroids against pan-HDACi TSA and SAHA 
was evaluated using Cell Titer-Glo ATP assays (methodology described in section 2.5.2).  Dose-
response curves are illustrated in figure 5.13. Both monoculture and triculture AC10 spheroids 
demonstrated higher sensitivity to pan-HDACi exposure compared to 2D AC10 monolayers. 
IC50 values were obtained following 24-hour exposure to a single dose of pan-HDACi. The IC50 
values for TSA were 0.7 ± 0.2 and 0.8 ± 0.2 µM for monocultures and tricultures, respectively. 
The IC50 values for SAHA were 1.7 ± 0.3 µM and 1.3 ± 0.6 µM for monocultures and tricultures 




























1.3 ± 0.43 0.69 ± 0.2 0.8 ± 0.15 
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2.56 ± 0.76 1.7 ± 0.31 
 
1.30 ± 0.61 
Figure 5.13. AC10 spheroids display enhanced sensitivity to pan-HDACi. AC10 monoculture 
and triculture spheroid dose-response curves derived from 24-hour exposure to pan-HDACi 
TSA (A) and SAHA (B). Data are the mean ±SD of at least 3 separate experiments. Extrapolated 



















5.3.4.2 Pan-HDACi induce changes in whole-spheroid morphology 
 
Untreated AC10 spheroids were shown to maintain a uniform spherical shape over time. A 
study was designed to investigate whether structural changes in whole-spheroid morphology 
occurred following exposure to pan-HDACi compounds. For these studies, AC10 monoculture 
spheroids were grown for 14 days before being exposed to various concentrations of TSA for 
20 hours. Morphological features including whole-spheroid size, shape and diameter were 
monitored using brightfield imaging. Imaging indicates that TSA at 5 µM and 1 µM 
concentrations induced a disruption in spheroid morphology and appearance: this is 
demonstrated by the occurrence of uneven spheroid borders, displaying through peripheral 
protrusions and blebbing (figure 5.14A). Following exposure to TSA concentrations between 
0.5 µM and 0.2 µM, spheroid borders did not display blebbing or other disruptions, and 
appeared integral. However, whole-spheroid morphology appeared elliptical rather than 
spherical. To establish whether the transition from a spherical shaped spheroid into an 
elliptical shaped spheroid was a direct consequence of pan-HDACi exposure, AC10 spheroids 
were assessed using brightfield bioimaging before and after treatment with TSA. Spheroid size 
and morphology was recorded on the same sample prior to and post-treatment with TSA for 
20 hours. Imaging indicates an observable transition from spherical to elliptical shape in most 
treated spheroids (figure 5.14B) (sample size ≥ 20 spheroids per treatment, per experiment). 
Further analysis confirmed that the ratio of perpendicular spheroid diameters was 
significantly different (p<0.01) compared to vehicle exposure, confirming the occurrence of 















Figure 5.14 TSA causes whole-spheroid morphology changes in monoculture AC10 
spheroids. AC10 monoculture spheroids were cultured for 14 days and subsequently treated 
with various concentrations of TSA for 20 h. A. TSA induced edge blebbing and protrusions at 
concentrations between 5-1µM, and induced whole-spheroid morphological changes at 
concentrations between 1-0.2µM. B. Whole-spheroid morphology was compared before and 
after exposure to TSA, showing transition from spherical to elliptical shapes at concentrations 
between 1-0.2µM. Images are 10x magnification, scale bar 200µm C. Diameter ratio of whole-
spheroids was compared, indicating ratios of non-spherical shaped spheroids were 
significantly (p<0.01) different compared to control. Data are the mean and SEM from at least 
3 separate experiments (≥20 spheroids per treatment). Tested by ANOVA and Tukey’s post 
hoc modifications. **= p<0.01 
 
Figure 5.44 TSA inFigure 5.18 SAHA induces internal structural perturbations in AC10 
monoculture spheroids at sub-cytotoxic concentrations. AC10 monoculture spheroids were 
cultured in ULA plates for 14 days, exposed to vehicle DMSO control and SAHA for 20 hours, 











































5.3.4.3 Pan-HDACi induce disruption of internal spheroid structures 
 
Whole-spheroid morphological assessment confirmed the occurrence of pan-HDACi-induced 
spheroid restructuring in AC10 monoculture spheroids. To investigate the effects of pan-
HDACi compounds on the internal framework of the spheroid, experiments were designed to 
visualise spheroid section stacks using immunofluorescence analysis for relevant structural 
markers. Specifically, AC10 spheroids were cultured for 14 days, then fixed and stained for 
cardiac troponin I (cTnI), phalloidin to highlight F-actin, and Hoechst-33342 dye to stain nuclei 
(methodology described in section 2.10). 
Ultrastructural analysis of spheroid mid-sections demonstrated that pan-HDACi TSA induced 
a marked increase in cTnI signal at both cytotoxic and sub-cytotoxic concentrations. CTnI 
staining however did not highlight specific intracellular structures, but rather resulted in 
accumulation within the spheroid, confirming cTnI release likely occurred due to disruption 
typical of cardiac structural damage. Additionally, phalloidin staining for f-actin evidenced a 
marked disruption following both TSA tested concentrations. Following exposure to the 
cytotoxic concentration of 1 µM, TSA induced a significant (p<0.01) increase in phalloidin 
signal intensity, suggesting the occurrence of a perturbation within the f-actin cytoskeletal 
filament network (Figures 5.15, 5.16 and 5.17) 
Interestingly, following exposure to the sub-cytotoxic concentration of 200 nM, TSA did not 
induce an increase in phalloidin signal intensity, albeit the F-actin network appeared 
remarkably fragmented, suggesting the occurrence of a disruptive effect on cytoskeletal 
organisation. Analogous findings were observed following exposure to sub-cytotoxic 
concentrations of SAHA, where at 200 nM no significant increases were observed in cTnI signal 
intensity. However, a significant decrease (p<0.05) in phalloidin signal intensity evidenced a 
disruption to F-actin filaments, and f-actin fragmentation was also observed (figure 5.18 and 
5.19). 
Overall, these results indicate that pan-HDACi elicited marked alterations of the internal 
spheroid structure. TSA induced particularly strong effects, with evident disruptions to cTnI 
indicative of cardiomyocyte damage. While the effects of cytotoxic TSA concentrations also 




death, sub-cytotoxic concentrations of TSA and SAHA demonstrated a clear F-actin 




















Figure 5.15 TSA induces internal structural perturbations in AC10 monoculture spheroids at cytotoxic concentrations.   AC10 
monoculture spheroids were cultured in ULA plates for 14 days, exposed to TSA for 20 hours fixed and stained with anti-cardiac 
troponin I (green), Hoechst to stain the cell nuclei (blue) and phalloidin to stain cytoskeletal structures (red). TSA induced cTnI 
disruption with visible intra-spheroid accumulation (blue arrow). TSA induced a marked disruption in f-actin organisation. Images are 
maximum intensity projections representative of a mid-section of each spheroid, typical of at least 3 different spheroids.  Images were 




Figure 5.16 TSA induces internal structural perturbations in AC10 monoculture spheroids at sub-cytotoxic concentrations.   




Figure 5.16 [continued] TSA induces internal structural perturbations in AC10 monoculture 
spheroids at sub-cytotoxic concentrations. AC10 monoculture spheroids were cultured in 
ULA plates for 14 days, exposed to TSA and vehicle DMSO control for 20 hours, fixed and 
stained with anti-cardiac troponin I (green), Hoechst to stain the cell nuclei (blue) and 
phalloidin to stain cytoskeletal structures (red).TSA induced cTnI disruption with visible intra-
spheroid accumulation (blue arrow). TSA induced fragmentation of f-actin network (yellow 
arrow; zoomed image). Images are maximum intensity projections representative of a mid-
section of each spheroid, typical of at least 3 different spheroids.  Images were taken at equal 



















Figure 5.17 TSA induces internal structural perturbations in AC10 monoculture spheroids -
Fluorescence signal intensity analysis AC10 monoculture spheroids were cultured in ULA 
plates for 14 days, exposed to TSA for 20 hours, fixed and stained with anti-cardiac troponin 
I, Hoechst to stain the cell nuclei and phalloidin to stain cytoskeletal structures. Signal 
intensity was evaluated on mid-spheroid section images taken at identical exposure settings. 
CTnI and f-actin signals were significantly increased following 1 µM TSA exposure. CTnI signal 
was increased following 200 nM TSA exposure. Hoechst stained nuclei signal was not affected 
and showed equal intensity. Data are the mean and SD of at least three independent 
determinations and are expressed as fold change relative to control. *= p<0.05 ; **= p<0.01 
 
Figure 5.17 TSA induces internal structural perturbations in AC10 monoculture spheroids -
Fluorescence signal intensity analysis AC10 monoculture spheroids were cultured in ULA 
plates for 14 days, exposed to TSA for 20 hours, fixed and stained with anti-cardiac troponin 
I, Hoechst to stain the cell nuclei and phalloidin to stain cytoskeletal structures. Signal 
intensity was evaluated on mid-spheroid section images taken at identical exposure settings. 
CTnI and f-actin signals were significantly increased following 1 µM TSA exposure. CTnI signal 
was increased following 200 nM TSA exposure. Hoechst stained nuclei signal was not affected 
and showed equal intensity. Data are the mean and SD of at least three independent 




Figure 5.18 SAHA induces internal structural perturbations in AC10 monoculture spheroids at sub-cytotoxic concentrations. AC10 
monoculture spheroids were cultured in ULA plates for 14 days, exposed to vehicle DMSO control and SAHA for 20 hours, fixed and 
stained with anti-cardiac troponin I (green), Hoechst to stain the cell nuclei (blue) and phalloidin to stain cytoskeletal structures 
(red).SAHA did not induce cTnI disruption. TSA induced fragmentation of f-actin network (yellow arrow). Images are maximum intensity 
projections representative of a mid-section of each spheroid, typical of at least 3 different spheroids.  Images were taken at equal 







Figure 5.19 SAHA induces internal structural perturbations in AC10 monoculture spheroids 
-Fluorescence signal intensity analysis.  analysis AC10 monoculture spheroids were cultured 
in ULA plates for 14 days, exposed to SAHA for 20 hours, fixed and stained with anti-cardiac 
troponin I, Hoechst to stain the cell nuclei and phalloidin to stain cytoskeletal structures. 
Signal intensity was evaluated on mid-spheroid section images taken at identical exposure 
settings. F-actin but not cTnI intensity was affected following 200nM SAHA exposure. Hoechst 
nuclei signal was unaffected. Data are the mean and SD of at least three independent 
determinations and are expressed as fold change relative to control.  *= p<0.05 
 
Figure 5.48 Integrated use of cardiac models.Figure 5.19 SAHA induces internal structural 
perturbations in AC10 monoculture spheroids -Fluorescence signal intensity analysis.  
analysis AC10 monoculture spheroids were cultured in ULA plates for 14 days, exposed to 
SAHA for 20 hours, fixed and stained with anti-cardiac troponin I, Hoechst to stain the cell 
nuclei and phalloidin to stain cytoskeletal structures. Signal intensity was evaluated on mid-
spheroid section images taken at identical exposure settings. F-actin but not cTnI intensity 
was affected following 200nM SAHA exposure. Hoechst nuclei signal was unaffected. Data 
are the mean and SD of at least three independent determinations and are expressed as fold 







The availability of simple and cost-effective models for early screening of cardiotoxicity is 
currently limited. While the study of acute functional cardiotoxicity has shown considerable 
advances in recent years due the advent of contractile and phenotypically relevant hiPSC-CM 
models, detection of drug-induced structural changes with these cell models remains limited 
(Földes et al. 2014). Similarly, early signs and markers of structural cardiotoxicity screening are 
still mostly not easily detectable or insufficient in models utilising hiPSC-CMs (Satsuka and 
Kanda 2019; Da Rocha et al. 2017; Johansson et al. 2020). Additionally, preclinical 
cardiotoxicity safety assays are often designed to provide high-throughput data collection, 
wherein the use of costly cardiac cell models such as hiPSC-CMs is carefully optimised to 
provide a sustainable cost-to-benefit ratio. As such, the use of hiPSC-CMs on a large scale is 
therefore limited, and generally relegated to the detection of drug-induced functional 
cardiotoxicity. The AC10 human ventricular cardiomyocyte cell line represents a source of 
readily expandable and cost-effective cardiac-like cells (Davidson et al. 2005), which remains 
unexplored for its potential application and utility in early structural cardiotoxicity screening. 
The aim of this chapter was to assess the suitability of AC10 cells as a model for the detection 
of drug-induced structural perturbations, both in combination with high-throughput 
impedance-based technologies, as well as through the use of advanced three-dimensional 
culture systems. 
The first phase of this study focused on the optimisation of a protocol for the use of two-
dimensional AC10 cell monolayers in combination with impedance-based technologies. AC10 
cells are typically described as cardiomyocyte-like cells that remain in a pre-contractile state 
(Davidson et al. 2005), and as such they do not form a functional contractile syncytium. Unlike 
terminally differentiated cardiomyocytes, AC10 cells also retain a proliferative capacity due to 
their immortalised nature. Therefore, to better represent and mimic the cardiac environment, 
studies were designed to understand the growth kinetics of AC10 cells, and subsequently 
identify optimal seeding densities for their use on the xCELLigence DP platform. This study 
indicated that AC10 cells could achieve an impedance cell index plateau due to cellular 




monolayer and maintaining stable impedance values for over 48 hours, therefore making 
them suitable for both acute and delayed-onset toxicity studies (section 5.2.1).  Using the 
optimised cell seeding protocol, the structural cardiotoxicant doxorubicin was used to 
evaluate effects upon cell index impedance: this resulted in the induction of detectable cell 
index perturbations. In particular, a sub-therapeutically relevant doxorubicin concentration 
induced a cell index increase imputable to cellular hypertrophic changes, a finding also 
previously reported in the AC10 model (Rockley 2018). At higher concentrations, doxorubicin 
induced a cytotoxic response in AC10 cells, as reflected by the decrease in cell index 
parameters (section 5.2.2).  In a recent study, doxorubicin has been successfully used as a 
proof-of-concept compound to investigate the mechanistic pathways of mitochondrial toxicity 
in the AC16 model, thus corroborating the relevance of this model for structural preliminary 
cardiac toxicity assessments (Yuan et al. 2016). 
The effects of HDACi on cardiac cell structure were evaluated in AC10 two-dimensional 
monolayers analysed using impedance-based systems (section 5.3.1). In agreement with the 
previously reported HL-1 cell model, the pan-HDACi TSA and SAHA elicited a marked transient 
decrease in impedance cell index values at both cytotoxic and sub-cytotoxic drug 
concentrations. This transient effect on cell index parameters was likely attributed to the 
compensatory expansion of adjacent AC10 cells, rather than a temporary/reversible change 
of individual cellular structures. To reinforce this hypothesis, imaging of individual AC10 cells 
demonstrated that pan-HDACi-induced structural alterations were irreversible, and occurred 
within 24 hours post compound addition (section 5.3.1). Further observations established that 
pan-HDACi caused cellular morphological elongation and hypotrophy, ultimately justifying the 
observed reduction in impedance cell index parameters. Although class I HDACs are 
fundamentally related to epigenetic regulation through histone acetylation, there are also 
many non-histone post-translational roles of HDACs established, including regulation of 
intracellular protein activities and localisation, activity of transcription factors, modification of 
cellular cytoskeletal interactions, and intracellular protein transport. These effects and roles 
have subsequently resulted in their re-classification of KDACs rather than just HDACs (Becker 
et al. 2018). The implications of HDAC/KDAC modulation on peculiar aspects of cellular 
morphology within individual organ systems have thus not been fully elucidated to date. In 




regulation of cytoskeletal preservation and functioning, particularly through tubulin 
deacetylation mechanisms that underpin cellular morphology (Valenzuela-Fernández et al. 
2009). In this study, pan-HDACi TSA and SAHA confirmed the occurrence of structural 
remodelling in AC10 cells, however the HDAC6 class IIb-selective inhibitor tubacin did not elicit 
any detectable morphological or cytotoxic changes, therefore suggesting either that HDACi-
induced structural perturbations are not solely dependent upon HDAC6 or that the 
cytoskeletal structure is less affected by tubulin in this model. The proposition that HDACi-
induced structural changes may depend on off-target secondary pharmacological activity was 
further supported by the assessment of acetylation levels of relevant HDACi targets in AC10 
cells: these results confirmed that cellular morphological changes occurred even at sub-
pharmacologically active pan-HDACi concentrations . A study proposed by Lee et al. identified 
the onset of mitochondrial elongation following treatment with SAHA in non-cardiac in-vitro 
primary cell models, with elongation being irrespective of apoptotic induction (Lee et al. 
2012). Furthermore, the study also reported that mitochondrial elongation was not correlated 
with microtubule-dependent mechanisms, but rather on the downregulation of two proteins 
involved in mitochondrial morphology modulation (Lee et al. 2012). Since cardiomyocytes 
possess the highest amount of mitochondria of any tissue due to the high energetic and 
metabolic requirements necessary for cardiac contractility, with mitochondria located in 
abundance throughout the cell (Sabbah 2020), it is possible that structural remodelling and 
morphological changes resulting in AC10 elongation could be a consequence of mitochondrial-
related structural toxicity. While pan-HDACis were shown to induce changes in mitochondrial 
respiration in the HL-1 model (chapter 4), further studies are required to investigate structural 
mitochondrial and metabolic toxicity in this model. Overall, the studies on 2D monolayers 
support the use of the AC10 model for preliminary drug-induced structural toxicity.  
While ease-of-use and accessibility of AC10 monolayers could provide a convenient platform 
to complement preclinical in-vitro assessments, several limitations associated with the cardiac 
representative nature this model still remain, primarily in relation to the rapid AC10 turnover 
rate and pre-differentiated state, single cell lineage, and monolayer structure limiting cellular 
interactions and communications. Advanced three-dimensional culture techniques were 
therefore hypothesised to enhance AC10 cardiac properties and subsequently improve the 




microenvironments in terms of providing superior performance and functionality of various 
models over respective 2D monolayer cultures (Gaskell et al. 2016). For example, several liver 
spheroid models have been characterised, and have demonstrated increased expression of 
tissue-specific markers, enhanced metabolic functionality and an improved sensitivity to toxic 
insults (Gaskell et al. 2016). These improvements have been strictly associated with the 
presence of a 3D microenvironment and a physiologically relevant extracellular matrix, which 
allows to enhance cell-cell interactions and ultimately mimics in-vivo systems. Several 
expandable cell line spheroid models are now routinely used in preclinical screening, as in the 
case of the immortalised hepatic line HepG2, which has demonstrated reduced proliferative 
rates when cultured in 3D spheroids (Wrzesinski et al. 2014). On this basis, an objective of this 
study was to evaluate and characterise for the first time the utility of AC10 cells for preclinical 
cardiotoxicity studies in three-dimensional spheroid cultures. This study confirmed that AC10 
cells can be used to successfully construct single-lineage monoculture spheroids as well as 
multi-lineage triculture spheroids (section 5.2.3). Both monoculture and triculture cardiac 
spheroids have been previously characterised using hiPSC-CMs in combination with non-
myocyte cells, demonstrating enhanced phenotypical maturity and contractility (Ravenscroft 
et al. 2016; Tomlinson et al. 2019). In this study, AC10 spheroids cultured with a standardised 
starting cell number of 500 cells/well (Ravenscroft et al. 2016), were cultured for a maximum 
of 20 days before displaying signs of cell death and spheroid disruption (section 5.2.3). The 
observed disruption of spheroids can be attributed to the inability of media nutrient and 
oxygen to efficiently diffuse through the spheroid tissue as the spheroid grows in size, leading 
to the formation of a necrotic core and ultimately leading to cell death (Barisam et al. 2018). 
Previous studies have shown that successful oxygenation can be achieved in spheroids ≤ 400 
µm, therefore AC10 spheroids were grown between 7 and 14 days, reaching a size sufficient 
to minimise the impact of a necrotic core formation (Mittler et al. 2017; Gaskell et al. 2016).  
Nonetheless, despite the culturing time span limitations that depend on the formation of a 
necrotic region, AC10 spheroids demonstrated successful viability for a longer period than 2D 
monolayer cultures, with spheroids fully viable for at least 14 days, and non-passaged 
monolayers viable for ≤ 80 hours post initial seeding.  Investigations on the internal AC10 
spheroid structure revealed the formation of an organised extracellular matrix, as evidenced 
by immunofluorescent staining of the F-actin network (section 5.2.3). Both AC10 monoculture 




indicated by the uneven presence of cardiac troponin I, in line with the pre-differentiated 
phenotypical features of the AC10 model (Davidson et al. 2005). It remains yet to be 
determined whether an improved syncytial formation could be achieved with dedicated work 
involving the promotion of terminal differentiation of AC10 cells into functional myocytes. 
Lastly, in AC10 tricultures, non-myocyte cell organisation within the spheroid evidenced the 
formation of a complex extracellular matrix network due to the presence of cardiac 
fibroblasts, as well as cardiac endothelial cell clustering reminiscent of rudimental vessel 
formation (section 5.2.3). 
Following the successful establishment of AC10 spheroids, the last phase of this study focused 
on the evaluation of the effects of HDACi compounds against AC10 spheroids. In this context, 
initial investigations revealed a remarkably enhanced sensitivity of AC10 spheroids to pan-
HDACi compounds compared to 2D monolayers (section 5.3.4.1). Similarly, enhanced spheroid 
chemosensitivity to toxic insults has been reported with the use of hepatic spheroids, where 
these have demonstrated higher sensitivity to relevant hepatotoxins, and consequently 
provided an improved toxicological predictivity profile (Gaskell et al, 2016).  
The pan-HDACIs were demonstrated to cause a whole-spheroid morphological shape change 
following exposure to sub-cytotoxic concentrations, causing structural remodelling from a 
spherical to an elliptical shape. Ultrastructural investigations demonstrated release of cardiac 
troponin I as a consequence of TSA exposure, particularly evident at cytotoxic concentrations, 
where a marked disruption to the cytoskeletal F-actin filaments was also detected. 
Concomitant intra-spheroid accumulation of troponin I (cTnI) and cytoskeletal f-actin 
alterations were also identified at sub-cytotoxic concentrations of TSA, but not SAHA, plausibly 
due to the higher pharmacological potency of TSA (Smith et al. 2010). Remarkably, 
fragmentation of the F-actin network occurred at all tested pan-HDACi concentrations. Studies 
have recently reported a HDACi-mediated effect on molecular pathways linked with cardiac 
remodelling, including the regulation of several proteins associated with cytoskeletal 
organization, cell-cell and cell-matrix interaction, metabolism, inflammation, and dysfunction 
of mitochondria in a cardiac in-vivo murine model (Scholz et al. 2019). The findings presented 
in this chapter clearly demonstrate the occurrence of pan-HDACi-induced structural 




therefore support the relevance of this model in the detection of drug-mediated structural 
cardiotoxicity. 
When evaluated under a comparative perspective, AC10 spheroids demonstrated a superior 
applicability over 2D monolayers for the preliminary screening of structural effects, because 
of greater cellular stability, multicellular capability, and a more relevant structural 
physiological representation. Given the prolonged culturing time span which allows the use of 
repeated/long term compound additions, AC10 spheroids provide a scalable and human-
derived model that can be used in both high-throughput applications, or in advanced multi-
system bioreactor and organ-on-chip technologies. Although further protocol optimisation is 
required to enhance the cardiac phenotype of AC10 cells, this study supports the use of both 
2D and 3D AC10 models in conjunction with currently existing methodologies, and provides 
















































6.1 Project outcomes 
 
Cardiotoxicity is a major cause of drug attrition (Laverty et al. 2011; Weaver and Valentin 
2019). Recent advances in drug discovery have determined the need for the development of 
improved in-vitro models that could accurately detect drug candidates with cardiac liabilities 
sufficiently early in the drug discovery pipeline (Gintant, Sager, and Stockbridge 2016b; 
Laverty et al. 2011). This would avoid their progression into late-stage project phases, 
ultimately maximising the advancement of safer novel drug candidates, and consequently 
reducing the cost of drug development. Current assessments of in-vitro preclinical drug-
induced cardiotoxicity predominantly rely on an integrated screening system of 
methodologies, evaluating acute proarrhythmic effects that could alter the electrical function 
of the heart. However, the current screening paradigm has several limitations for robust 
assessment of drug-induced cardiotoxicities, particularly in terms of longer-term assessments, 
instability and reduced longevity of cellular models and high experimental cost. Furthermore, 
drug-induced cardiotoxicity is known to be a multifaceted process involving both functional 
and structural cellular changes, with current models focusing almost exclusively on drug-
induced functional changes and drug-induced proarrhythmias, with limited scope for 
evaluation of morphological and structural cardiac cellular change. As such, there is an evident 
shortfall of models suitable for predictivity of structural cardiotoxicities 
On this basis, the overall aim of this project was the development and characterisation of in-
vitro cardiac cell models, along with the development of novel protocols, designed to be 
integrated with current methodologies for an enhanced detection of drug-induced 
cardiotoxicity. In this context, a particular focus was dedicated to the qualification of in-vitro 
models for the early screening of structural cardiotoxicity. The main outcomes of this thesis 
can be summarised as follows: 
 
1 This study demonstrated the successful development of a novel protocol for the use of 
the HL-1 murine atrial cell model in combination with impedance-based technologies 
(xCELLigence Cardio system), and qualified the HL-1 model for functional and structural 




2 This study characterised the use of the AC10 human ventricular cell line for the detection 
of structural drug-induced liabilities in two-dimensional monolayers through the use of 
impedance-based technologies (xCELLigence DP system), and established for the first 
time the use of AC10 three-dimensional spheroids for the detection of drug-induced 
structural cardiotoxicity. 
3 Lastly, through the integrated application of established hiPSC-CM in-vitro assays 
alongside the newly developed protocols, this study elucidated previously unexplored 
structural cardiotoxicity mechanisms induced by the histone deacetylase inhibitor class 
of molecular-targeted therapeutics. 
 
6.2 Integrative use of in-vitro models for preclinical detection of 
cardiotoxicity is beneficial to maximise predictivity 
 
 
At present, preclinical screening of drug-induced cardiotoxicity involves predominantly a 
multi-step approach of in-vitro and in-vivo methodologies, with a marked focus on the 
detection of proarrhythmias that could lead to Torsade de Pointes (TdP) (E14/S7B 2020; 
Gintant, Sager, and Stockbridge 2016a). Under a regulatory perspective, in-vivo tests are still 
fundamentally required, particularly for the assessment of multiparameter physiological and 
pathological cardiac disturbances, integration of ADME principles into the context of drug fate 
and subsequent toxicity, and ultimately integrated assessment, as outlined in the ICH E14 and 
S7B guidelines  (E14/S7B 2020). However, despite their imperative utility, the clinic translation 
of animal models are hindered by inter-species and metabolic differences. This in combination 
with restrictive scope of current in-vitro methodologies, namely the hERG assay, has led to 
either underdetection of cardiac liabilities, or false-positive findings and thus unwarranted 
drug attrition (Fermini et al. 2016). Furthermore, there is now an appreciation that this 
screening approach has overestimated the potential for drug-induced clinical proarrhythmia 
and the retardation of development of several viable drug candidates (Fermini et al. 2016).  
The advent of commercial human-derived induced pluripotent stem (hiPSC) cells has 
undoubtedly revolutionised the standardisation of preclinical investigations in-vitro, allowing 
the design of more comprehensive high-throughput screening, particularly when combined 




increasingly becoming implemented in standardised preclinical investigations, both using two-
dimensional and three-dimensional technologies to detect acute functional liabilities (Ribeiro 
et al. 2019), where hiPSC-CMs have demonstrated good predictivity for highly torsadogenic 
compounds (Blinova et al. 2018). Subsequently, this has resulted in development of a new 
screening paradigm to potentially integrate the hERG-focused approach (the CiPA initiative), 
incorporating in silico toxicity prediction and evaluation of drug candidates on hiPSC-CM, 
followed by evaluations in vivo (“Https://Cipaproject.Org/” n.d.; Cavero and Holzgrefe 2015). 
However, despite this significant advancement in preclinical drug-induced cardiotoxicity 
predictions, incorporating a focus on human cells, the use of hiPSC-CMs is partially hindered 
by a number of unresolved limitations, particularly in relation to the short culturing time span, 
persisting electrophysiological phenotype incongruities, lack of consistency between different 
manufacturers which leads to different predictions (Holbrook 2019) and, not least, high 
maintenance costs. Some of these limitations were evidenced in this study (chapter 3), where 
hiPSC-CMs were used in combination with high-throughput impedance and multi-electrode 
electrophysiology assessments (xCELLigence Cardio ECR system), demonstrating inaccuracies 
in response to proarrhythmic compounds, including calcium channel blockers and autonomic 
drugs. While electrophysiological fallacies may be partially revised through protocol 
optimisation and the advancement of multi-parametric technologies, challenges remain as to 
the full utility of these cell models. 
Despite hiPSC-CMs significantly improving the identification of drug-induced proarrhythmias, 
the relevance of this model for identification of drug-induced perturbations non-functional 
cardiotoxicity is very limited. This was exemplified in this thesis with the assessment of HDACi 
compounds, which have elicited the occurrence of morphological alterations imputable to 
structural cardiotoxic effects in the HL-1 and AC10 models, but not in hiPSC-CMs. One reason 
can be that current hiPSC-CM assays are mostly designed to detect acute effects that develop 
within a 24-48-hour timeframe, thus neglecting sub-acute and long-term effects. This is a key 
issue, considering many known structural cardiotoxic drugs (i.e., Anthracyclines) manifest 
some of their irreversible effects with a delayed onset, leading to heart failure (Curigliano et 
al. 2010; Findlay et al. 2019). Additionally, there is the possibility that hiPSC-CM models may 
elude the detection of acute structural cardiotoxicity endpoints, either because of insufficient 




the increasing diversity of novel drug candidates. The use of complex modelling involving 
multifluidics and/or organ-on-chip systems paired with the use of hiPSC-CMs may improve the 
ability of this cell model to identify a level of structural liabilities. However, the need for 
specialised training, dedicated equipment and robust validation, alongside the high costs 
associated with the implementation of such systems have led to a low uptake of these 
technologies within the pharmaceutical sector to date (Gintant, Sager, and Stockbridge 2016b; 
Weaver and Valentin 2019). In this regard, the utilisation of a low-cost model with an 
enhanced sensitivity against structural cardiotoxicants finds its scope, particularly within a 
model informed drug design and discovery (MID3) perspective (Figure 6.1). The AC10 human 
ventricular cell line demonstrated a significant sensitivity to HDACi-induced toxicity, both in 
two-dimensional and three-dimensional models, and enabled the early identification of sub-
acute morphological changes occurring even at sub-pharmacologically active concentrations 
(chapter 5). Similarly, the HL-1 murine atrial cell line exhibited structural and contractile 
alterations in response to HDACi compounds, showcasing sub-acute irreversible changes in 
contractility and mitochondrial toxicity (chapter 4). The integrated use of these models, in 2D 
and 3D, was therefore essential in the early identification of several potential mechanisms 
underpinning HDACi-induced off-target cardiotoxicity. These newly identified effects, 
including cytoskeletal remodelling, cardiac troponin release, delayed-onset (≥ 80 hours) of 
contractile aberrations and metabolic changes, were de facto undetected in hiPSC-CM models 
exposed to similar drug concentrations. While HDACi-induced cardiac effects have previously 
been reported in-vitro (Kopljar et al. 2016) and in-vivo (Wallner et al. 2020; Kuai et al. 2016; 
Freundt et al. 2019), these were exclusively determined at pharmacologically active, supra-
pharmacological, or elevated cytotoxic concentrations. The proposed HDACi off-target 
mechanisms defined with the use of HL-1 and AC10 models are indeed supportive of several 
recent in-vivo findings, where HDACis have been linked to reduction of left-ventricular 
hypertrophy (and thus cardiac restructuring) in a HFpEF model (Wallner et al. 2020). In this 
context, the studies presented herein have demonstrated the occurrence of structural and 
morphological cardiomyocyte remodelling: while the reduction of cardiac hypertrophy may 
be considered as a cardioprotective effect under a pathological perspective, the occurrence 
of structural remodelling in healthy subjects may in fact underpin cardiotoxicity (M. H. Shah 
et al. 2006). In this regard, these studies prove that a full elucidation of HDACi-induced cardiac 




This work additionally supports the use of HL-1 and AC10 models for the assessment of 
cardiotoxicity of highly promiscuous drugs, such is the case of HDACi, where an exhaustive 
record of molecular targets has not been fully defined. Despite the initial in-vitro 
pharmacological profiling that is routinely performed against a panel of undesirable targets 
(Jenkinson et al. 2020), It has been reported that highly promiscuous drugs are more likely to 
be discontinued during late-stage clinical development as a result of latent secondary 
pharmacology (off-target) effects (Bowes et al. 2012; Valentin et al. 2018). The scalable use of 
a battery of 2D and 3D models paired with high-content assessments can therefore not only 
aid the early identification of hazards, but also assist in the identification of on-and-off target 
effects that can inform and direct subsequent in-vivo toxicity studies. 
As demonstrated throughout the studies presented in this thesis, the synergistic use of two-
dimensional and three-dimensional cell line-based models provides an effective and scalable 
strategy for the enhancement of early hazard identification, which can guide and, and 











Figure 6.1 Integrated use of cardiac models for cardiotoxicity screening.  2D and 3D cell line-
based models characterised in this thesis can be integrated to enhance preclinical 
cardiotoxicity screening and early hazard identification in the drug discovery process. The 
complexity of these models can be upscaled for high-throughput applications (2D systems), or 




















Model is widely used 
for acute functional 
studies 
Very limited for acute 
studies, not established 
for long-term studies 
Established 
(Ravenscroft et al. 
2016) 
• 2D: validated 








• 3D: up to 28 
days 
HL-1 murine atrial 
cell line 
Characterised for use 
with patch clamping 
(Kammonen et al. 2017) 
Characterised with 
impedance systems 





Forms spheroids with 
CF and EC*. 
Characterisation is 
required 
• 2D: up to 
150 hours 
between 
passages Low cost. 
Expandable 
• 3D: up to 14 
days* 
AC10 human 
ventricular cell line 
Model lacks syncytia 
and sarcomere 
structures, therefore is 
not suitable for 
contractility assays 
 




to anthracyclines and 
HDACi 
Forms spheroid as 
mono and triculture 




• 2D: up to 72 
hours 
between 
passages Low cost. 
Expandable 
• 3D: up to 20 
days 
Table 6-1. Summary of appraised in-vitro cardiac models, evaluated for their suitability for the detection of functional, structural 
cardiotoxicity studies, use in 3D cultures and suitability for long-term and sub-acute studies. Suitability  for each category is 





6.3  Limitations and future perspectives 
 
The integration of multiple models and technologies is crucial for the effective investigation 
of drug-induced cardiotoxicity. While the proposed novel protocols presented in this thesis 
could offer additional resources to be integrated within the constantly evolving screening 
paradigms, a few limitations need to be considered. Most efforts in-vitro have thus far been 
centred on the detection of cardiotoxic effects on cardiac myocytes. Even though 
cardiomyocytes are indeed the cell type primarily involved in cardiac contractility, in-vivo 
these cells rely on the synergistic interaction with other cell lineages, including cardiac 
fibroblasts and endothelial cells. Given the multifactorial nature of xenobiotic toxicity, more 
heterogeneous and physiologically representative models are needed to fully evaluate 
cardiotoxicity. The lack of cell lineage diversity is a well-established limitation of current in-
vitro models, and studies aimed at the construction of three-dimensional multi-lineage co-
cultures have partly attempted to resolve the issue (Wrzesinski et al. 2014; Ravenscroft et al. 
2016; Tomlinson et al. 2019) . Work in this thesis has demonstrated the successful 
construction of 3D multi-lineage spheroids, however, despite the tangible advantages of 3D 
microtissues and spheroids over 2D platforms, tissue perfusion and functional vascularisation 
of such cultures remains an unresolved aspect. The development of protocols aimed at 
achieving successful vascularisation would plausibly determine a significant improvement in 
model complexity and, consequently, positively impact their predictive power. Additionally, 
the integration of cardiac models into multi-compartmental/multi-organ bioreactors could 
further enhance predictivity, however standardisation and accessibility of such methodologies 
should be revised. In this context, the development of novel 3D bioprinting technologies is 
demonstrating a promising potential.  
In-vitro-in-vivo extrapolation (IVIVE) and data translatability is another key limitation 
associated with the use of in-vitro models that requires improvements (Weaver and Valentin 
2019). The continuous optimisation of more representative and complex models that support 
multiparametric and long-term studies can advance the mechanistic understanding of drug-
induced toxicity, and therefore assist in the process of data extrapolation and translation to 




the limited genotype that hiPSC-CMs and cell lines offer, as these are limited to a single 
genotype (derived from individual donor/progenitor cell)  that does not necessarily reflect the 
wider population, particularly when it comes to the detection of cardiotoxicity in patient 
populations with co-morbidities (Poluzzi et al. 2017). The availability of more complex 
standardised models can certainly enhance in-vitro-in-vivo translatability, nonetheless future 
efforts should also be directed towards the implementation of more genotypically inclusive 
models.  
The use of multiple models and assays inevitably leads to the generation of an extensive 
amount of data. In this context, significant advances in the use of machine learning and 
artificial intelligence could further maximise preclinical data extrapolation. These innovative 
approaches have the potential of revolutionising the vast amount of data analysis that derives 
from the integration of increasingly complex high throughput assays and models (Basile, Yahi, 
and Tatonetti 2019).  It is hoped that, in the near future, efforts will be made to incorporate 

























Abassi, Yama A., Biao Xi, Nan Li, Wei Ouyang, Alexander Seiler, Manfred Watzele, Ralf 
Kettenhofen, et al. 2012. “Dynamic Monitoring of Beating Periodicity of Stem Cell-
Derived Cardiomyocytes as a Predictive Tool for Preclinical Safety Assessment.” British 
Journal of Pharmacology 165 (5): 1424–41. https://doi.org/10.1111/j.1476-
5381.2011.01623.x. 
Adamcova, Michaela, Veronika Skarkova, Jitka Seifertova, and Emil Rudolf. 2019. “Cardiac 
Troponins Are Among Targets of Doxorubicin-Induced Cardiotoxicity in HiPCS-CMs.” 
International Journal of Molecular Sciences Article. 
https://doi.org/10.3390/ijms20112638. 
Alameddine, Raafat S., Ahmad Sharif Yakan, Hadi Skouri, Deborah Mukherji, Sally Temraz, 
and Ali Shamseddine. 2014. “Cardiac and Vascular Toxicities of Angiogenesis Inhibitors: 
The Other Side of the Coin.” Critical Reviews in Oncology/Hematology. Elsevier Ireland 
Ltd. https://doi.org/10.1016/j.critrevonc.2015.05.004. 
Álamo, Juan C. del, Derek Lemons, Ricardo Serrano, Alex Savchenko, Fabio Cerignoli, Rolf 
Bodmer, and Mark Mercola. 2016. “High Throughput Physiological Screening of IPSC-
Derived Cardiomyocytes for Drug Development.” Biochimica et Biophysica Acta - 
Molecular Cell Research. https://doi.org/10.1016/j.bbamcr.2016.03.003. 
Ando, Hiroyuki, Takashi Yoshinaga, Wataru Yamamoto, Keiichi Asakura, Takaaki Uda, 
Tomohiko Taniguchi, Atsuko Ojima, et al. 2017. “A New Paradigm for Drug-Induced 
Torsadogenic Risk Assessment Using Human IPS Cell-Derived Cardiomyocytes.” Journal 
of Pharmacological and Toxicological Methods. 
https://doi.org/10.1016/j.vascn.2016.12.003. 
Babuin, Luciano, and Allan S. Jaffe. 2005. “Troponin: The Biomarker of Choice for the 
Detection of Cardiac Injury.” CMAJ : Canadian Medical Association Journal 173 (10): 
1191. https://doi.org/10.1503/CMAJ.050141. 
Backs, Johannes, Kunhua Song, Svetlana Bezprozvannaya, Shurong Chang, and Eric N. Olson. 
2006. “CaM Kinase II Selectively Signals to Histone Deacetylase 4 during Cardiomyocyte 
Hypertrophy.” Journal of Clinical Investigation 116 (7): 1853–64. 
https://doi.org/10.1172/JCI27438. 
Bagnes, Claudia, Patricia Panchuk, and Gonzalo Recondo. 2009. “Antineoplastic 
Chemotherapy Induced QTc Prolongation.” Current Drug Safety 5 (1): 93–96. 
https://doi.org/10.2174/157488610789869111. 
Banerjee, Amitava, Robin Chung, and Arjun Kumar Ghosh. 2018. “Open Access 





Barisam, Maryam, Mohammad Said Saidi, Navid Kashaninejad, and Nam Trung Nguyen. 
2018. “Prediction of Necrotic Core and Hypoxic Zone of Multicellular Spheroids in a 
Microbioreactor with a U-Shaped Barrier.” Micromachines 9 (3). 
https://doi.org/10.3390/mi9030094. 
Bartos, Daniel C., Eleonora Grandi, and Crystal M. Ripplinger. 2015. “Ion Channels in the 
Heart.” In Comprehensive Physiology, 5:1423–64. Hoboken, NJ, USA: John Wiley & Sons, 
Inc. https://doi.org/10.1002/cphy.c140069. 
Basile, Anna O., Alexandre Yahi, and Nicholas P. Tatonetti. 2019. “Artificial Intelligence for 
Drug Toxicity and Safety.” Trends in Pharmacological Sciences. Elsevier Ltd. 
https://doi.org/10.1016/j.tips.2019.07.005. 
Becker, Lore, Melanie Schmitt Nogueira, Caroline Klima, Martin Hrabe De Angelis, and 
Shahaf Peleg. 2018. “Rapid and Transient Oxygen Consumption Increase Following 
Acute HDAC/KDAC Inhibition in Drosophila Tissue.” Scientific Reports 8 (1): 1–7. 
https://doi.org/10.1038/s41598-018-22674-2. 
Bellinger, Andrew M., Carlos L. Arteaga, Thomas Force, Benjamin D. Humphreys, George D. 
Demetri, Brian J. Druker, and Javid J. Moslehi. 2015. “Cardio-Oncology: How New 
Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular 
Discovery.” Circulation. Lippincott Williams and Wilkins. 
https://doi.org/10.1161/CIRCULATIONAHA.115.010484. 
Bendels, Stefanie, Caterina Bissantz, Bernhard Fasching, Grégori Gerebtzoff, Wolfgang Guba, 
Manfred Kansy, Jacques Migeon, et al. 2018. “Safety Screening in Early Drug Discovery: 
An Optimized Assay Panel.” Journal of Pharmacological and Toxicological Methods 99 
(September). https://doi.org/10.1016/j.vascn.2019.106609. 
Bergmann, Olaf, Sofia Zdunek, Anastasia Felker, Mehran Salehpour, Kanar Alkass, Samuel 
Bernard, Staffan L. Sjostrom, et al. 2015. “Dynamics of Cell Generation and Turnover in 
the Human Heart.” Cell 161 (7): 1566–75. https://doi.org/10.1016/j.cell.2015.05.026. 
Bers, Donald. 2002. “Cardiac Excitation–Contraction Coupling.” Nature 415: 198–205. 
https://doi.org/10.1038/415198a. 
Blinova, Ksenia, Qianyu Dang, Daniel Millard, Godfrey Smith, Jennifer Pierson, Liang Guo, 
Mathew Brock, et al. 2018. “International Multisite Study of Human-Induced 
Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential 
Assessment.” Cell Reports. https://doi.org/10.1016/j.celrep.2018.08.079. 
Bowes, Joanne, Andrew J. Brown, Jacques Hamon, Wolfgang Jarolimek, Arun Sridhar, Gareth 
Waldron, and Steven Whitebread. 2012. “Reducing Safety-Related Drug Attrition: The 
Use of in Vitro Pharmacological Profiling.” Nature Reviews Drug Discovery. Nature 
Publishing Group. https://doi.org/10.1038/nrd3845. 
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Appendix 1:  
 





























[continued from previous page] Internal structure of HL-1 triculture spheroids. Spheroids 
were cultured on ULA plates for 14 days, fixed and stained with anti-alpha actinin (green), 
Hoechst to stain the cell nuclei (blue), phalloidin to stain cytoskeletal structures (red) and anti 
CD31 antibody to stain endothelial cells (white). Images are maximum intensity projections 
representative of a mid-section of each spheroid, typical of at least 3 different spheroids. At 



































Evaluation of in-vitro cellular models for use in functional and structural studies of drug-induced 
cardiotoxicity  
C. De Santis; JH Gill 
 
Keywords: Cardiotoxicity; Histone deacetylase inhibitors; Human-induced stem cell-derived 
cardiomyocytes; Cellular impedance.  
 
Detrimental effects upon the cardiac system are a major cause of drug attrition. Current in vitro 
methodologies for assessment of drug-induced cardiotoxicity involve sub-optimal screens of non-
cardiac cell lines engineered to express cardiac ion channels, or primary tissue with limited utility for 
clinical translation. The advent of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-
CM), with the ability to synchronously beat (contract) in vitro; opened up opportunities for improved 
identification of cardiotoxicity. However, these cells are costly, time-limited, and require complex 
maintenance techniques, posing constraints in terms of widespread use. One resolution is the use of 
immortalised cardiac cell lines, with capability for continuous growth and clinical translation. However, 
the limitations of these models for detecting both structural and functional cardiotoxicity is unknown. 
In this study we assess the predictive value of an immortalised non-contractile human cardiac cell line 
(AC10) and functionally-responsive hiPSC-CM to determine toxicity of the histone deacetylase inhibitor 
(HDACi) class of drug, thus highlighting the advantages of each type of cell model in relation to 
structural and functional cardiotoxicity. This not only supports the value of comprehensive cellular 
screening models, but offers a predictive tool to assess cardiotoxicity that would allow development 
of efficacious and safer drugs in this class. 
Invited keynote speaker and poster presentation at the In-vitro toxicology society IVTS annual 
meeting 2017, London, UK 
 

















Qualification of cardiac cell models for preclinical predictive studies of drug-induced cardiotoxicity  
Carol De Santis1; Simon Findlay1; Jason H. Gill1,2  
1Northern Institute for Cancer Research, Newcastle University, UK; 2School of Pharmacy, Newcastle 
University, UK.  
 
Cardiotoxicity is a major cause of drug attrition and life-threatening complication of many anticancer 
therapies. Current in-vitro methodologies for identification of drug-induced structural and/or 
functional cardiotoxicity and their underlying mechanism are sub-optimal, involving either non-cardiac 
cell lines expressing specific ion channels, or ex-vivo cardiac tissues with limited utility for longer-term 
analyses and clinical translation.  
The emergence of innovative technologies combined with the use of human induced pluripotent stem 
cell-derived cardiomyocytes (hiPSC-CM), with the ability to synchronously contract in-vitro, 
revolutionised identification of drug-induced cardiotoxicity. However, major limitations to this 
approach are their complexity, specialised culture conditions, high cost and subsequent limitations for 
assessment of drug-induced cardiotoxicity. One resolution is incorporation of cardiac cell lines into the 
initial screening paradigm. The study objective was to evaluate the responsiveness of current cardiac 
cell-lines to both structural and functional cardiotoxicants, specifically the human ventricular 
cardiomyocyte cell-line, AC10, and the murine atrial cell-line, HL-1, relative to both primary neonatal 
rodent cardiomyocytes and hiPSC-CM. Real-time assessment of pathophysiological changes were 
determined by impedance-based in vitro methodologies (xCELLigence RTCA), with known cardiac 
therapeutics and the histone deacetylase inhibitor (HDACi) class of drugs being evaluated in this 
context.  
The AC10 cell-line, although non-contractile, was able to detect drug-induced structural changes. The 
HL-1 cell-line was also able to detect structural cardiotoxicants, and exhibited a contractile phenotype 
in vitro, albeit non-uniformly and time-limited. This study indicates there is scope for inclusion of 
cardiac cell-lines alongside primary cells and hiPSC-CM in preclinical evaluation of drug-induced 
cardiotoxicity. 
 














 Qualification of in vitro cardiomyocyte cell models for prediction of drug-induced toxicity 
studies  
 
Carol De Santis1; Jason H. Gill1,2  
1Northern Institute for Cancer Research, Newcastle University, UK; 2School of Pharmacy, Newcastle 
University, UK.  
 
Detrimental effects upon the cardiac system are a major cause of attrition during drug development, 
withdrawal of marketed medicines, and development of heart failure in survivors of chronic therapies. 
Drug-induced cardiotoxicity is a consequence of effects upon a range of molecular pathways involved 
with either structural or functional attributes of the heart. Current in vitro methodologies for 
assessment of drug-induced cardiotoxicity involve either sub-optimal screens involving non-cardiac 
cell lines engineered to express individual cardiac ion channels, or primary animal cardiomyocytes and 
cardiac tissue with their limited utility for in vitro culture and clinical translation. The emergence of 
innovative technologies combined with the use of human induced pluripotent stem cell-derived 
cardiomyocytes (hiPSC-CM), with the ability to synchronously beat (contract) in vitro, opened up 
opportunities for improved identification of cardiotoxicity. However, the costly and complex 
maintenance techniques pose limitations in terms of widespread use. A possible solution to these 
limitations is the utilisation of a panel of cardiac cell lines, with defined attributes for clinical 
translation, scope for molecular manipulation, and the beneficial capability for continuous and 
expandable in vitro growth. However, the advantages and limitations for these cell models for 
prediction and detection of the various perturbations of structural and functional cardiotoxicity are as 
yet unclear. The objective of this study was to characterise and profile the capabilities for toxicity 
prediction of different cardiac cell lines, specifically the immortalized human ventricular 
cardiomyocyte cell line - AC10, the immortalized murine atrial cell line - HL1, and the rat embryonic 
cardiomyoblast cell line - H9c2, relative to primary cardiomyocytes and ultimately hiPSC-CM. This study 
evaluated these cell systems using impedance based real-time analyses (xCELLigence RTCA) to address 
the ability of these cardiac cell models to detect both structural and functional drug-induced 
cardiotoxicity. Data is presented of the evaluation of these cell models against a panel of drugs with 
known cardiotoxic effects, identifying their advantages and limitations for screening of drug-induced 
cardiotoxicity. 











Cardiotoxicity is a major cause of drug attrition and life-threatening complication of many anticancer 
therapies. Current preclinical methodologies for identification of drug-induced structural and/or 
functional cardiotoxicity and their underlying mechanism are sub-optimal, involving either non cardiac 
cell lines expressing specific ion channels, or ex-vivo cardiac tissues with limited utility for longer-term 
analyses and clinical translation. The emergence of innovative technologies combined with the use of 
human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM), with the ability to 
synchronously contract in-vitro, revolutionised identification of drug-induced cardiotoxicity. However, 
major limitations to this approach are their complexity, specialised culture conditions, high cost and 
subsequent limitations for assessment of drug-induced cardiotoxicity. One resolution is incorporation 
of cardiac cell lines into the initial screening paradigm. The study objective was to evaluate the 
responsiveness of current cardiac cell-lines to both structural and functional cardiotoxicants, 
specifically the human ventricular cardiomyocyte cell-line, AC10, and the murine atrial cell-line, HL-1, 
relative to both primary neonatal rodent cardiomyocytes and hiPSC-CM. Real-time assessment of 
pathophysiological changes were determined by impedance-based in vitro methodologies 
(xCELLigence RTCA), with known cardiac therapeutics and the histone deacetylase inhibitor (HDACi) 
class of drugs being evaluated in this context. The AC10 cell-line, although non-contractile, was able to 
detect drug-induced structural changes. The HL-1 cell-line was also able to detect structural 
cardiotoxicants, and exhibited a contractile phenotype in vitro, albeit non-uniformly and time-limited. 
This study indicates there is scope for inclusion of cardiac cell-lines alongside primary cells and hiPSC-
CM in preclinical evaluation of drug-induced cardiotoxicity. 
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